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Abstract 
The vast array of cells and tissues in the human body contain nearly identical genetic 
information, yet each tissue expresses only a subset of genes present in the genome. The precise 
spatiotemporal expression patterns of these genes are regulated by transcription factors, which 
bind to short sequences of DNA called transcription factor binding sites (TFBSs). While it is 
well-established that mutations within protein-coding sequences cause human disease, sequence 
variation within TFBSs (regulatory SNPs; rSNPs) can result in allele-specific differences in 
DNA binding affinity, which can also cause or modify disease phenotypes. Our objective was to 
identify rSNPs that impact regulatory function at loci important for peripheral nerve function. 
Such rSNPs represent excellent candidate modifier loci that may explain phenotypic variability 
in patients with peripheral neuropathies. 
A challenge in studying the effects of rSNPs on gene function is absent or incomplete 
catalogs of TFBSs. To address this, we developed a computational and functional pipeline to 
identify and characterize putative TFBSs. We utilized genome-wide sequence conservation to 
prioritize candidate regulatory regions that harbor a SNP. We assessed a pilot set of 159 regions 
on chromosomes 21, 22, and X for regulatory activity in cells relevant for the peripheral nerve. 
We identified 28 active regions, of which 13 showed allele-specific differences in regulatory 
activity. We next incorporated known transcription factor binding site information into our 
pipeline. The transcription factor SOX10 is essential for Schwann cell function and has a well-
characterized consensus site. We assessed the allele-specific activity of 22 prioritized regions 
that contain a conserved SOX10 consensus site overlapping a SNP. We deeply characterized one 
 xvi 
region and identified a candidate target gene: Tubb2b. Finally, we performed an unbiased search 
for conserved SOX10-response elements that revealed a previously undescribed potential 
function for SOX10 in repressing myelination. Importantly, the approach and datasets described 
here are broadly applicable to studies on SOX protein and Schwann cell biology, regulatory 
function in the peripheral nerve, and the function of highly conserved sequences in the human 
genome. 
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Introduction 
Methods to Identify Cis-Regulatory Elements 
Patients with peripheral neuropathies (specifically Charcot-Marie-Tooth disease) exhibit large 
phenotypic variability such as age of onset from the first to seventh decade and severity of 
sensory loss, often despite identical coding mutations (Thomas et al. 1997; Pareyson et al. 2006; 
Pareyson and Marchesi 2009). While the cause of the variability is unknown, genetic modifiers 
in the form of regulatory SNPs may be involved. To this end, the main focus of the thesis work 
presented here is to identify functional, non-coding variation critical for the peripheral nerve. 
Throughout this thesis work I will employ a variety of in silico, in vitro, and in vivo experiments 
to address this aim. In this chapter, I will discuss these techniques, the advantages and limitations 
of each, and how combinations of these experimental methods can lead to the identification of 
cis-regulatory elements (CREs). In the second half of this chapter, I will discuss a transcription 
factor SOX10 and the critical function it performs in Schwann cells. The combination of 
experiments discussed here to identify CREs will be employed with SOX10 binding site 
information to identify functional SOX10 response elements harboring SNPs which are 
candidate genetic modifiers of peripheral nerve disease. 
  
 2 
Cis-Regulatory Elements 
Cis-regulatory elements (CREs) are regions of the genome that regulate the spatial-temporal 
expression of a gene (or multiple genes). CREs are generally short stretches of DNA that allow 
for transcription factors to bind. These have been shown to be critical for nearly all cellular 
processes in almost every species, ranging from humans to bacteria and viruses. CREs can have 
varying effects on gene function including increasing (enhancers) or decreasing (repressors) gene 
expression or preventing ectopic CRE activity (insulators). In most cases, for enhancers and 
repressors, they exert their effects on the promoter element (Figure 1.1 - Adapted from (Noonan 
and McCallion 2010)). Identification of promoters is relatively easy because the core promoter 
sequences are generally known (e.g., TATA box and initiator elements), sequences are 
frequently located immediately upstream (with the exception of downstream promoter elements) 
of a gene, and usually there is only one promoter per isoform of a gene (Pedersen et al. 1999; 
Sandelin et al. 2007). Conversely, it is difficult to identify CREs because there are many 
different transcription factor binding sites, they can exert their effects over great distances, and 
can reside anywhere in the genome: upstream of a gene, downstream of a gene, or within introns 
(or exons) of the target gene or other genes. There can also be many CREs per isoform (Vyas et 
al. 1995). In this chapter, I will discuss a brief history of eukaryotic CREs, methods to identify 
and functionally assess CREs, their effects on human diseases, and major questions still 
unresolved in the field. 
The first CRE described in detail was in 1981 by Banerji and colleagues (Banerji et al. 1981). In 
this paper, they transfected HeLa cells with the rabbit β-globin gene, but the transient 
transfection alone was insufficient to detect rabbit β-globin transcripts; however, upon co-
transfection of a plasmid harboring the SV40 viral DNA with the plasmid expressing the rabbit  
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Figure 1.1 Schematic of the General Function of Cis Regulatory Elements (CREs). (A) The 
function of single promoter acting on one gene leads to a certain level of gene expression. (B) 
Two enhancers, one upstream and one in the intron on the gene, act on one promoter to 
ultimately increase gene expression. (C) One repressor acts on the promoter to decrease gene 
expression. (D and E) The effects of an insulator on gene regulation. (D) An insulator element 
prevents ectopic enhancer activity on a second gene. (E) An insulator element prevents the 
spreading of heterochromatin to maintain enhancer activity. Blue boxes represent exons, arrows 
indicate the transcription start site, and size of the arrows reflects gene expression (thicker = 
higher, thinner = lower). Prom = promoter, E = enhancer, R = repressor, I = insulator, and purple 
circles = heterchromatin. Figure adapted from Noonan & McCallion, 2010. 
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β-globin gene, the authors were able to detect 200 times higher transcript levels. They went on to 
map the region of SV40 that gave the “enhancer effect.” The authors narrowed down the region 
of the SV40 sequence by creating random deletions and reassessing each partially deleted 
construct in the co-transfection assay. These experiments have since been termed promoter 
bashing, and while the methods for detecting enhancer activity has changed (e.g., CAT, LacZ, or 
luciferase reporter constructs [discussed below]), this type of assay has been used extensively to 
characterize many CREs (Kong et al. 1999; Guo et al. 2002; Kobolak et al. 2009). These 
experiments gave rise to the term ‘enhancer’ and gave birth to a new field of study in genetics: 
gene regulation. 
Banerji and colleagues went on to identify the first human enhancer at the immunoglobulin 
heavy chain locus (Banerji et al. 1983), by performing nearly identical experiments to 
characterize this enhancer as were previously performed on the SV40 enhancer. One experiment 
involved cloning the enhancer fragment into various locations (e.g., upstream and downstream) 
of the vector relative to the rabbit β-globin gene reporter. They also altered the orientation of 
the enhancer and in both cases observed a similar level of expression. This lead the authors to 
conclude that enhancers generally exhibit both location and orientation independence relative to 
the transcription start site of a gene (Banerji et al. 1983). Since these initial observations, one of 
the main questions and challenges in the field has been to identify and functionally evaluate 
CREs.  
 
 5 
DNase I Footprinting 
One of the earliest methods employed to identify CREs via protein-DNA interactions is DNase I 
footprinting. In this experiment, DNA is subjected to the enzyme DNase I that cuts exposed 
DNA; however, regions of DNA that are bound by proteins are generally protected from DNase I 
activity and leave a ‘footprint’ when the reaction is run out on a polyacrylamide gel (Galas and 
Schmitz 1978; Carlberg et al. 1988). In the case of CREs, the DNA will be protected by the 
transcription factor binding the DNA. Perhaps the most well studied CRE that made use of 
DNase I footprinting is the β-globin locus control region (LCR) (Grosveld et al. 1987). The 
locus control region consists of multiple CREs that regulate the expression of related genes in the 
appropriate tissue and to physiological levels. For the β-globin gene cluster, the LCR regulates 
the differentially expressed globin genes to ensure proper expression at multiple stages of 
development. DNase I experiments were able to originally identify the LCR in erythroid cells 
and subsequent experiments using transgenic mice demonstrated that this region was necessary 
for endogenous gene expression patterns (Levings and Bungert 2002). This experimental 
procedure is extremely successful in identifying open regions of the genome but is limited by the 
number of regions in the genome that can be assessed.  
A new genome-wide method termed DNase-Seq (Crawford et al. 2004; Sabo et al. 2004) has 
been developed to assess open chromatin patterns within the entire genome. DNase-Seq uses the 
same theory as DNase I footprinting, however the method leverages next-generation sequencing 
technologies to assess the whole genome in one experiment. Additionally, DNase-Seq is 
currently one of the most effective single experiments used to predict CREs (Kwasnieski et al. 
2014), yet combining multiple genomic datasets (e.g. ChIP-Seq, GC content, and transcription 
factor motifs) can provide higher confidence predictions of CREs and more easily separate active 
 6 
from inactive transcription factor binding sites. In addition to DNase-Seq, other experimental 
procedures have been employed to search for open chromatin: ATAC-Seq (Buenrostro et al. 
2013), FAIRE-Seq (Giresi et al. 2007), and MNase-Seq (Schones et al. 2008). The experiments 
used to identify open chromatin patterns genome-wide has lead to a plethora of novel putative 
CREs. 
One of the drawbacks of using DNase I footprinting (or DNase-Seq) is the inability to predict 
what protein is binding to the DNA, as the protein typically is generated from protein lysates of 
cells or tissues of interest. This problem is being partially alleviated with increased sequencing 
depth of DNase-Seq experiments which allow high-resolution detection of the transcription 
factor binding to DNA (Neph et al. 2012). These high-resolution maps demonstrate, on the single 
base pair level, how a specific transcription factor uniquely binds to DNA. Curating a database 
of the unique interactions may eventually allow DNase-Seq experiments to also predict the 
transcription factor binding to the DNA; however, these may be limited by only predicting high 
affinity binding sites while excluding functionally relevant low affinity binding sites (Rowan et 
al. 2010; Parker et al. 2011; Ramos and Barolo 2013). 
 
Chromatin Immunoprecipitation (ChIP) 
Compared to DNase-Seq that identifies occupied DNA in an unbiased manner, chromatin 
immunoprecipitation (ChIP) relies on physically crosslinking proteins with the DNA sequences 
that they bind to and isolating the protein (and bound DNA) of interest with an antibody specific 
to the protein (e.g., transcription factor) of interest. One of the first experiments describing ChIP 
was performed by Gilmour and Lis (Gilmour and Lis 1985) to identify RNA-polymerase II 
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occupancy on the Hsp70 gene in Drosophila Schneider line 2 cells. They were able to 
successfully demonstrate RNA-polymerase II binding throughout Hsp70 when cells were 
induced by heat shock but binding was confined to the 5’ end of the gene in uninduced cells. 
From this early work, it became possible to identify in vivo interactions between CREs and the 
transcription factor of interest; however, traditional ChIP experiments required prior knowledge 
of both the transcription factor and the predicted CREs being studied. 
The advent of ChIP-chip experiments alleviated the need for prior knowledge of CREs. This 
technique combines ChIP experiments with DNA microarrays into a single method. In ChIP-chip 
experiments, a standard ChIP assay is performed, but instead of analyzing known sites via 
labeled probes or PCR, the enriched DNA is hybridized to microarrays (Singh-Gasson et al. 
1999; Ren et al. 2000). For organisms with smaller genomes, one chip could contain tiling 
probes against nearly the entire genome (Ren et al. 2000; Iyer et al. 2001; Zeitlinger et al. 2007). 
Conversely, for organisms with larger genomes, only selected target regions could be examined 
(Kim et al. 2005; Akerfelt et al. 2008). In addition, microarrays generally only cover the non-
repetitive regions of the genome (Kim et al. 2005). It is known, however, that CREs can also 
reside within repetitive regions (Bourque et al. 2008), and this signal will be lost using the ChIP-
chip method. While ChIP-chip was a vast improvement over traditional ChIP, it left many CREs 
unidentified. 
The newest advancement with ChIP technologies is ChIP-Seq (Barski et al. 2007; Johnson et al. 
2007), which relies on next-generation sequencing technologies, similar to DNase-Seq. In 
contrast to ChIP-chip, ChIP-Seq does not require predefined probes to capture the bound DNA 
fragments. Rather, the enriched DNA is subjected to linker ligation, amplified using PCR, and 
sequenced using next-generation sequencing. This method solves many of the limitations of 
 8 
ChIP-chip, and as such it has become pervasive in the identification of CREs, with thousands of 
studies utilizing ChIP-Seq experiments. This includes the ENCODE consortium (discussed 
below) which has conducted hundreds of ChIP-Seq experiments across multiple cell and tissue 
types (ENCODE Project Consortium 2012; Landt et al. 2012). 
The major limitation to all ChIP experiments is the reliance on antibodies as some transcription 
factors do not have any effective antibodies. One of these issues is the lack of antibodies for 
every transcription factor. This can be resolved by expressing a tagged version of the 
transcription factor, however the tagged version must be carefully examined to ensure identical 
functions to the endogenous, untagged transcription factor. In addition, the level of expression of 
the tagged version must be controlled because overexpression of transcription factors could alter 
the occupancy of sites, potentially confounding the interpretation of results (DeKoter and Singh 
2000; Fernandez et al. 2003). Traditionally, bacterial artificial chromosomes (BACs; discussed 
below) were used to conserve as many of the endogenous CREs as possible to express the tagged 
transcription factor at approximately endogenous expression levels (Hua et al. 2009), however 
newer methods have been implemented to tag the endogenous locus directly (Savic et al. 2015). 
Another problem with antibodies is they need to be highly specific. Variation in antibody quality 
can vary among different batches (even from the same company), and careful control 
experiments are necessary to prevent confounding results (Landt et al. 2012). Despite the 
potential limitations of ChIP-Seq and related technologies, these methods have proven extremely 
successful at demonstrating where transcription factors bind within a genome, ultimately leading 
to the identification of novel CREs. 
 
 9 
Phylogenetic Footprinting 
Another method used to identify CREs is phylogenetic footprinting. Phylogenetic footprinting 
was first used to predict CREs that were necessary for ε and γ globin expression in primates 
(Tagle et al. 1988). This method relies on the alignment of multiple species sequences at 
orthologous regions, supported by the theory that conserved non-coding regions, even among 
divergent species, may be evolutionarily constrained due to necessary function (Hardison 2000). 
This method proved successful in identifying CREs near specific genes of interest (Aparicio et al. 
1995; Loots et al. 2000; Nobrega et al. 2003; Antonellis et al. 2008). A major drawback for this 
approach was the lack of whole genome sequencing data for multiple species. 
This problem was resolved in the early 2000s, when the genomes of multiple species became 
available, starting with the completion of the human genome project in 2001 (Lander et al. 2001), 
and the mouse genome project in 2002 (Waterston et al. 2002). With these sequences, as well as 
those from other species (Gibbs et al. 2004; Hillier et al. 2004), CREs could be identified for the 
first time using genome-wide phylogenetic footprinting, rather than short alignments of 
homologous regions near target genes. Many different approaches were used to try to identify 
CREs, including increased time of divergence between species (Aparicio et al. 1995) and length 
of the conserved region (Bejerano et al. 2004). 
One particular example that demonstrated the strength of phylogenetic footprinting and 
increasing divergence between species was shown by Nobrega and colleagues at the Dach locus 
(Nobrega et al. 2003). Dach is flanked on both the 5’ and 3’ sides by gene deserts, each 
approximately one million base pairs in length. Alignment of the human and mouse genomes 
revealed 1,098 regions that were at least 100 base pairs in length and with greater than 70% 
conservation. The authors were able to narrow down these regions to 32 conserved sequences 
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when including frog, zebrafish, and two pufferfish genomes in the phylogenetic footprinting 
experiments. Of the 32 regions assessed, the authors tested nine regions in a transgenic mouse 
assay (discussed below) and reported that seven of them were able to at least partially 
recapitulate native Dach expression (Nobrega et al. 2003). In addition to the conservation 
approach, this paper was one of the first to illustrate the great distances CREs can reside from the 
gene(s) on which they act. 
While phylogenetic footprinting has been used successfully many times (Zerucha et al. 2000; 
Goode et al. 2003; Kimura-Yoshida et al. 2004), it is critical to functionally evaluate these 
predictions, as sequence constraint does not guarantee conserved functions. One example was 
demonstrated with ultraconserved elements (UCE), which are regions of the genome that are 
100% identical in sequence between human, mouse, and rat and at least 200 base pairs in length 
(Bejerano et al. 2004). These particular UCEs tended to cluster near genes involved in RNA 
processing, development, or transcriptional regulation, but functional evaluation of 84 UCEs 
using transgenic mouse reporter assays demonstrated that only 51 of them could direct LacZ 
expression (Pennacchio et al. 2006), leaving 33 UCEs without a visable function. It is important 
to note, the 33 nonfunctional UCEs may have had function at different developmental timepoints 
than those assessed by the authors. In another example, four UCEs were deleted in vivo from 
mice (Ahituv et al. 2007), and the resulting mice were viable and had no overt unusual 
phenotypes. While it is possible the mice could have some phenotype below the level of 
detection, this does illustrate the fact that conservation (even extreme levels) does not necessarily 
reflect function.  
Similarly, using phylogenetic footprinting can result in false negatives due to conserved 
functionality without sequence conservation (Fisher et al. 2006; McGaughey et al. 2008). In one 
 11 
case, CREs identified at the human RET locus were able to functionally recapitulate appropriate 
expression patterns in zebrafish, despite lacking sequence conservation between human and 
zebrafish (Fisher et al. 2006). Some potential explanations given by the authors for this result are 
small changes within the transcription factor binding sites, coevolution of the transcription factor 
and the binding site, or rearrangement of individual binding sites within a CRE. Some of these 
issues may be resolved utilizing stringent conservation over short sequence stretches (e.g. tens of 
base pairs or less) rather than arbitrary conservations thresholds over large distance (e.g. 70% 
conservation over hundreds of base pairs). Indeed, studies of Drosophila enhancer evolution 
demonstrated similar confounding issues facing phylogenetic footprinting (Ludwig et al. 2000; 
Berman et al. 2004). 
 
Transgenic Animal Models 
While accuracy in predicting CREs has been increasing through a variety of methods, the need 
for functional assessment is clear. One of the earliest methods for functionally assessing CRE 
transcriptional activity involved fusing upstream flanking DNA near a gene of interest to a 
reporter cassette, often LacZ or GFP. These reporter genes could then be injected into a 
developing embryo such as mouse (DiLeone et al. 1998) or Drosophila (Rubin and Spradling 
1982; Stanojevic et al. 1991; Malicki et al. 1992), allowed to stably integrate randomly into the 
genome, and assessed for spatial and temporal reporter gene expression patterns. These 
experiments were frequently coupled with promoter bashing experiments to try to identify the 
required base pairs within a CRE(s) (Kong et al. 1999; Guo et al. 2002).  
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The first experiment to demonstrate successful expression of an exogenous transgene in 
Drosophila laid the groundwork for future studies focusing on CREs (Rubin and Spradling 1982). 
Some of the earliest work to elucidate the function of CREs was based on transgenic reporter 
assays in Drosophila (Stanojevic et al. 1991; Small et al. 1992). These pioneering studies were 
able to demonstrate a fundamental concept of CREs: combinatorial control. Combinatorial 
control refers to the ability of many CREs working together to regulate the expression of a single 
gene. This concept has been shown for a number of different CREs and has become a defining 
feature of how CREs establish complex expression patterns (Stanojevic et al. 1991; Small et al. 
1992; Ferretti et al. 2005). 
One of the major limitations of transgenic reporter assays was the size of the elements that could 
be tested, generally a few hundred to a few thousand base pairs. This limitation was ameliorated 
with the development of bacterial artificial chromosomes (BACs). BACs are large 
(approximately 200 kilobase pairs) stretches of DNA from any organism that can be stably 
maintained in E. coli (O'Connor et al. 1989). Similar to transgenic reporters, BACs can be 
generated that harbor large portions of a genome, such as human or mouse, which are predicted 
to harbor CREs and overlap the gene of interest. Once the suspected genomic regions have been 
cloned into the BACs, a reporter gene can be inserted into the BAC (either downstream or in 
frame with the gene of interest) which will recapitulate the endogenous gene expression patterns. 
One of the first uses of BACs to identify CREs was performed by DiLeone and colleagues 
(DiLeone et al. 2000). Of note, the authors in this study used co-injection of the BACs with a 
reporter gene plasmid and relied on co-integration of the plasmid at the same site in the genome. 
The authors used a BAC overlapping the Bmp5 gene to recapitulate a majority of the expression 
pattern predicted from previous work using transgenic reporter assays (DiLeone et al. 1998) to 
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describe individual CREs. They went on to study putative CREs in two overlapping BACs and 
were able to identify novel CREs regulating Bmp5 greater than 200 kilobase pairs away from the 
transcription start site. While it was known that enhancers could exert their effects on genes at 
great distances, this work and studies of a sonic hedgehog enhancer demonstrated the extreme 
distances (greater than one million base pairs) CREs can be separated from their target genes 
(Lettice et al. 2002; Lettice et al. 2003).  
One of the major drawbacks of these types of transgenic reporter assays is the inability to control 
the genomic site of integration.  Often the injected linearized transgene can integrate at multiple 
locations in the genome and/or multiple copies can insert into one location in a head-to-tail 
configuration called concatemers (Wilkie and Palmiter 1987; Hamada et al. 1993; Dai et al. 
2010). Additionally, the random nature of the integration can affect the expression of the 
transgene, such as the transgene integrating into a region of heterochromatin and becoming 
silenced. These effects have been termed position effects and represent a major problem in the 
interpretation of the regulatory activity of CREs (Levis et al. 1985). 
One method developed to circumvent random integration utilizes homologous recombination to 
insert a reporter gene into the endogenous locus (Bronson et al. 1996). In this type of experiment, 
a BAC containing the gene of interest is modified to express an in-frame reporter cassette 
flanked by unmodified arms of homology. When this modified BAC is injected into an embryo, 
the arms of homology will allow the BAC to recombine with the wildtype locus to insert the 
modified version of the gene. The reporter gene is now under control of all the endogenous 
CREs (Mansour et al. 1990; Guillot et al. 2000). Similar experiments have been performed 
successfully with yeast artificial chromosomes (Tyas et al. 2006). While single, homology-driven 
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integration experiments can be used to alleviate the random integration problem, the rates of 
homologous recombination are very low. 
A different method to resolve the problem of random integration is site-directed integration, with 
one of the most common methods employing a modified version of the phage integrase ΦC31 
(Thorpe and Smith 1998). This method relies on previously integrated attP sites in the genome of 
the model organism. A transgene can then be inserted directly into a single attP site, if the 
plasmid carrying the transgene also carries an attB site, and ΦC31 integrase is expressed. While 
these initial attP integration sites are random, and subject to the same problems as random 
integration, many different founders with different insertion sites can be prescreened to 
determine any detrimental position effects. This method has been used extensively to 
characterize many CREs in Drosophila (Groth et al. 2004; Bischof et al. 2007; Kvon et al. 2014). 
One of the more exhaustive experiments using this method involved screening 7,705 candidate 
enhancers (Kvon et al. 2014). The authors placed each putative enhancer upstream of a minimal 
promoter and used ΦC31 site directed integration to assess for function using a GAL4 reporter. 
Of the 7,705 regions tested, 3,557 regions displayed some level of activity during at least one 
developmental time point (Kvon et al. 2014). This method has also been used to a lesser extent in 
mice (Tasic et al. 2011).  
 
Luciferase Assays and Next-Generation Sequencing Approaches 
While the transgenic animal experiments discussed above identified many CREs, they were 
limited in a number of ways. Specifically, these experiments were generally focused on a small 
subset of candidate CREs acting on few target genes. Additionally, they were laborious and 
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expensive. Different methods were devised to increase both the number of regions examined and 
shorten the length of time for experiments. One of the first in vitro methods to functionally 
assess CRE activity relied on reporter assays. These methods are nearly identical to those 
described above with a few notable exceptions. First, the transgene is not stably integrated into 
the genome. The plasmid is transiently expressed, and the cells are assessed shortly after 
transfection. Second, the type of reporter gene is different. Before, LacZ or GFP were used to 
visualize CRE function, while the reporter genes luciferase (Wood et al. 1984; Dewet et al. 
1985) or renilla (Matthews et al. 1977) are generally used to assess regions using this in vitro 
method (Sherf et al. 1996). It is important to note, these assays generally rely on immortalized 
cells and may not faithfully recapitulate the in vivo tissues. 
Briefly, the CRE is cloned upstream of luciferase (the gene responsible for producing light in 
fireflies), and the plasmid is transfected into cells. The cells are allowed to grow for a certain 
(generally 48-72 hours) period of time before being harvested, and the proteins are isolated. If 
the substrate for luciferase is mixed into the protein lysate, a certain amount of light will be 
produced which can be detected and quantified by intensity. The amount of light detected for an 
individual CRE directing luciferase is proportional to the amount of luciferase present in the 
protein lysate. This value is indicative of the strength of the CRE directing expression of the 
luciferase reporter, which may (or may not) be reflective of the strength in vivo. These 
experiments generally include a co-transfected control reporter gene (often Renilla) controlled by 
a standardized CRE (such as CMV) to normalize the activity of luciferase to renilla and account 
for different transfection efficiencies and cell viability (Sherf et al. 1996). 
The method described above has been used in many different experiments and in many different 
species (McNabb et al. 2005; Rodda et al. 2005; Antonellis et al. 2008). Despite the prevalence 
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of the use of dual luciferase assays in identifying CREs, there are some limitations, many of 
which are common between luciferase assay and animal transgenic reporter assay. Similarly, 
only relatively short sequences can be assessed in luciferase assays, which may result in false 
positive results. For example, an enhancer being studied may be cloned separated from a 
repressor, which in vivo acts to neutralize the enhancer’s effect. Additionally, while the in vitro 
nature of this experiment eludes position effects confounding the results, the CRE on the plasmid 
does not have endogenous chromatin marks (Reeves et al. 1985; Hebbar and Archer 2008). This 
can also lead to false positive results, if the CRE is endogenously bound up in heterochromatin 
and unable to act in vivo, but is able to function in the in vitro luciferase assays. Another 
limitation of luciferase assays is the use of a minimal promoter. The aim is to identify a single 
core promoter motif that is capable of interacting with multiple CREs, since not all promoters 
can respond to every CRE (Li and Noll 1994; Zabidi et al. 2015). 
Despite these limitations, luciferase assays continue to be used frequently to functionally assess 
CREs. One example exploiting the advantages of luciferase assays was demonstrated by 
Antonellis and colleagues (Antonellis et al. 2010). In this paper the authors identified a patient 
variant within a CRE near myelin protein zero (MPZ). They first used luciferase assays to 
demonstrate that the wildtype allele induced reporter gene activity in relevant cell lines while the 
patient variant was significantly less active compared to the wildtype allele. While luciferase 
assays are by design in vitro (and may not reflect in vivo regulatory activity), the authors utilized 
the knowledge gained to assess the region in vivo in zebrafish. They observed appropriate 
expression patterns in the expected tissues, but were unable to conclusively demonstrate that the 
patient variant altered MPZ expression. Nevertheless, this study demonstrated the ability to 
rapidly assess CREs and putative mutations in relevant cell lines. 
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While luciferase assays are relatively quick to perform, they are still only able to assess a small 
number of predictions at one time. This problem has been partially resolved with two similar 
methods: STARR-Seq (Arnold et al. 2013) and CRE-Seq (Kwasnieski et al. 2012). In these 
methods, candidate CREs are obtained either by synthetic synthesis of approximately 150 base 
pair stretches of oligonucleotides (CRE-Seq) or random sheering of genomic DNA followed by 
size selection (STARR-Seq). The resulting DNA fragments are then cloned into reporter gene 
plasmids (one CRE per plasmid), and the entire pool of plasmids is transfected into millions of 
cells. In the case of CRE-Seq, the plasmids contain a unique barcode that is transcribed at the 
end of the reporter. For STARR-Seq, the CRE is cloned directly within the reporter gene 
transcript. For both CRE-Seq and STARR-Seq, the cells are harvested, DNA and RNA are 
isolated, and next generation sequencing of both the DNA and RNA is performed. The ratio of 
the copies of RNA relative to the copies of DNA can provide a readout of the CRE strength. For 
CRE-Seq, the barcode and the CRE are matched using the DNA sequencing data. STARR-Seq 
does not require this step because the RNA already contains the sequence of the CRE within the 
transcript, and can be used to directly quantify CRE strength.  
An additional advantage of both CRE-Seq and STARR-Seq is the ability to test multiple reporter 
promoter elements, which can help control for promoter-specific affects. One example of this 
was demonstrated by Zabidi and colleagues (Zabidi et al. 2015), where the authors used STARR-
Seq to test an identical set of candidate enhancers with either the Ribosome protein gene 12 
(RpS12) core promoter or a synthetic core promoter. The authors were able to demonstrate only 
32% of the 9,542 candidate enhancers tested were able to function with either promoter element. 
The remaining enhancers activated one of the promoter elements at least two fold more than the 
other promoter (Zabidi et al. 2015).  
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Electromobility Gel Shift Assays (EMSAs) 
While luciferase assays and massively paralleled reporter assays such as STARR-Seq (Arnold et 
al. 2013) and CRE-Seq (Kwasnieski et al. 2012) continue to help uncover novel CREs, another 
in vitro method used to assess if CREs can bind to a candidate sequence are electromobility gel 
shift assays (EMSAs) (Fried and Crothers 1981; Garner and Revzin 1981). These assays involve 
generating a labeled DNA probe (using either radioactivity or more recently using biotinylation) 
that contains the locus-specific, predicted transcription factor binding site. These probes are then 
mixed with protein extract from the cell or tissue of interest, the transcription factors are allowed 
to bind to the probes, the complex is run on a gel, and the probe-transcription factor complex is 
detected as a high shift relative to unbound probe. The addition of high concentrations of cold 
(unlabeled and wild-type or mutated) competitor probes are used to demonstrate the specificity 
of observed DNA:protein interactions. Similar to other methods, the decision about what specific 
sequence to use can greatly affect the results. EMSAs are more sensitive to this limitation 
because the probes are much shorter (50-100 base pairs) than regions assessed in other in vitro 
functional assays. 
While this traditional form of EMSA can detect proteins interacting with the DNA probe, it was 
difficult to know what protein is responsible for the interaction. New iterations of EMSAs were 
developed to alleviate this problem. One method, termed supershift assays, involves the addition 
of an antibody against the predicted transcription factor (Kristie and Roizman 1986), (Gille et al. 
1997). The addition of the antibody against the predicted protein results in a higher shift 
(supershift) relative to the protein-DNA complex alone. Another potential outcome in supershift 
assays is that the antibody disrupts the protein’s ability to bind DNA. This results in the loss of a 
band, rather than the supershift observed in other situations (Ou et al. 2003). A major limitation 
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of supershift assays, similar to ChIP experiments, is that they require highly specific antibodies 
(see above).  
Another variation of EMSA employed to specifically identify the protein of interest uses 
recombinant protein rather than protein lysate. This results in only one protein being present to 
bind the probe, and any resulting shift must be due to the recombinant protein (Hunt and Jackson 
1974; Zhang et al. 1998). One potential pitfall with using recombinant protein rather than protein 
lysate is the potential dependence on co-factors. For example, if the recombinant protein requires 
an additional protein to bind DNA, the EMSA may fail to result in a shift, even though the probe 
may contain a functional CRE. 
 
General Characteristics of CREs 
Through the use of the above-described (and other) functional assays, many CREs have been 
discovered. These pioneering experiments on CREs have lead to some general guidelines about 
what defines a CRE. As stated above, CREs can function over great distances, sometimes greater 
than one megabase pairs away (Lettice et al. 2002; Nobrega et al. 2003). In addition, it has been 
proposed that CREs can function in orientation-independent fashion relative to the promoter 
(Banerji et al. 1983; Rogers et al. 1986).  
Yet, most of these initial experiments demonstrating CRE orientation independence were 
performed in an in vitro transgenic reporter assay, which may not recapitulate the endogenous 
activity. Indeed, orientation-dependent enhancer activity has been demonstrated in transgenic 
mice harboring the wildtype enhancer in either the endogenous or inverted orientations 
(Swamynathan and Piatigorsky 2002). The authors saw significantly reduced gene expression 
 20 
when the enhancer was in the inverted orientation relative to the wildtype. Another example of 
orientation-dependent activity was demonstrated when a GATA-1 enhancer was examined 
(Nishimura et al. 2000). The authors observed orientation independence of the enhancer when 
tested in vitro using a luciferase assay; however, when these constructs were examined in mice, 
the orientation of the enhancer was necessary for proper activity. Transgenic mice that carried 
the enhancer in the endogenous orientation showed LacZ expression in six out of nine embryos 
(the authors attribute position effects to the three negative embryos) but they failed to detect any 
LacZ expression in eight mice that contained the transgene with an inverted enhancer. 
While it remains unclear exactly how orientation generally affects CREs, the location 
independence (Grosveld et al. 1987) of CREs has been repeatedly demonstrated. CREs can 
function either upstream or downstream of the regulated gene, and in some cases in the introns of 
non-target genes (ENCODE Project Consortium 2012). How can these CREs exert their effects 
at long distances from their targets across the genome? Currently, the most supported model to 
explain CRE function is the looping model. 
The looping model was first described by Dunn and colleagues (Dunn et al. 1984). In this paper, 
the authors studied a repressive element at the L-arbinose operon in E. coli. They demonstrated 
that by altering the position of the CRE relative to the promoter element by increments of 10 
base pairs (approximately one turn of the DNA helix) they were able to preserve the repressive 
effects. Comparatively, when they altered the CRE by increments of five (half the turn of a DNA 
helix) the repressive effects were lost. From this, the authors deduced that the DNA is looping 
back on itself to bring the CRE and the promoter into close proximity (Dunn et al. 1984). The 
DNA looping model was further supported by electron microscopy of λ repressors binding 
cooperatively to two binding sites and bending DNA when separated by five helical turns. If the 
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binding sites are separated by non-integer turns, such as 4.5 or 5.5 turns, the DNA bending effect 
was lost (Griffith et al. 1986).  
 
Chromosome Conformation Capture Technologies 
In addition to the studies described above, many other experiments have supported the DNA 
looping model. A new method, chromosome conformation capture (3C), was developed to 
exploit this model to functionally assess CREs (Dekker et al. 2002) (Figure 1.2). In this method, 
the DNA and proteins are first crosslinked to maintain the interaction between the CRE and the 
promoter of the target gene. The underlying principle is based on the DNA looping model, where 
the CRE element is bound by the transcription factor, the DNA loops to bring the transcription 
factor into close proximity with the basal transcription machinery and ultimately the promoter of 
the target gene. The DNA is then digested with restriction enzymes, the protein-DNA crosslink is 
reversed by degrading the proteins, and PCR using primers designed within the CRE and the 
promoter can be performed to detect the interaction. This technology has been used extensively 
to validate many interactions of CREs and their target genes (Tolhuis et al. 2002; Murrell et al. 
2004; Spilianakis et al. 2005; Gheldof et al. 2010). 
One of the limitations of 3C technologies is that prior knowledge of both the CRE and the target 
gene are required to design primers. While it has been suggested that 3C can be used to validate 
predicted CREs and target gene interactions (Gheldof et al. 2010), different iterations of 3C have 
been developed to eliminate the need for prior knowledge of both interacting partners. The first 
method developed was circularized chromosome confirmation capture (4C) (Zhao et al. 2006). 
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Figure 1.2 DNA Looping Model and Chromatin Conformation Experiments. (A) A general 
schematic of a gene, with a promoter element and upstream cis-regulatory element (CRE). The 
blue boxes represent exons, the arrow represents the transcription start site, and prom represents 
the promoter. The green triangle is a transcription factor, and the red hexagon represents the 
basal transcription machinery. (B) For the CRE to act on the promoter of a gene, the DNA must 
form a loop to ultimately bring the CRE and promoter into close proximity (DNA looping 
model). (C) In preparation for a chromosome conformation capture experiment, the proteins and 
DNA are crosslinked and subjected to restriction enzyme digest. (D) The sticky ends are ligated, 
and the proteins are digested to link the CRE and the promoter together. The plasmid is then 
processed for the corresponding technique (see text for details). The purple boxes represent the 
religated sticky ends. For 3C and 4C the orange arrows represent primers and the dashed line 
represent amplified PCR product. For 4C, the linear fragment is digest and ligated a second time 
to form a “plasmid”. For 5C the arrows represent complementary probes, and the green and blue 
lines are adapters. For Hi-C, the red lines with circles represent biotinylated nucleotides, and the 
blue boxes are next generation sequencing (NGS) adapters. 
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The methodology for 4C is identical to 3C, however, rather than performing PCR on the 
linearized fragment, the DNA is subjected to an additional restriction enzyme digest and the 
resulting DNA is ligated together. Because the fragment containing the CRE and the promoter 
has been circularized, it is only necessary to know one interacting partner. Primers are designed 
within the known sequence, and inverse PCR is used to detect the unknown interacting partner. 
While in theory 4C can be used to detect novel interactions between CREs and promoters, in 
practice only a small number of experiments have demonstrated this utility (Verdin et al. 2015). 
Similar to 3C, 4C is limited by the requirement of prior knowledge of one interacting partner. 
The next iteration of 3C technologies to alleviate this problem was carbon-copy chromosome 
confirmation caption (5C) (Dostie et al. 2006). This method is, again, very similar to 3C and 4C 
until the protein crosslinking is reversed. In 5C technology, large pools of single-stranded probes 
are designed immediately flanking the restriction sites used within the genome of interest. The 
probes are allowed to bind to the DNA and are ligated together. In addition, the probes have 
adapters on the ends to facilitate additional amplification by PCR and ultimately detection by 
microarrays or next generation sequencing. 5C technologies remove the requirement for knowing 
either interacting partner. Similar to 4C, 5C has been used only a limited number of times to 
detect novel interactions (Fraser et al. 2009; Bau et al. 2011). This may be reflective of the large 
number of probes necessary for a 5C experiment. Additionally, not all restriction enzyme sites 
may have a probe flanking the cut site, which will result in false negatives. 
While each of the chromosome capture technologies has been used to detect known and novel 
CRE interactions, none have the resolution to detect all interactions within a cell. The most 
current improvement in chromosome capture technologies solves this problem with Hi-C 
(Lieberman-Aiden et al. 2009). Similar to the other chromosome capture technologies, Hi-C 
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involves crosslinking and restriction enzyme digest, however the molecules are not ligated 
together. Instead, the sticky ends are filled in with nucleotides, where one nucleotide, specifically 
cytosine, is biotinylated. The fragments are then blunt-end ligated together, the DNA is sheared, 
and the interaction junction is purified using streptavidin beads in preparation for next generation 
sequencing. Unlike the other chromosome capture technologies, Hi-C has the resolution to define 
all DNA-DNA interactions within a cell. Indeed, many studies have used Hi-C (and slight 
variations) to characterize putative CREs and their interactions within the cell (Lan et al. 2012; 
Martin et al. 2015).   
 
The Encyclopedia of DNA Elements (ENCODE) Consortium 
While each of the prediction methods and functional assays have been used to great success in 
annotating CREs, the most effective strategies to detect CREs involve combinations of many of 
the assays previously described. Perhaps the best example for this comes from the encyclopedia 
of DNA elements (ENCODE) consortium (Birney et al. 2007). One of the aims of the ENCODE 
consortium is to identify all functional CREs within the human genome. To this end, ENCODE 
employed a number of relevant assays previously discussed including DNase-Seq, ChIP-Seq, 
and 5C (or Hi-C) experiments across a large number of cell lines and tissues. In the most recent 
publications, the ENCODE consortium claimed, “The vast majority (80.4%) of the human 
genome participates in at least one biochemical RNA- and/or chromatin-associated event in at 
least one cell type. (Birney et al. 2007)” This claim has been meet with criticism, perhaps most 
chiefly by the definition of ‘function’ and ‘event’ as well as the lack of attention paid to 
evolutionary constraints (Graur et al. 2013). Nonetheless, the ENCODE datasets have increased 
our knowledge about CREs and their function throughout the genome and have supplied 
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valuable datasets for the scientific community to perform additional physiological relevant 
studies. 
Perhaps the methods that benefitted the greatest from ENCODE’s large datasets were the 
transcription factor binding site prediction algorithms. By aligning ChIP-Seq datasets for one 
specific transcription factor, a consensus binding site motif or position weight matrix (PWM) 
(Stormo et al. 1982) can be generated. PWMs were generated prior to the ENCODE datasets, 
often using a technique called SELEX (systematic evolution of ligands by exponential 
enrichment) (Tuerk and Gold 1990) to identify sequences transcription factors will bind to. In 
this experiment, pools of double-stranded DNA oligonucleotides of random sequence are 
combined with the transcription factor of interest. The transcription factor is allowed to bind to 
the DNA oligonucleotides, the protein-DNA complex is isolated, the DNA is PCR amplified, and 
the process is repeated with the enriched sequences. Through multiple rounds of selection, the 
strongest and most specific DNA-protein interactions will be purified. The resulting pool of 
oligonucleotides can be sequenced to generate the in vitro preferred binding site (Tuerk and Gold 
1990). 
The limitations of SELEX experiments are similar to EMSA experiments (e.g., potential need for 
a co-factor, in vitro binding sites may not reflect in vivo binding, non-specific binding due to in 
vitro conditions), however SELEX has been used successfully to generate PWMs of many 
transcriptions factors (Wright et al. 1991; Robison et al. 1998; Yagura and Itoh 2006; Jolma et al. 
2013). One potential use of the data generated from SELEX experiments is to use the PWM 
generated to identify novel transcription factor binding sites within a genome of interest. While 
there are many programs that have been used to accomplish this task, the two most commonly 
used are TRANSFAC (Wingender 1988; Matys et al. 2003) and JASPAR (Sandelin et al. 2004).  
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Both TRANSFAC and JASPAR are similar in that they collect functional data from the literature 
about transcription factor binding sites and combine them together to generate PWMs for 
individual transcription factors. This allows investigators to extract the PWMs and identify novel 
transcription factor binding sites genome wide, or conversely, upload a region of interest and 
allow the programs to predict what transcription factors may be acting on the sequence (Kel et al. 
2003). A major limitation of these programs is the reliance on the initial starting datasets to 
provide accurate PWMs which initially often came from experiments like SELEX, which can 
result in poor PWMs (Frech et al. 1997). Additionally the low number of datasets used to 
generate a PWM results in inaccurate predictions of protein-DNA interactions (O'Flanagan et al. 
2005). The ENCODE consortium datasets have started to address the limitations of TRANSFAC, 
JASPAR, and similar programs by providing large datasets generated from multiple 
experimental conditions and across may diverse cell and tissue types. 
 
CREs in Human Disease 
Another interesting observation from the ENCODE consortium was the effect of variation on 
transcription factor binding sites within humans and how these variations can affect human 
diseases (Boyle et al. 2012; ENCODE Project Consortium 2012; Schaub et al. 2012). 
Specifically, many of the significant single nucleotide polymorphisms (SNPs) identified from 
genome-wide association studies reside within non-coding regions of the genome, rather than 
gene-coding regions (Schaub et al. 2012). These studies, and others, are currently trying to 
understand the functional effects (if any) of the disease associated SNPs on CREs. 
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While the ENCODE consortium has produced vast datasets and has begun to understand the role 
of CREs in human disease, it is certainly not the first effort to do so. Indeed, many of the first 
CREs characterized in humans were identified by their phenotypic effects. One of the earliest 
examples was demonstrated in the human blood disorders thalassemias—a group of inherited 
blood disorders that disrupt α- and β-globin levels (Marengo-Rowe 2007). These diseases 
generally result from coding mutations within either the α-globin (α-thalassemia) or β-globin (β-
thalassemia) genes; however, a subset of patients were identified that did not contain coding 
mutations yet still suffered from β-thalassemia (Kioussis et al. 1983; Driscoll and Dobkin 1989). 
Upon further inspection, a translocation of the 5’ upstream regions (harboring CREs), which was 
sensitive to DNase I digestion, was the cause of the disease. This region was later termed the 
locus control region (LCR), which contains many different individual CREs, whose combined 
input directs appropriate spatial and temporal gene expression of linked genes, in this case the 
globin genes.  
From this initial characterization, many different translocations and mutations have been 
observed in the LCR. In addition to β-globin, mutations have been observed within CREs 
regulating α-globin. Of particular note is a pathogenic SNP located between the α-globin gene 
cluster and the upstream regulatory elements identified in a patient with α-thalassemia (Gobbi et 
al. 2006). In this study, the authors were able to identify seven previously uncharacterized SNPs 
within the disease-associated region, however only one SNP was specific to the α-thalassemia 
genotype. This SNP creates a novel GATA-1 binding site resulting in a promoter-like element 
that hijacks the upstream CREs and leads to decreased α-globin expression by outcompeting the 
endogenous α-globin promoter, and ultimately causes the α-thalassemia phenotype in patients 
(Gobbi et al. 2006). 
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Another example of defects in CREs resulting in human disease was demonstrated at the gene 
POU3F4. Mutations within POU3F4 result in X-linked deafness in humans (DFN3) (de Kok et 
al. 1995). It was noticed, however, that a cohort of patients with DFN3 did not contain mutations 
within POU3F4 but harbored deletions approximately 400 kilobase pairs upstream of POU3F4. 
This region was further mapped with greater numbers of patients who had variable deletions that 
overlapped to a minimal eight kilobase pair region approximately 900 kilobase pairs upstream of 
POU3F4 (deKok et al. 1996). 
While there are many examples where mutations or deletions within CREs result in human 
diseases, there are a growing number of examples of SNPs that modify either the risk or severity 
of human disease. These SNPs are generally referred to as regulatory SNPs (rSNPs), and they 
exert their effect by altering transcription factor binding sites and ultimately disrupting the 
endogenous protein-DNA interaction (Figure 1.3 - adapted from (Chorley et al. 2008)). This can 
result in an up- (Feigelson et al. 1998) or down-regulation (Bosma et al. 1995) in the target gene, 
complete ablation of the binding site (Vasiliev et al. 1999), or creation of a novel transcription 
factor binding site (Knight et al. 1999; Gobbi et al. 2006). 
One example of a rSNP altering disease risk was demonstrated at the RET locus. Mutations 
within RET cause Hirschsprung disease - a disorder characterized by the loss of the enteric 
neurons (Parisi 2015). A subset of patients were identified with Hirschsprung disease that lacked 
overt coding mutations within RET, despite the disease-associated region overlapping RET 
(Emison et al. 2005). The region was narrowed down to the first intron of RET, and the authors 
employed phylogenetic footprinting to identify a functional CRE. This CRE contained a single 
rSNP that resulted in the mutant minor allele conferring a 2.1-5.7 times greater disease risk  
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Figure 1.3 Potential Regulatory SNP (rSNP) Effects on Gene Expression. (Top) Schematic of a 
gene with an upstream enhancer element bound by a transcription factor (TF). The purple boxes 
are exons, the transcription start site (TSS) is marked by the arrow, and the letters in the grey box 
upstream represent a transcription factor binding site (TFBS). The red letter indicates a rSNP (A 
to C). In this scenario, a certain amount of mRNA is produced and depicted by the blue lines. 
(Below) The potential outcomes of a rSNP on TFBS affinity, and ultimately on mRNA 
production. The number of blue lines indicates an increase (more lines) or decrease (less lines) in 
mRNA. The red “X” indicates no mRNA expression and the “?” indicates the gene is under 
control of a novel transcription factor and the spatial and temporal mRNA expression is 
unknown. Figure adapted from Chorley et al. 2008. 
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compared to the major allele (Emison et al. 2005). The authors further evaluated this mutation 
and demonstrated the mutation disrupted a SOX10 binding site (Emison et al. 2010). 
 
The Transcription Factor SOX10 
While many of the genome-wide experiments described above to identify CREs can be 
performed in a transcription factor independent manner (DNase-Seq, STARR-Seq, Cre-Seq, ect.), 
using a transcription factor-centric approach may lead to a greater understanding of transcription 
hierarchies in a particular cell line (or tissue) of interest. Since the aim of this thesis work is to 
identify CREs and rSNPs critical for the peripheral nervous system, utilizing a transcription 
factor-centric approach for a relevant transcription factor in Schwann cells may provide a deeper 
understanding of transcriptional hierarchies regulating Schwann cell development. The 
transcription factor SOX10 resides atop the transcriptional hierarchy and is involved in the 
regulation of many genes critical for Schwann cell development (discussed in detail below). 
Therefore, we decided to utilize the knowledge of SOX10 binding sites to identify novel SOX10 
responsive CREs harboring rSNPs and SOX10 regulated genes critical for Schwann cells. 
SOX10 was first identified from a RT-PCR screen using total RNA isolated from mouse 
embryos (Wright et al. 1993). This was performed using degenerate primers targeting the high 
mobility group (HMG) box, a 79 amino acid DNA binding domain, and the resulting products 
were sequenced to identify novel SOX genes, including SOX10. SOX10, and all SOX family 
members, are grouped together based on homology of the HMG domain with the sex-
determining region Y chromosome (SRY) and are further subdivided based on homology of the 
HMG domain to other SOX family members. (Gubbay et al. 1990). The HMG superfamily 
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consists of gene families grouped together based on the variable number of HMG domains and 
the DNA binding sequence specificity (Laudet et al. 1993). SOX protein family members are a 
subset of the HMG domain containing superfamily. They are distinct due to the presence of a 
single HMG domain which binds DNA in a sequence specific manner (Nasrin et al. 1991) and 
must share at least 50% identity with the SRY HMG domain. The SOX family proteins bind to 
the minor groove of the DNA helix, generally to the sequence 5’-(A/T)(A/T)CAA(A/T)G-3’ 
(Harley et al. 1992; Laudet et al. 1993; Harley et al. 1994). 
The SOX family of proteins can be further subdivided into eight currently recognized 
subfamilies based on primary amino acid sequence (Bowles et al. 2000). SOX10 resides with the 
SOXE subfamily along with SOX8 and SOX9, which share greater than 90% identity of the 
HMG domain (Wright et al. 1993). While these proteins are very similar, they are not entirely 
functionally redundant, as evidenced by the replacement of Sox10 with Sox8 in mice (Kellerer et 
al. 2006). The replacement of Sox10 with Sox8 was able to rescue the phenotype of Sox10 null 
mice to various degrees in various tissues. For example, the peripheral nervous system was 
nearly normal, while Sox8 was unable to fully rescue the defects observed in melanocytes and 
enteric neurons in Sox10 null mice (Kellerer et al. 2006). 
 
SOX10 Structure 
SOX10 is 466 amino acids long and contains four major domains: dimerization domain, HMG 
domain, K2 domain, and transactivation domain (Figure 1.4). The dimerization domain 
encompasses amino acids 61-101 and allows SOX10 to dimerize as both a homodimer and 
heterodimer (Peirano and Wegner 2000; Schlierf et al. 2002). A homodimeric SOX10 binding 
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site consists of two monomeric sites, oriented in a head-to-head fashion with an intermonomeric 
sequence. For example, one core monomeric site may be 5’-ACAAA-3’ while the other core 
monomeric site will be the reverse complement of the consensus site 5’-TGTGT-3’. The two 
monomeric sites are separated by an intermonomeric sequence spacer that varies in size, 
however a six base pair spacer is most often observed (Schlierf et al. 2002). This is likely due to 
both monomeric sites residing on the same face of the DNA helix (i.e. 10 total base pairs from 
position one of one monomer to position one of the second monomer). 
The HMG domain consists of amino acids 101-180 and allows SOX10 to bind to DNA in the 
minor groove (Peirano and Wegner 2000). Upon SOX10 binding to DNA, a bend is induced in 
the DNA helix of approximately 75-80° or 103-122° for monomeric or dimeric sites respectively 
(Schlierf et al. 2002). This observation has lead to the hypothesis that SOX10 not only regulates 
target genes but also alters the three-dimensional chromatin architecture (Giese et al. 1992). 
While the general consensus sequence for SOX family members is 5’-(A/T)(A/T)CAA(A/T)G-3’, 
the SOX10 core consensus sequence is altered slightly (all listed 5’ to 3’): ACAAA, ACACA, 
ACAAT, or ACAAG (Srinivasan et al. 2012; Brewer et al. 2014). The reverse compliment of 
each sequence can also function as a monomer. 
The K2 domain contains amino acids 233-306, and its function remains unclear. The K2 domain 
has been termed a “cell-specific transactivation domain” (Schreiner et al. 2007). Evidence for 
this comes from transgenic mouse studies where the endogenous Sox10 locus was replaced with 
a SOX10 mutant lacking the K2 domain. Upon loss of the K2 domain, both early neural crest 
development and oligodendrocyte differentiation remained unaffected. In contrast, Schwann cell  
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Figure 1.4 SOX10 Protein Domain Structure. The four major of SOX10 are displayed: 
dimerization domain (DIM; blue box), HMG domain (HMG; yellow box), K2 domain (K2; 
green box), and transactivation domain (TA; orange box). The numbers on the top are the amino 
acids numbered from the N to C terminus. All domain boxes sizes are accurate relative to size of 
SOX10. 
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myelination, melanocyte development, and enteric nervous system development were all 
disrupted to various degrees (Schreiner et al. 2007). For example in Schwann cells, two myelin 
genes (MPZ and MBP) were not expressed in mice lacking the K2 domain. These data suggest 
the K2 domain can activate gene expression in a cell type-dependent fashion. 
Compared to the K2 domain, the transactivation (TA) domain is the main activation domain used 
to regulate SOX10 target genes. The TA domain resides on the extreme C terminus of SOX10, 
from amino acids 400-466. Additionally, the TA domain is sufficient to induce reporter gene 
activity (Pusch et al. 1998). Loss of the TA domain of SOX10 results in complete inability to 
activate target genes in vitro (Bondurand et al. 2000; Potterf et al. 2000). Loss of the TA domain 
in humans results in a very severe syndrome PCWH (discussed below), a very severe syndrome 
affecting many different tissue types. 
 
SOX10 Functions in the Neural Crest and Oligodendrocytes 
As briefly discussed above, loss of SOX10 (or portions of SOX10) can result in multiple tissue 
types being affected, specifically tissues derived from the neural crest or oligodendrocytes. Of 
note, because the main focus of this thesis work is on Schwann cells, the remainder of the 
chapter will focus on the role of SOX10 in the neural crest or Schwann cells. Perhaps the earliest 
example of the role of SOX10 in neural crest development was a spontaneous mutation that 
arose in mice termed Dom (Dominant meglacolon) (Lane and Liu 1984; Herbarth et al. 1998; 
Southard-Smith et al. 1998). This mouse displays symptoms similar to patients with 
Hirschsprung disease, and the mutation was mapped to Sox10. The authors further characterized 
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Sox10 expression patterns using in situ hybridization and observed expression in both the neural 
crest and the migrating neural crest derivatives (Southard-Smith et al. 1998). 
The neural crest is a highly migratory cell population that is formed when the neural plate fuses 
to generate the neural tube. The neural crest cells first migrate ventrally, and then dorsolaterally 
giving rise to many distinct tissues including: melanocytes, enteric neurons, sensory neurons and 
glia of the dorsal root ganglia, and Schwann cells (Erickson and Reedy 1998).  
SOX10 plays a critical role in neural crest cells, despite SOX10 being dispensable for neural 
crest formation. Neural crest cells can be observed in mice containing a homozygous deletion for 
Sox10 (Paratore et al. 2001); however, significant cell death is observed later in development, 
suggesting that SOX10 is necessary for the survival of neural crest stem cells. There also appears 
to be an additional requirement for SOX10 in the peripheral nervous system. This was observed 
in neural crest stem cells generated from either Sox10 heterozygous or homozygous deletion 
mice exposed to gliogenic conditions. Despite the gliogenic conditions resulting in large 
numbers of glia cells in wild-type neural crest stem cells, no glial features were detected in the 
Sox10 deleted neural crest stem cells in the same conditions (Paratore et al. 2001). Similarly, 
Sox10 expression continues in both melanocytes and glia, but its expression is turned off in other 
neural crest derivatives (Herbarth et al. 1998; Kuhlbrodt et al. 1998; Pusch et al. 1998; Britsch et 
al. 2001). 
 
SOX10 is Necessary for Schwann cells 
Schwann cells are the myelinating cells of the peripheral nervous system, and as previously 
discussed, they originate from the neural crest. Schwann cells can be divided into two main 
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classes: myelinating and nonmyelinating (Jessen and Mirsky 2005). The Schwann cell precursors 
differentiate between these two types in a process called radial sorting. In this process, Schwann 
cell precursor cells associate with axons. If the precursor cell associates with a large (i.e greater 
than 1 μM) diameter axon, then the precursor will become a myelinating Schwann cell and form 
a one-to-one relationship with the axon (Martin and Webster 1973; Jessen and Mirsky 2005). 
This is in contrast to oligodendrocytes, the myelinating cells in the central nervous system, where 
one cell can myelinate many axons at once. Nonmyelinating Schwann cells can associate with 
multiple small (i.e. less than 1 μM) diameter axons and form Remak bundles. While these cells 
do not generate myelin, they do ensheath small diameter axons with their cytoplasm (Jessen and 
Mirsky 2005). 
The differentiation process from a migrating neural crest cell into either a myelinating or 
nonmyelinating Schwann cell involves many different transcription factors and genes. 
Interestingly, Sox10 remains expressed throughout the differentiation process and is necessary 
for all stages of myelinating Schwann cell development. Loss of Sox10 in migrating neural crest 
cells results in cell death prior to glial differentiation (Britsch et al. 2001; Paratore et al. 2001). 
Conditional deletion of Sox10 in the immature Schwann cell stage results in lethality in mice 
(Finzsch et al. 2010). Additionally, loss of Sox10 in Schwann cells of adult mice results in severe 
myelination defects, despite the Schwann cells still remaining in mice (Bremer et al. 2011). This 
suggests that SOX10 may play a larger role in both the differentiation process and maintenance 
of the mature differentiated state, rather than survival. Taken together, these data demonstrate 
SOX10 is necessary for both development and maintenance of Schwann cells. 
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SOX10 Target Genes and Transcriptional Hierarchy in Schwann Cells 
SOX10 regulates many target genes necessary for Schwann cell development. One of the earliest 
in Schwann cell development is ErbB3 (Figure 1.5), which allows Schwann cell precursors to 
respond to Neuregulin 1 (Nrg1). NRG1 signaling is critical for inhibiting neuronal development 
and allowing Schwann cells to develop normally (Shah et al. 1994). While Sox10 does not 
regulate Nrg1, it does directly regulate a critical Nrg1 receptor, ErbB3 (Britsch et al. 2001; 
Prasad et al. 2011). In the absence of ErbB3, Schwann cell precursors are unable to respond to 
Nrg1 signaling meaning they cannot proliferate and are subsequently lost (Britsch et al. 1998). 
Another critical transcription factor for developing Schwann cells is OCT6 (POU3F1). OCT6 is 
required for the transition from promyelin cells to myelinating Schwann cells (Jaegle and Meijer 
1998; Mandemakers et al. 2000). A critical CRE, termed the SCE or Schwann cell enhancer, is 
both necessary and sufficient to direct appropriate spatial and temporal Oct6 expression patterns 
(Mandemakers et al. 2000). Within the SCE is a dimeric SOX10 binding site, which is necessary 
for SCE function, indicating that SOX10 directly regulates Oct6 (Jagalur et al. 2011). 
Upon upregulation of Oct6 by SOX10 and other transcription factors, SOX10, Oct6, and Brn2 
(Pou3F2), a closely related transcription factor to Oct6 with similar expression patterns, act 
synergistically to activate Egr2 (Krox20) expression through an enhancer termed the myelinating 
Schwann cell element (MSE) (Ghislain and Charnay 2006). Egr2 has many characteristics of a 
“master regulator of myelination” (Ghislain and Charnay 2006), and as such, mutations in EGR2 
have been identified in patients with demyelinating peripheral neuropathies (Warner et al. 1998). 
Additionally, no myelination is observed in Egr2 homozygous knockout mice because the 
Schwann cells are halted at the promyelinating stage (Topilko et al. 1994). Finally, Egr2 has 
been shown to regulate many genes necessary for myelination (Nagarajan et al. 2001). 
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Figure 1.5 Transcriptional Hierarchies in Schwann Cells. One of the earliest known targets of 
SOX10 in Schwann cell development is ErbB3. This gene is a receptor for neuregulin 1 signaling 
that is necessary for inhibiting neuronal differentiation and allows Schwann cell precursors to 
proliferate. Sox10 upregulates Oct6 expression through the Schwann cell enhancer (SCE) in 
immature Schwann cells, which then acts synergistically with Sox10 and Brn2 at the myelinating 
Schwann cell enhancer (MSE) to upregulate Egr2. Upon activation of Egr2, promyelinating 
Schwann cells become mature myelinating Schwann cells and Sox10 and Egr2 regulate many 
myelination genes including Pmp22. Boxes with arrows represent genes, shapes represent 
transcription factors, colored boxes represent cis-regulatory elements (CRE), and arrows from 
the CRE to the gene represents activation.  
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In addition to regulating other transcription factors necessary for myelination, SOX10 also 
directly regulates, either independently or synergistically with other transcription factors (often 
EGR2), many myelin-associated genes including PMP22 (Jones et al. 2011b), MPZ (Peirano et 
al. 2000), GJB1 (CX32) (Bondurand et al. 2001), and CNTF (Ito et al. 2006). Combined, these 
data demonstrate a transcriptional hierarchy in Schwann cells with SOX10 acting as an essential 
transcriptional regulator at all Schwann cell developmental stages (Figure 1.5). 
 
Mutations in SOX10 and Target Genes 
Not surprisingly, mutations within human SOX10 result in various neurocristopathy symptoms 
depending on the specific type of mutation. These mutations can manifest as Waardenburg-
Hirschsprung disease (WS4) (Pingault et al. 1998) or as a more severe syndrome termed PCWH 
(peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg 
syndrome, and Hirschsprung disease) (Inoue et al. 2002). The discrepancy between these two 
distinct phenotypes depends on the type of SOX10 mutation. Mutations that cause a premature 
stop codon and undergo nonsense-mediated decay, resulting in haploinsufficiency, are associated 
with the more mild Waardenburg-Hirschsprung disease. This disease is essentially the 
combination of both Waardenburg syndrome and Hirschsprung disease. It is characterized by 
hypopigmentation of the hair and skin, heterochromia irides, and impaired hearing 
(Waardenburg syndrome) combined with aganglionic megacolon (Hirschsprung disease) 
(Omenn et al. 1979). Comparatively, mutations that cause a premature stop codon, but escape 
nonsense mediated decay, are associated with the more severe PCWH phenotype. The additional 
phenotypes observed in patients underscores the additional role of SOX10 in central nervous 
system myelination, specifically through the expression of SOX10 in oligodendrocytes. The 
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molecular mechanism of PCWH was first elucidated by Inoue and colleagues (Inoue et al. 2004), 
where they demonstrated mutations associated with PCWH act by a dominant-negative 
mechanism, ultimately resulting in a more severe (greater than 50%) depletion of SOX10 
function. 
In addition to the peripheral neuropathy observed in patients with PCWH, mutations within 
SOX10 target genes result in peripheral neuropathies. One example in particular is Charcot-
Marie-Tooth (CMT) disease, which is characterized by distal muscle wasting and sensory loss 
(Dyck and Lambert 1968; Szigeti and Lupski 2009). CMT can be subdivided into two major 
classifications based on motor nerve conduction velocities (MNCVs). Patients with CMT type 1 
(CMT1) have reduced MNCVs due to the primary defect arising in the Schwann cells. 
Conversely, patients with CMT type 2 (CMT2) have normal MNCVs, but reduced amplitude 
because the primary defect is in the axon (Pagon et al. 1993). 
Unsurprisingly, many genes critical for proper myelination in Schwann cells also are mutated in 
CMT1: PMP22 (Lupski et al. 1991; Raeymaekers et al. 1991), MPZ (Kulkens et al. 1993), 
(Hayasaka et al. 1993), and GJB1 (Ionasescu and Searby 1994). All of these genes are regulated 
by SOX10 (discussed above). In addition, mutations within SOX10 binding sites at some of 
these genes have been reported to cause CMT. One such example was observed at the PMP22 
locus which is duplicated in patients with CMT1A (Lupski et al. 1991; Raeymaekers et al. 1991). 
Patients with CMT1A were identified that did not harbor the PMP22 duplication, but rather the 
upstream genomic regions were duplicated resulting in a milder form of CMT (Weterman et al. 
2010). Recent work identified functional EGR2 and SOX10 binding sites within the upstream 
duplicated regions which were able to direct appropriate peripheral nerve expression patterns 
within zebrafish (Jones et al. 2011a). Additionally, mutations within the GJB1 promoter have 
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been shown to cause CMT (Houlden et al. 2004). These mutations disrupt a SOX10 monomeric 
site and ultimately lead to reduced levels of GJB1 expression. 
Another example was demonstrated at the MPZ locus. A rare, non-coding variant was detected in 
a patient with hypomyelination in the central nervous system (Antonellis et al. 2010). This 
variant disrupted a SOX10 binding site, and was shown to be less active in luciferase assays; 
however the authors were unable to implicate the variant in human disease. This variant may be 
causative for human disease, or perhaps this variant functions as a modifier of disease. 
Indeed, large phenotypic variability such as age of onset from the first to seventh decade and 
severity of sensory loss is observed in patients with CMT, often despite identical coding 
mutations (Thomas et al. 1997; Pareyson et al. 2006; Pareyson and Marchesi 2009). This 
variability was even described in two sets of unrelated identical twins with identical duplications 
of PMP22 (Garcia et al. 1995). The cause of this variability is unknown, however rSNPs may 
provide an explanation. For example, if two individuals have a duplication of PMP22 (resulting 
in CMT1A), and one individual has the major allele and the other has the minor allele at a 
specific rSNP, this may account for some of the phenotypic variability observed. The rSNP in 
this case could be located in the upstream SOX10 binding sites at PMP22 and thus possessing 
the allele that disrupts SOX10 binding could be beneficial due to decreased PMP22 expression. 
The rSNP however, does not need to act on the same gene that is mutated but could affect a gene 
in the same genetic pathway. One example was an rSNP identified at the SH3TC2 locus (Brewer 
et al. 2014). In this study, Brewer and colleagues identified and functionally evaluated a rSNP 
which appears to be a modifier of the CMT1A phenotype. Unfortunately, the low minor allele 
frequency associated with this SNP precluded association studies. Identification of both putative 
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SOX10 binding sites and rSNPs could elucidate the mechanism of phenotypic variability 
observed in patients with CMT and could potentially provide therapeutic targets in the future. 
 
Summary 
In this chapter, I reviewed some of the methods used to identify and characterize CREs. These 
included in silico, in vitro, and in vivo methods, which have been used to great success. Indeed, 
these pioneering papers helped discover many CREs and define general characteristics of CREs. 
Current and future studies are applying this knowledge to identify additional CREs, often 
combining many of the methods discussed above. In this thesis work, we will also use a variety 
of methods to identify functional, non-coding variation critical for the peripheral nerve. In 
chapter 2, I will discuss our methods to uncover novel CREs harboring putative rSNPs using an 
in silico phylogenetic footprinting method followed by functional evaluation using luciferase 
assays. 
I also discussed the importance of CREs within human disease, with an emphasis on both the 
peripheral nervous system and the transcription factor SOX10. As SOX10 is a master regulator 
of Schwann cell development and maintenance, identification of SOX10 response elements and 
rSNPs affecting the binding sites may uncover novel mechanisms of phenotypic variation 
observed in patients with peripheral neuropathies. Additionally, this work may uncover novel 
SOX10 target genes, allowing for a greater understanding of fundamental Schwann cell function. 
In chapter 3, I will apply the methods developed in chapter 2 to specifically identify putative 
SOX10 binding sites harboring rSNPs. I will deeply characterize one of the identified SOX10 
response elements to try to uncover the regulated gene(s). 
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I have discussed how Sox10 expression is required for all developmental stages of Schwann cells 
and expression remains consistent throughout Schwann cell development. One question that 
arises is how can SOX10 be expressed in all Schwann cell precursors but only activate myelin 
genes within myelinating Schwann cells? In chapter 4, I will utilize our computational pipeline 
to identify SOX10 responsive elements residing near genes involved in negative regulation of 
myelination and discuss some possibilities of how SOX10 (and additional factors) may mediate 
the switch from negative regulators to positive regulator of myelination. Finally, in chapter 5, I 
will summarize the findings and impact of the research presented in this thesis and present 
possible lines of future investigation. 
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Identification of Regulatory SNPs Relevant the Peripheral Nerve 
Introduction 
Cis-regulatory elements (CREs) are comprised of promoters, enhancers, repressors, and 
insulators and are critical for regulating gene expression in a spatial and temporal manner. They 
are typically short (five to ten) stretches of base pairs that contain one (or more) transcription 
factor binding sites (TFBS). One functional CRE may contain multiple TFBSs to exert the 
appropriate regulation of a gene. While it is easy to identify genes and promoters by the mRNA 
sequence and the 5’ location to genes respectively, it remains difficult to identify CREs, due to 
location independence and lack of knowledge about many TFBS (Chapter 1). 
Many methods have been developed and used to successfully identify CREs. One of the largest 
efforts to discover novel CREs is the encyclopedia of DNA elements (ENCODE) consortium 
(Birney et al. 2007). The ENCODE consortium has performed many assays across a diverse 
subset of cell types and has vastly increased the vocabulary of CREs. Despite the immense 
datasets, the ENCODE project has been limited by the cell types assessed and criticized for the 
lack of consideration for evolutionary constraints (Graur et al. 2013).  
One method to predict CREs and alleviate the limitations of the cell types used in the ENCODE 
project is phylogenetic footprinting (Tagle et al. 1988). This method relies on the hypothesis that 
regions conserved across multiple species may imply a function for the sequence, such as a 
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TFBS. While this method can predict CREs regardless of cell type, a major consideration with 
using this technique is which species to include in the analysis. Including many closely related 
species may lead to false positives, while the inclusion of many diverse species can lead to false 
negatives. In addition, while many studies have used in silico techniques to predict CREs, 
functional evaluation of the predictions is necessary because conservation does not always 
translate into function (Fisher et al. 2006; Pennacchio et al. 2006). 
Identification of CREs does not only reveal novel biology about a system (i.e. how a gene is 
regulated) but can also explain disease etiology. Indeed, disruption of CREs can result in many 
human diseases including Charcot-Marie-Tooth (CMT) disease. CMT disease is a clinically 
heterogeneous disease that affects the peripheral nervous system and is characterized by 
progressive distal muscle wasting (Dyck and Lambert 1968). CMT is subdivided based on 
whether the primary defect occurs in the Schwann cell (CMT1) or in the axon (CMT2). The most 
common coding mutation observed in patients with CMT is a duplication of PMP22 (CMT1A) 
(Lupski et al. 1991; Raeymaekers et al. 1991). However, a subset of patients with CMT1A were 
identified that did not harbor a duplication of PMP22 but did contain a duplication of upstream 
CREs (Weterman et al. 2010; Jones et al. 2011a). These patients generally have a more mild 
form of CMT, relative to patients containing a PMP22 duplication. While in this case the clinical 
variability between the two patient cohorts may be due to the relative levels of PMP22 protein 
(Huxley et al. 1998), variability can be observed among patients with molecularly 
indistinguishable duplications of a 1.4 megabase pair region including PMP22 (Garcia et al. 
1995; Thomas et al. 1997). The cause of the clinical variability is unknown, however one 
possible explanation may be regulatory single nucleotide polymorphisms (rSNPs). 
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rSNPs are base pair changes within CREs that alter the DNA binding affinity of a transcription 
factor. This can result in an increase (Feigelson et al. 1998) or decrease (Bosma et al. 1995) in 
gene expression, ablate a TFBS (Vasiliev et al. 1999), or create a novel TFBS (Knight et al. 
1999) (Figure 1.3). These changes could alter disease risk or modify disease severity leading to 
clinical variability despite identical coding mutations. For example, a patient with a duplication 
of PMP22 that also harbors a rSNP in a CRE that ultimately reduced expression of PMP22, may 
have a more mild phenotype relative to a patient lacking the rSNP. 
In this chapter, we developed a novel computation pipeline based on phylogenetic footprinting to 
predict CREs. This dataset was overlapped with validated SNPs within the human genome to 
identify putative rSNPs. We functionally assessed a subset of these predicted CREs harboring 
rSNPs using luciferase assays within three cell lines to approximate a functional peripheral nerve 
unit: Schwann cells (S16), motor neurons (MN-1), and muscle cells (C2C12). Any region that 
displayed at least a five-fold increase in luciferase expression relative to an empty control vector 
was mutated to the minor allele and reassessed in the appropriate cell line. Finally, an in silico 
TFBS prediction program (TRANSFAC) (Matys et al. 2003) was used to predict differential 
binding of transcription factors. The active regions harboring putative rSNPs identified represent 
excellent candidate modifiers of CMT disease and other peripheral neuropathies. 
All of the work in this chapter was performed by the author with the exception of the generation 
of the human, mouse, and chicken genome alignments which was performed by Dr. Tony 
Antonellis and Dr. Arjun Prasad (Antonellis et al. 2006), and a subset of the conserved regions 
were PCR amplified, cloned into pDONR, and cloned into pE1B forward and reverse by Aimée 
Vester, Chani Hodonsky, and Chetna Gopinath. 
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Methods 
Computational Identification of Conserved Regions Harboring a SNP 
The human (hg18), mouse (mm9), and chicken (Gal3) genomes were downloaded from the 
UCSC Genome Browser (Kent et al. 2002), aligned using MultiPipMaker(Schwartz et al. 2000), 
and the alignments were analyzed using ExactPlus (Antonellis et al. 2006) to identify genomic 
segments that are identical among the three species and at least five base pairs in length 
(Gopinath and Law, manuscript in preparation). Next, genome-wide SNPs (dbSNP130) were 
downloaded from the UCSC Table Browser (Karolchik et al. 2004) that were validated “by-
frequency.” The “by-frequency” validation method requires SNPs to have frequency data about 
all alleles when they were submitted. A custom Perl script was written to identify the overlap 
between the two datasets to generate fully conserved regions harboring a SNP. This dataset was 
uploaded to the UCSC Table Browser (Karolchik et al. 2004), and conserved regions containing 
SNPs were removed that had any overlap with hg18 RefSeq (Pruitt et al. 2012) exons, to remove 
regions that were conserved due to gene function. 
 
PCR and Cloning for Each Region 
PCR was performed to amplify a region surrounding each of the 144 fully conserved, non-coding 
regions with SNPs (see Appendix I for primers). The surrounding region to amplify was chosen 
based on general conservation using the PhastCons 17-way vertebrate alignment dataset (Siepel 
et al. 2005). For example, our conserved regions (generally short stretches of sequences; tens of 
base pairs or less) frequently resided within a ‘block’ of conservation based on PhastCons 
(generally large stretches of sequences; hundreds of base pairs). Primers were designed to 
amplify the entire ‘block’ of conservation, rather than imposing arbitrary sequence length 
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restrictions. Primers were designed using the online Primer3 program 
(http://bioinfo.ut.ee/primer3/) with default parameters except the primer tm Min = 55°C, Opt = 
58°C, and Max = 60°C, and the conserved region was excluded from primer design using the 
Excluding Regions tool (i.e. < and >). The primers were modified to include gateway adapters, 
ordered from IDT, and diluted to 200 μM in ultrapure water. The primers were diluted 1:10 (20 
μM) in ultrapure water prior to PCR reactions. Each region was PCR amplified from mixed 
human genomic DNA using gateway adapted primers and BP cloned into pDONR221 using the 
Gateway cloning technology (Life Sciences). For an individual BP reaction: 1 μL of PCR 
product was mixed with 0.5 μL (150 ng/μL) of pDONR221, 1 μL BP clonase (ThermoFisher cat 
no 11789-020), and 2.5 μL TE. The reaction was incubated for one hour at room temperature. 
After incubation, 1 μL of Proteinase K solution was added to stop the reaction by degrading the 
recombinase. The regions were transformed into Top10 E. Coli (ThermoFisher cat no C4040-
06): 12.5 μL of bacteria was mixed with 3 μL of the BP reaction and incubated on ice for 25 
minutes. The bacteria were heat shocked at 42°C for 45 seconds, 62.5 μL of SOC media 
(ThermoFisher cat no C4040-06) was added, and the mixture was incubated at 37°C shaking for 
one hour. All 78 μL was plated on 25 mg/mL kanamycin selective plates and incubated 
overnight at 37°C. Individual colonies were picked and grown in 6 mL of kanamycin selective 
media shacking at 225 RPM overnight at 37°C. Plasmid DNA was isolated using the Qiagen 
miniprep kit as per the manufacturer’s protocol (Qiagen cat no 27106) using 5 mL of the media 
(1 mL was saved for storage at -80°C). The DNA was assessed for proper recombination using a 
diagnostic BsrGI digest: 6.75 μL water, 1 μL (150 ng) plasmid DNA, 1 μL BSA, 1 μL NEBuffer 
2, 0.25 μL BsrGI (NEB cat no R0575S) (2.5 units). The reaction was incubated for one hour at 
37°C, and 1 μL of the reaction was assessed on a 1% agarose in TBE (Fisher cat no 50-751-
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7033) gel. The regions were then sequenced to verify the cloned allele and subsequently LR 
cloned into both pE1B forward and reverse luciferase vectors (Antonellis et al. 2006). pE1B is a 
Gateway compatible vector with the minimal promoter E1B from adenovirus directing luciferase 
gene expression. For an individual LR reaction, 1 μL (150 ng/μL) of pDONR221 plasmid was 
mixed with 0.5 μL (150 ng/μL) of pE1B plasmid, 1 μL LR clonase (ThermoFisher cat no 11791-
020), and 2.5 μL TE. The reaction was transformed, plasmid DNA was isolated, and a diagnostic 
BsrGI digest was performed as above with the exception of 100 mg/mL ampicillin selective 
plates and media rather than kanamycin. 
  
Cell Culture and Lipofectamine 2000 Transfection 
The S16 (Goda et al. 1991) and MN-1 (Salazar-Grueso et al. 1991) cells were cultured at 37°C in 
5% CO2 in general media (GM): Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen cat 
no ILT12430054) and supplemented with 10% fetal bovine serum (FBS; ThermoFisher cat no 
26140-079), 2 mM L-glutamine (Corning cat no COR25005CIS), and 1X Penicillin-
Streptomycin (50 units of penicillin and 50 μg of streptomycin; ThermoFisher cat no 15070-063). 
The S16 and MN-1 cells were plated at 10,000 cells per well of a tissue culture treated 96-well 
plate (Corning cat no 07-200-565). The cells were transfected the following day using 
Lipofectamine 2000 (ThermoFisher cat no 11668-019). To transfect a single well of a 96-well 
plate: 0.25 μL Lipofectamine 2000 was mixed with 25 μL OptiMem (ThermoFisher cat no 
31985-062) and incubated for 10 minutes at room temperature (cocktail 1). While cocktail 1 
incubated, 200 ng of DNA plasmid was mixed with 2 ng of CMV-renilla plasmid and 25 μL of 
OptiMEM (cocktail 2). Prior to transfection, the plasmid for each region was diluted to 200 
ng/μL, and a fresh aliquot of 2 ng/μL of CMV-renilla was prepared. A master mix of CMV-
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renilla and OptiMEM was made and aliquoted to each tube of DNA. After the 10 minute 
incubation of cocktail 1, 25 μL of cocktail 1 was added to cocktail 2 (transfection mixture), 
briefly vortexed, and incubated at room temperature for 20 minutes. During the incubation, the 
cells were washed with 75 μL of 1X PBS (ThermoFisher cat no 10010-023). After the 20-minute 
incubation, the PBS was aspirated, and 50 μL of the transfection mixture was added to an 
individual well. The cells were incubated for 4 hours at 37°C in 5% CO2. After 4 hours, the 
transfection mixture was removed, and 75 μL of GM was added. No PBS wash was performed 
between removal of transfection mixture and addition of GM. After 48 hours, the cells were 
harvested: cells were washed with 75 μL of 1X PBS, 20 μL of 1X passive lysis buffer (4 μL 5X 
passive lysis buffer mixed with 16 μL ultrapure water [Promega cat no E1980]) was added, and 
the plate was shaken on medium speed for one hour at room temperature. After one hour, 10 μL 
of the lysate was transferred to a white, opaque 96-well plate (Corning cat no CLS3789) and 
assessed using the Dual-Luciferase Reporter system (Promega cat no E1980): 25 μL of luciferase 
activating reagent (LAR) was added, 10 seconds of light was recorded, 25 μL of Stop and Glo 
(SNG) was added, and 10 seconds of light was recorded using a luminometer. Luciferase activity 
was normalized to renilla activity, and the activity of each region was compared to an empty 
control vector that does not contain an insert and the activity has been set to a value of ‘1’. Bar 
graphs represent at least 8 replicates and statistical calculations were performed using a two-
tailed Student’s t-test. 
The C2C12 cells were maintained and plated in GM at a concentration of 5,000 cells per well of 
a 96-well plate and transfected as described above. 24 hours post transfection the cells were 
washed with 1X PBS, and the media was changed to differentiation media (DM): Dulbecco’s 
Modified Eagle Medium (DMEM; Invitrogen) and supplemented with 5% horse serum 
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(Invitrogen cat no 16050122) (2007), 2 mM L-glutamine, and 1X Penicillin-Streptomycin. The 
cells were processed and assessed 48 hours post transfection as described above. 
 
Mutagenesis 
Major alleles of active regions were mutagenized to the minor allele in pDONR221 and 
sequenced to verify the integrity of the insert. The mutagenic primers were designed using the 
online QuikChange Primer Design program with default parameters 
(http://www.genomics.agilent.com/primerDesignProgram.jsp). The primers were ordered from 
IDT and diluted to 1,250 ng/μL in ultrapure water. Primers were diluted 1:10 (125 ng/μL) in 
ultrapure water for mutagenesis reactions. The mutagenesis reaction was performed using the 
QuikChange II XL Site Directed Mutagenesis Kit (Agilent cat no 200522). One mutagenesis 
PCR reaction contains the following: 5 μL 10X buffer, 1 μL major allele pDONR template (20 
ng/μL), 1 μL forward primer, 1 μL reverse primer, 1 μL dNTPs, 3 μL QuikSolution, 38 μL 
ultrapure water, and 1 μL Pfu taq. The reaction was performed on a thermocycler with the 
following conditions: 95°C (2 minutes), 95°C (15 seconds), 50°C (50 seconds), 68°C (10 
minutes), repeat step two through four 18 times, 68°C (10 minutes), and 4°C (hold). After 
amplification, 1 μL of DpnI (10U; from QuikChange Kit) was added to the total reaction and 
placed at 37°C for two hours. The reaction was then ethanol precipitated: 52 μL QuikChange 
reaction, 156 μL (3X PCR reaction) 100% ethanol, and 5.2 μL (0.1X PCR reaction) 3M sodium 
acetate. The reaction was mixed and placed at -80°C for one hour and then spun at maximum 
speed (13,200 rpm) at 4°C for 30 minutes. After the spin, the supernatant was removed, and the 
DNA pellet was air dried for 15 minutes. The DNA was then dissolved in 10 μL of ultrapure 
 52 
water and transformed into bacteria as described above. The regions are then sequenced to verify 
the presence of the desired mutation and the integrity of the surrounding sequence. 
 
TRANSFAC Analysis 
The major allele sequence for each active region was obtained from the UCSC genome browser 
(Kent et al. 2002). The conserved region was centered and additional base pairs were included on 
both the 5’ and 3’ ends to generate a total of 30 base pairs of sequence. The minor allele for the 
candidate rSNP was substituted into the major allele sequence to generate the minor allele 
sequence. Both the major and minor alleles were assessed using the TRANSFAC Match tool 
(Kel et al. 2003). Default parameters were used with the vertebrate, non-redundant profile 
minimizing the sum of the false positive and negative error rates. The results were filtered to 
exclude any predicted binding sites that were identical between the major and minor allele (i.e. 
only binding site predictions that differed between the major and minor allele were included), 
regardless of the core or matrix scores, and only differential predictions is displayed.  
 
Results 
Identification of Genome-wide Conserved Non-Coding Regions Harboring SNPs 
To identify conserved non-coding regions harboring SNPs, we developed a novel computational 
pipeline (Figure 2.1). The human (hg18), mouse (mm9), and chicken (gal4) genomes were 
downloaded from the UCSC genome browser (Kent et al. 2002). The genomes were aligned 
using MultiPipMaker (Schwartz et al. 2000), and regions that were identical among the three 
species and at least five base pairs in length were isolated using ExactPlus (Antonellis et al. 
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2006). This revealed over two million multi-species conserved sequences (MCSs). Next, all 
SNPs from dbSNP130 that contained information about allele frequencies (i.e. validated ‘by-
frequency’), regardless of the minor allele frequency (MAF), were downloaded from the UCSC 
Table Browser (Karolchik et al. 2004). A custom Perl script was designed to overlap the two 
datasets and generate fully conserved regions harboring SNPs. This dataset was uploaded to the 
UCSC Table Browser, and regions were filtered out that harbored any overlap with RefSeq 
exons (Pruitt et al. 2012). The final dataset was comprised of 6,164 fully conserved non-coding 
regions containing SNPs genome-wide. A similar analysis has been performed with the SNP 
identified from the 1,000 Genomes Project (Altshuler et al. 2012) from dbSNP137 (Figure 2.2) 
and all SNPs from dbSNP142 (Figure 2.3). 
 
Functional Assessment of Regions Important for the Peripheral Nerve 
To functionally evaluate our computational predictions, we assessed the ability of a pilot set of 
regions on chromosomes 21 (37 regions), 22 (29 regions), and X (94 regions) to direct luciferase 
reporter gene expression in three cell lines: Schwann cells (S16), motor neurons (MN-1), and 
muscle cells (C2C12). These cell lines were chosen to approximate a peripheral nerve and a 
target tissue (muscle). The S16 cells (Goda et al. 1991) are a rat immortalized Schwann cell line 
that express many myelin associated genes (e.g. Pmp22, Mpz, and Mbp) and critical Schwann 
cell transcription factors (e.g. Sox10 and Egr2), and are currently the best model cell line of 
myelinating Schwann cells (Hai et al. 2002). The MN-1 cells (Salazar-Grueso et al. 1991) were 
generated by somatic cell fusion between a mouse spinal motor neuron and a mouse 
neuroblastoma cell, and exhibit traits similar to motor neurons, including the ability to induce 
neurite projections. The C2C12 cells (Yaffe and Saxel 1977a) were generated following a crush  
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Figure 2.1 A Computational Pipeline to Identify Putative Regulatory SNPs Using Validated ‘by-
frequency’ SNPs from dbSNP130. The human (hg18), mouse (mm9), and chicken (gal3) 
genomes were aligned, and genomic segments that are five base pairs in length or greater and 
identical in all three species were identified to generate a dataset of multiple-species conserved 
sequences (MCS). Overlap between the MCS dataset and SNPs validated ‘by-frequency’ from 
dbSNP130 was determined. Exons were excluded using the RefSeq gene list, and the final 
dataset was parsed into chromosome 21, 22, and X. Numbers below each dataset label represent 
the number of entries in that dataset. 
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Figure 2.2 A Computational Pipeline to Identify Putative Regulatory SNPs Using the 1000 
Genomes Project SNPs. The human (hg18), mouse (mm9), and chicken (gal3) genomes were 
aligned, and genomic segments that are five base pairs in length or greater and identical in all 
three species were identified to generate a dataset of multiple-species conserved sequences 
(MCS). Overlap between the MCS dataset and the SNPs identified from the 1000 Genomes 
Project was determined. Exons were excluded using the RefSeq gene list, and the final dataset 
was parsed into chromosome 21, 22, and X. Numbers below each dataset label represent the 
number of entries in that dataset. 
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Figure 2.3 A Computational Pipeline to Identify Putative Regulatory SNPs Using All dbSNP142 
SNPs. The human (hg18), mouse (mm9), and chicken (gal3) genomes were aligned, and genomic 
segments that are five base pairs in length or greater and identical in all three species were 
identified to generate a dataset of multiple-species conserved sequences (MCS). Overlap 
between the MCS dataset and all SNPs contained within dbSNP142 was determined. Exons were 
excluded using the RefSeq gene list, and the final dataset was parsed into chromosome 21, 22, 
and X. Numbers below each dataset label represent the number of entries in that dataset. 
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injury to mouse muscle tissue, and the resulting myoblasts were cultured to generate the 
immortal line. These cells can undergo myogenic differentiation in low serum concentrations to 
form multinucleated myotubes which model adult skeletal muscle (Yaffe and Saxel 1977b).  
Briefly, a region surrounding each putative enhancer element was PCR amplified based on 
general conservation of the surrounding sequence using the PhastCons 17-way vertebrate 
alignment dataset (Siepel et al. 2005). These regions were cloned upstream of a minimal E1B 
promoter sequence directing luciferase gene expression in both the forward and reverse 
directions (relative to the promoter) and transfected into all three cell lines. Luciferase activity 
was measured relative to an empty control vector with no insert upstream of the E1B promoter 
that has been set to a value of ‘1’. Regions demonstrating a greater than five-fold increase in 
luciferase activity relative to the empty control vector were considered to have ‘strong’ activity 
and were used in further analyses. 
We successfully cloned and assessed 144 regions out of the initial 159 prioritized regions. There 
were 15 regions that were not assessed: six were amplified with another region in the same PCR 
product (and were thus tested simultaneously), eight failed to PCR amplify, and one could not be 
cloned into pDONR221. The regions were named SNP conservation (‘SC’) followed by the 
chromosome and were numbered from the p-arm to the q-arm. For example, SCX-1 is the most 
distal region identified on the p-arm of chromosome X. Each of the 144 putative enhancers was 
subjected to Sanger sequencing to verify the presence of the major allele, cloned into the 
luciferase expression plasmid, and then transfected into the three cell lines. Additionally, we 
assessed the activity of each region in both the forward and reverse orientations with respect to 
the minimal promoter element.  
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Of the 144 regions tested, 13 demonstrated ‘strong’ (i.e. greater than five-fold activity over an 
empty control) regulatory activity in S16 cells: SC21-13, SC21-16, SC21-20, SCX-3, SCX-4, 
SCX-21, SCX-39, SCX-58, SCX-60, SCX-65, SCX-67, SCX-78, and SCX-81 (Figure 2.4). In 
experiments using MN-1 cells, 11 of the 144 regions demonstrated ‘strong’ regulatory activity: 
SC21-10, SC21-12, SC22-1, SC22-8, SCX-3, SCX-4, SCX-21, SCX-45, SCX-58, SCX-60, and 
SCX-63 (Figure 2.5). We observed ‘strong’ regulatory activity in 21 of 144 regions in a C2C12 
cells: SC21-10, SC21-16, SC21-18, SC21-27, SC21-33, SC21-34, SC22-1, SC22-8, SC22-14, 
SCX-3, SCX-4, SCX-18, SCX-20, SCX-21, SCX-33, SCX-45, SCX-52, SCX-58, SCX-60, 
SCX-63, and SCX-67 (Figure 2.6). In sum, we identified 28 unique regions out of 144 regions 
tested (19.4%) with strong regulatory activity in at least one cell line (Table 2.1). 
 
The SNP Significantly Affects the Regulatory Activity of 13 Regions 
To determine if the SNP has any effect on regulatory activity, all 28 regions with ‘strong’ 
activity in at least one cell line were mutagenized to the minor allele, and reassessed in the 
relevant cell line(s). If a region displayed strong activity in more than one cell line, then the 
minor allele was assessed in all cell lines where the major allele demonstrated ‘strong’ activity. 
Each allele was tested in both orientations regardless of the original orientation activity. The 
more active allele of each region was normalized to a value of ‘100’, and the less active allele 
activity is relative to the more active allele. In Schwann cells, seven of the 13 active regions 
(53.8%) demonstrated allele-specific differences in regulatory activity: SC21-13, SCX-4, SCX-
58, SCX-60, SCX-67, SCX-78, and SCX-81 (Figure 2.7). In motor neurons, four of the 11 active 
regions (36.4%) demonstrated allele-specific differences in regulatory activity: SC21-10, SCX-4, 
SCX-58, and SCX-60 (Figure 2.8). While in the C2C12 cell line, seven of the 21 active regions
 59 
  
Figure 2.4 Identification of Regulatory Activity for Regions on Chromosomes 21, 22, and X in Schwann Cells. All 144 
genomic regions containing the major allele were cloned upstream of a luciferase reporter gene and tested in the forward (Top) 
or reverse (Bottom) orientations. Luciferase activity is measured relative to a renilla control vector. The activity of each 
genomic segment is expressed relative to a control vector with no insert (‘Empty’) whose activity has been set to ‘1’. A dashed 
line is set to a five-fold increase in activity over the empty control and indicates ‘strong’ enhancer activity, and error bars 
represent standard deviation. 
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Figure 2.5 Identification of Regulatory Activity for Regions on Chromosomes 21, 22, and X in Motor Neurons. All 144 
genomic regions containing the major allele were cloned upstream of a luciferase reporter gene and tested in the forward (Top) 
or reverse (Bottom) orientations. Luciferase activity is measured relative to a renilla control vector. The activity of each 
genomic segment is expressed relative to a control vector with no insert (‘Empty’) whose activity has been set to ‘1’. A dashed 
line is set to a five-fold increase in activity over the empty control and indicates ‘strong’ enhancer activity, and error bars 
represent standard deviation. 
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Figure 2.6 Identification of Regulatory Activity for Regions on Chromosomes 21, 22, and X in Muscle Cells. All 144 genomic 
regions containing the major allele were cloned upstream of a luciferase reporter gene and tested in the forward (Top) or 
reverse (Bottom) orientations. Luciferase activity is measured relative to a renilla control vector. The activity of each genomic 
segment is expressed relative to a control vector with no insert (‘Empty’) whose activity has been set to ‘1’. A dashed line is 
set to a five-fold increase in activity over the empty control and indicates ‘strong’ enhancer activity, and error bars represent 
standard deviation. 
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Table 2.1 Luciferase Activity of Regions Displaying ‘Strong’ Activity. 
 
1Activity only shown for cell line(s) where region was active. S = S16, M = MN-1, C = C2C12. 
2Coordinates for conserved region in hg18. 
Region Forward1 Reverse1 Coordinates (hg18)2 rs Number 
SC21-10 
5.91 (M) 
8.10 (C) 
0.25 (M) 
0.33 (C) chr21:21313182-21313188 rs7277262 
SC21-12 9.95 (M) 5.34 (M) chr21:22535874-22535880 rs2827297 
SC21-13 11.42 (S) 1.04 (S) chr21:27318695-27318702 rs233616 
SC21-16 
28.67 (S)  
30.17 (C) 
2.73 (S) 
3.56 (C) chr21:29424534-29424540 rs2832203 
SC21-18 1.37 (C) 8.90 (C) chr21:33139128-33139135 rs2833975 
SC21-20 5.81 (S) 5.04 (S) chr21:33273214-33273219 rs2834040 
SC21-27 16.05 (C) 4.71 (C) chr21:36269198-36269214 rs2835196 
SC21-33 13.85 (C) 3.40 (C) chr21:38940551-38940556 rs16996658 
SC21-34 6.22 (C) 0.33 (C) chr21:38958107-38958118 rs8130434 
SC22-1 
2.58 (M) 
2.17 (C) 
6.68 (M) 
6.35 (C) chr22:16689437-16689442 rs5992119 
SC22-8 
1.00 (M) 
1.05 (C) 
5.73 (M) 
7.53 (C) chr22:25678449-25678472 rs5761863 
SC22-14 4.70 (C) 13.83 (C) chr22:26146779-26146784 rs733164 
SCX-3 
0.20 (S) 
3.34 (M) 
3.21 (C) 
6.97 (S) 
13.56 (M) 
10.79 (C) chrX:15529186-15529192 rs4646115 
SCX-4 
0.17 (S) 
0.67 (M) 
0.86 (C) 
6.85 (S) 
9.25 (M) 
8.31 (C) chrX:17730099-17730104 rs2187846 
SCX-18 14.59 (C) 0.98 (C) chrX:31252044-31252049 rs7884417 
SCX-20 7.39 (C) 1.59 (C) chrX:31435143-31435149 rs3788892 
SCX-21 
8.63 (S) 
25.00 (M) 
6.60 (C) 
0.18 (S) 
0.84 (M) 
0.75 (C) chrX:31764702-31764707 rs1379871 
SCX-33 0.67 (C) 13.92 (C) chrX:85443058-85443064 rs6623642 
SCX-39 5.84 (S) 0.50 (S) chrX:86429198-86429205 rs16980794 
SCX-45 
0.37 (M) 
0.31 (C) 
10.62 (M) 
5.49 (C) chrX:92656893-92656900 rs12687113 
SCX-52 0.50 (C) 5.02 (C) chrX:99454087-99454093 rs7064056 
SCX-58 
6.33 (S) 
13.83 (M) 
14.69 (C) 
0.64 (S) 
0.93 (M) 
1.56 (C) chrX:121682472-121682478 rs17273301 
SCX-60 
0.43 (S) 
0.41 (M) 
0.50 (C) 
5.73 (S) 
21.81 (M) 
8.86 (C) chrX:123382405-123382410 rs2076164 
SCX-63 
21.68 (M) 
12.81 (C) 
1.04 (M) 
0.42 (C) chrX:125247437-125247470 rs16998722 
SCX-65 15.05 (S) 0.41 (S) chrX:125925884-125925893 rs5930055 
SCX-67 
8.97 (S) 
0.56 (C) 
6.90 (S) 
8.91 (C) chrX:127229700-127229720 rs17266605 
SCX-78 5.21 (S) 5.80 (S) chrX:146960885-146960891 rs6525876 
SCX-81 1.09 (S) 12.85 (S) chrX:147430625-147430635 rs17252118 
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Figure 2.7 Seven Regions Display a Significant Effect of the SNP on Luciferase Activity in 
Schwann Cells. The 13 regions displaying ‘strong’ activity in Schwann cells were mutagenized 
to the minor allele and reassessed in the forward (A) or reverse (B) orientations. The relative 
activity between the two alleles is displayed with the more active allele set to a value of ‘100’. 
Black and grey bars represent the major and minor allele respectively. Bold and underlined 
regions indicate the more active orientation, and the asterisks represent a significant (p < 0.05) 
difference between the two alleles using the Student’s T test. Bars represent at least eight 
technical replicates. 
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Figure 2.8 Four Regions Display a Significant Effect of the SNP on Luciferase Activity in Motor 
Neurons. The 11 regions displaying ‘strong’ activity in Schwann cells were mutagenized to the 
minor allele and reassessed in the forward (A) or reverse (B) orientations. The relative activity 
between the two alleles is displayed with the more active allele set to a value of ‘100’. Black and 
grey bars represent the major and minor allele respectively. Bold and underlined regions indicate 
the more active orientation, and the asterisks represent a significant (p < 0.05) difference 
between the two alleles using the Student’s T test. Bars represent at least eight technical 
replicates. 
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Figure 2.9 Seven Regions Display a Significant Effect of the SNP on Luciferase Activity in 
Muscle Cells. The 21 regions displaying ‘strong’ activity in Schwann cells were mutagenized to 
the minor allele and reassessed in the forward (A) or reverse (B) orientations. The relative 
activity between the two alleles is displayed with the more active allele set to a value of ‘100’. 
Black and grey bars represent the major and minor allele respectively. Bold and underlined 
regions indicate the more active orientation, and the asterisks represent a significant (p < 0.05) 
difference between the two alleles using the Student’s T test. Bars represent at least eight 
technical replicates. 
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(33.3%) demonstrated allele-specific differences in regulatory activity: SC21-18, SC21-27, 
SC22-8, SCX-4, SCX-21, SCX-45, and SCX-67 (Figure 2.9). Taken together, 13 SNPs of the 28 
(46.4%) strong regions demonstrated allele-specific differences in regulatory activity in at least 
one cell line relevant to the peripheral nerve. 
 
Predicting Differential Transcription Factor Binding to Active Regions Harboring a Putative 
rSNP Using TRANSFAC 
One possible explanation for the allele specific differences is that the SNP may alter transcription 
factor binding to the regions. To predict transcription factors that may differentially bind to the 
major or minor allele of the active regions, we used an in silico transcription factor binding site 
prediction program, TRANSFAC (Matys et al. 2003). Briefly, a total of 30 base pairs 
surrounding (and including) each conserved region containing the major allele was generated. 
Next, we generated the minor allele sequence by substituting in the minor SNP allele. Both 
sequences were uploaded to TRANSFAC then analyzed for TFBSs using the TRANSFAC 
Match algorithm (Kel et al. 2003). We used the vertebrate database of transcription factors and 
minimized the sum of the false positive and false negative error rates. 
Because the different alleles of the SNP altered the regulatory activity of these regions, the 
results were filtered to display only unique differences in predicted TFBSs. In Schwann cells, all 
seven regions assessed had at least one predicted TFBS unique to either the major or minor allele 
(Figure 2.10). Interestingly, none of the three Schwann cell specific regions (SC21-13, SCX-78, 
and SCX-81) harbored any predicted TFBS of transcription factors known to be important for 
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Schwann cells. While these results may be due to the limitations of TRANSFAC, they may also 
illustrate potentially novel roles of the predicted transcription factors in Schwann cells. 
Conversely in the motor neurons, one region, SC21-10, did not have any unique predictions 
(Figure 2.11). There were four predicted TFBS for SC21-10 for the major allele, however all 
four TFBS were also predicted at the same location and orientation in the minor allele, and 
therefore no predicted TFBS are displayed. This may indicate that the SNP does not ablate a 
TFBS, but rather alters binding site affinity. Unlike Schwann cells, no region which 
demonstrated allele-specific differences was specific to motor neurons. The four regions (SC21-
10, SCX-4, SCX-58, and SCX-60) all displayed regulatory activity in at least one additional cell 
line. 
Similar to Schwann cells, all regions assessed in muscle had at least one unique TFBS prediction 
in either the major or minor allele (Figure 2.12). Only two of the regions, however, were limited 
in regulatory activity to muscle cells (SC21-18 and SC21-27). Strikingly, a putative LEF-1 
binding site is created within the minor allele of SC21-27. Lef-1 expression has been shown to be 
upregulated in muscle cells within mice following an injury to the muscle (Amin et al. 2014). 
Within our data the minor allele of SC21-27 demonstrated significantly less regulatory activity 
compared to the major allele. This result could be due to loss of an enhancer element within the 
major allele, or the gain of a repressive element in the minor allele. Indeed, Lef-1 has been 
shown to act as a transcriptional repressor (Billin et al. 2000; Mao and Byers 2011);however 
further study will be necessary to determine the role (if any) of this putative LEF-1 binding site. 
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Figure 2.10 TRANSFAC Predictions of Differential Transcription Factor Binding Sites of the 
Seven rSNPs in Schwann Cells. TRANSFAC was used to predict differential TFBSs between the 
major and minor alleles for SNPs that had a significant effect on luciferase activity. A total of 30 
base pairs surrounding the conserved sequences of the seven ‘strong’ regions were used as input 
sequence for TRANSFAC. The dashed arrows indicate the position and direction of the 
predicted TFBS, the transcription factor is indicated above the arrows, and the core and matrix 
scores are indicated at the right. Only unique differential TFBS predictions between the major 
and minor alleles are displayed. The underlined base pairs indicate the conserved bases, and the 
SNP is shown in red and bold. 
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Figure 2.11 TRANSFAC Predictions of Differential Transcription Factor Binding Sites of the 
Four rSNPs in Motor Neurons. TRANSFAC was used to predict differential TFBSs between the 
major and minor alleles for SNPs that had a significant effect on luciferase activity. A total of 30 
base pairs surrounding the conserved sequences of the seven ‘strong’ regions were used as input 
sequence for TRANSFAC. The dashed arrows indicate the position and direction of the 
predicted TFBS, the transcription factor is indicated above the arrows, and the core and matrix 
scores are indicated at the right. Only unique differential TFBS predictions between the major 
and minor alleles are displayed. The underlined base pairs indicate the conserved bases, and the 
SNP is shown in red and bold. 
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Figure 2.12 TRANSFAC Predictions of Differential Transcription Factor Binding Sites of the 
Seven rSNPs in Muscle Cells. TRANSFAC was used to predict differential TFBSs between the 
major and minor alleles for SNPs that had a significant effect on luciferase activity. A total of 30 
base pairs surrounding the conserved sequences of the seven ‘strong’ regions were used as input 
sequence for TRANSFAC. The dashed arrows indicate the position and direction of the 
predicted TFBS, the transcription factor is indicated above the arrows, and the core and matrix 
scores are indicated at the right. Only unique differential TFBS predictions between the major 
and minor alleles are displayed. The underlined base pairs indicate the conserved bases, and the 
SNP is shown in red and bold. 
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Discussion 
Regulatory variation is known to modify the severity or risk of human diseases (Emison et al. 
2005) and in some cases, cause genetic diseases (Houlden et al. 2004; Gobbi et al. 2006). 
Understanding how regulatory variation impacts gene expression may help explain disease 
etiology; however significant challenges remain in identification of cis-regulatory elements and 
functional variation. In this chapter, we used a combination of phylogenetic footprinting and 
whole genome datasets to computationally predict regulatory regions harboring a putative rSNP. 
The human, mouse, and chicken genomes were used for our conservation analysis because we 
were interested in identifying functional SNPs critical for the peripheral nervous system. The 
zebrafish genome was not included for a few reasons, including: (1) the zebrafish genome is 
partially duplicated, which makes DNA sequence alignments more challenging (Meyer and 
Schartl 1999; Howe et al. 2013), and (2) we previously identified functional CREs that are 
conserved between human, mouse, and chicken, but that were not conserved in zebrafish 
(Antonellis et al. 2008; Hodonsky et al. 2012). Despite these observations, inclusion of a more 
distally related species, such as zebrafish, has been shown to reduce false positive results when 
using phylogenetic footprinting assays and may help prioritize future datasets to generate more 
accurate predictions (Nobrega et al. 2003).  
We validated a subset of the genome-wide computational predictions using luciferase assays. 
Our analysis was performed in a transcription factor blind approach and revealed 6,164 regions 
at least five base pairs in length and conserved among human, mouse, and chicken that harbored 
a SNP. A subset of these regions on chromosome 21 (37 regions), 22 (29 regions), and X (93 
regions) were assessed in luciferase assays in three cell lines to approximate a peripheral nerve 
and muscle target: Schwann cells (S16), motor neurons (MN-1) and muscle cells (C2C12). We 
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selected chromosomes 21, 22, and X to ensure our pipeline could accurately predict CREs and 
putative rSNPs on both the autosomes and sex chromosomes. Additionally in humans, SOX10 
resides on chromosome 22 and as discussed in chapter 1, SOX10 is critical for proper Schwann 
cell development and function (see chapter 1). Identification of regulatory variation impacting 
SOX10 expression could lead to a greater phenotypic variation because SOX10 regulates many 
critical Schwann cell genes. 
We identified 28 regions with ‘strong’ regulatory activity when assessing the major allele. 
Surprisingly, only four of the 28 regions displayed orientation independent enhancer activity (i.e. 
‘strong’ activity in both orientations). While this orientation dependence may be inherent to our 
experimental design, such as the inability of the region to interact with the promoter due to steric 
hindrance, there are examples of orientation dependent enhancer activity (Nishimura et al. 2000; 
Wei and Brennan 2000; Swamynathan and Piatigorsky 2002). Additionally, there is no 
relationship between the more active orientation and position of the SNP within the PCR 
amplicon (Figure 2.13). Further studies of these regions will be necessary to determine if the 
orientation dependence is inherent to the CRE or an artifact of our luciferase expression plasmid. 
It is important to note that we only tested the major allele activity in our luciferase assays, thus 
excluding the potential for the minor allele to display ‘strong’ regulatory activity through the 
creation of a novel TFBS or increasing the binding affinity of an existing TFBS. Our study 
design also excludes the potential for the SNP alleles to affect a repressive regulatory element as 
we required the major allele to display ‘strong’ activity. Future studies could modify the 
luciferase assay to address these other potential SNP affects, such as replacing the minimal E1B 
promoter with an active promoter element. This would potentially allow for the identification of 
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Figure 2.13 Relative Location of SNPs Within ‘Strong’ Region PCR Amplicons. For the 28 active regions, the relative position of 
the SNP is displayed. The distance from the 5’ end of the PCR amplicon to the 5’ end of the SNP was determined and divided by 
the total length of the PCR amplicon. Each square represents an active region, and the regions were separated by active orientation 
(Forward; blue boxes or Reverse; red boxes). The location on the X-axis represents the percent distance from the 5’ end of the 
PCR amplicon (0 = at the 5’ end and 1 = at the 3’ end). Four regions were active in both orientations and were included in both the 
forward and the reverse datasets. 
 74 
repressive elements within the major allele, and mutation to the minor allele could test for an 
allele-specific increase in activity.  
To assess for potential repressor elements within our regions, we generated lists of the top 20 
regions displaying the least regulatory activity for each cell line and orientation. Interestingly, 
four regions in the forward orientation were in the top 20 least active regions common to all 
three cell lines (Table 2.2 - Shaded Boxes). An additional five regions were in the top 20 least 
active regions common to all cell lines in the reverse orientation (Table 2.2 - Unshaded Boxes). 
One region in particular, SCX-6, was the least active region in the reverse orientation for all 
three cell lines and was in the top 20 least active regions in the forward orientation in both S16 
and MN-1 cells. It was the 24th least active region in the forward orientation in C2C12 cells. This 
region is a strong candidate for harboring repressive elements within the PCR amplicon. 
Additional efforts should focus on SCX-6 and other regions that displayed levels of activity 
much lower than the empty control vector that does not harbor a genomic insert. 
While our computational model was successful in predicting CREs, we were only able to test a 
subset of our predictions. A more high throughput assay such as STARR-Seq (Arnold et al. 
2013) or Cre-Seq (Kwasnieski et al. 2012) could be employed to test a greater number of our 
computational predictions. Based on our rates of identification of active regions (greater than 
five-fold; 19.4%) and rSNPs within active regions (46.4%), we anticipate identification of 1,195 
active regions of which 554 regions would contain a rSNPs. While we should be cautious when 
extrapolating from data, the previously identified regions in Chapter 2 demonstrate there are a 
large number of CREs remaining to be identified that are functional in the peripheral nerve or 
muscle cells. Finally, our five-fold threshold for luciferase activity only allows for identification 
of relatively strong enhancer elements. While these ’strong’ regulatory regions give greater  
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Table 2.2 Nine Regions Common to Top 20 Least Active Regions Across the Three Cell Lines. 
 
 
1 Activity only shown for cell line(s) where region was active. S=S16, M=MN-1, C=C2C12. 
2 Coordinates for conserved region in hg18. 
The top 20 least active regions for each cell line was determined for both orientations 
independently. The regions displayed are in the top 20 least active and are common to all three 
cell lines for a given orientation. The shaded rows indicate regions in the forward orientation that 
were within the top 20 least active and common in all three cell lines, while the unshaded rows 
indicate the same criteria for the reverse orientation. 
 
Region Forward1 Reverse1 Coordinates (hg18)2 rs Number 
SCX-2 
0.10 (S) 
0.26 (M) 
0.19 (C) 
0.77 (S) 
0.95 (M) 
1.99 (C) chrX:13701570-13701575 rs13187 
SCX-47 
0.10 (S) 
0.14 (M) 
0.17 (C) 
0.24 (S) 
0.71 (M) 
0.49 (C) chrX:94777246-94777251 rs5990383 
SCX-53 
0.14 (S) 
0.16 (M) 
0.23 (C) 
0.17 (S) 
0.37 (M) 
0.42 (C) chrX:103711687-103711695 rs1004122 
SCX-62 
0.07 (S) 
0.18 (M) 
0.31 (C) 
0.23 (S) 
0.61 (M) 
0.35 (C) chrX:124339837-124339845 rs3126112 
SC21-3 
0.17 (S) 
0.42 (M) 
0.40 (C) 
0.16 (S) 
0.24 (M) 
0.08 (C) chr21:15652270-15652285 rs16982386 
SC22-10 
0.15 (S) 
0.28 (M) 
0.42 (C) 
0.18 (S) 
0.20 (M) 
0.06 (C) chr22:25769441-25769477 rs17429199 
SCX-6 
0.14 (S) 
0.37 (M) 
0.35 (C) 
0.02 (S) 
0.03 (M) 
0.01 (C) chrX:22421316-22421332 rs5970650 
SCX-31 
0.24 (S) 
0.43 (M) 
0.46 (C) 
0.10 (S) 
0.22 (M) 
0.05 (C) chrX:85404361-85404385 rs6653101 
SCX-34 
0.15 (S) 
0.48 (M) 
0.38 (C) 
0.14 (S) 
0.24 (M) 
0.04 (C) chrX:85764274-85764279 rs16980611 
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confidence for assessing a functional role in vivo, it is known that low-affinity binding sites 
(which may not exceed our threshold) can be critical for endogenous gene expression (Rowan et 
al. 2010; Ramos and Barolo 2013). Despite these limitations, we were able to detect an allele-
specific difference in 13 of the 28 active regions. Interestingly, if a region was active in multiple 
cell lines, the SNP did not necessarily affect them all similarly. For example, the major alleles of 
SCX-58 and SCX-60 demonstrated strong luciferase activity in all three cell lines, but the minor 
allele only decreased activity in Schwann cells and motor neurons with no effect in muscle cells. 
Additionally, SCX-67 was active in both orientations in Schwann cells, and the minor allele 
significantly decreased activity in both the forward and reverse orientations. The major SNP 
allele of SCX-67 also displayed ‘strong’ activity in the reverse orientation in muscle cells, but 
unlike Schwann cells, the minor SNP allele significantly increased luciferase activity relative to 
the major allele in the reverse orientation. Conversely other regions displayed identical allele-
specific differences across all cell lines where the region was active. For example, the major 
allele of SCX-4 demonstrated ‘strong’ luciferase activity in the reverse orientation in all three 
cell lines, and the minor allele significantly reduced luciferase activity by approximately the 
same relative change in all three cell lines.  
The allele-specific similarities and differences between different cell lines could be informative 
as to which transcription factor(s) is binding to the region. For instance, SC21-13 demonstrates 
significantly greater regulatory activity in the minor allele compared to the major allele, and the 
region only displayed regulatory activity in Schwann cells. From this, we would predict the 
minor allele either creates a novel TFBS or increases the binding affinity of an existing TFBS. 
Additionally, since the effect was only observed in Schwann cells, we would anticipate the 
transcription factor to be expressed in Schwann cells but not in motor neurons or muscle cells. 
 77 
Conversely, the major allele of SCX-4 displayed a nearly identical decrease across all cell lines. 
From this, we would predict a more ubiquitous (i.e. expressed in at least these three cell lines) 
TFBS to be disrupted. 
Using TRANSFAC, we were able to predict potential TFBSs for each region displaying strong 
activity. While we only considered whether a transcription factor binding site was predicted in 
one of the alleles, it may in fact be the effect of the SNP is to alter binding affinity, but not ablate 
the TFBS. This may be reflected in the difference of either (or both) the core and matrix scores. 
Further analysis of the TRANSFAC prediction and additional studies, such as overexpression of 
the predicted transcription factor, will be necessary to elucidate which (if any) of the putative 
TFBS are functional. 
While the primary focus of this chapter was on the identification of regulatory SNPs, it should be 
noted that the additional 15 regions (from the 28 active regions) which did not display significant 
differences in regulatory activity between the two alleles, still demonstrated ‘strong’ regulatory 
activity in a cell line relevant for the peripheral nerve and are promising candidate enhancer 
elements. Indeed, some of these regions reside within appealing candidate genes such as SCX-18 
and SCX-20. These regions only displayed regulatory activity within muscle cells and both 
regions reside within DMD which when mutated in humans, results in Duchenne muscular 
dystrophy (Nowak and Davies 2004). Further study will be necessary to elucidate the functional 
significance of these regions. 
In this chapter, we developed a novel computational pipeline to predict CREs harboring SNPs 
and functionally assessed these predictions in cell types relevant to the peripheral nerve. Our 
method was successful by identifying 28 unique regions with ‘strong’ luciferase activity in at 
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least one cell line and 13 of these regions demonstrated significant allele-specific differences in 
regulatory activity. Both the CREs and rSNPs identified here represent excellent candidate 
modifiers of peripheral nerve diseases. In Chapter 3, we will modify our existing pipeline to 
identify rSNPs in a transcription factor centric approach, specifically identifying rSNPs affecting 
SOX10 binding sites. 
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Identification of Regulatory SNPs in SOX10 Response Elements 
Introduction 
Cis-regulatory elements (CREs) have been implicated in many human diseases. These diseases 
can be caused by duplications (Jones et al. 2011a), deletions (Balemans et al. 2002), or point 
mutations (Gobbi et al. 2006) that affect CREs. The last class, point mutations, have become 
increasingly noteworthy because many genome-wide association studies (GWAS) have 
identified candidate SNPs associated with a disease that do not reside within coding regions of 
the genome but rather in non-coding regions. Interestingly, many of the variants identified from 
GWAS reside within genomic features associated with CREs such as DNase I hypersensitivity 
sites or have histone marks associated with CREs (ENCODE Project Consortium 2012; Maurano 
et al. 2012). The current prevailing hypothesis is that the SNPs are disrupting transcription factor 
binding sites (TFBSs) and are either causing disease or modifying disease risk or severity. 
SNPs that affect CREs are called regulatory SNPs (rSNPs) and can impact TFBSs in a number of 
ways, including increasing (Feigelson et al. 1998) or decreasing (Bosma et al. 1995) gene 
expression, ablating a TFBS (Vasiliev et al. 1999), or creating a novel TFBS (Knight et al. 1999), 
(Gobbi et al. 2006) (Figure 1.3). While rSNPs may cause disease, they can also modify the risk 
or severity of disease. For example, a rSNP was identified within the first intron of RET that 
increases the risk of Hirschsprung disease ~2.1-5.7 times compared to the major allele (Emison 
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et al. 2005). It was found in this case that the rSNP disrupted a single SOX10 binding site 
(Emison et al. 2010). 
SOX10 is a member of the SOX protein family and contains four major domains: dimerization 
domain, HMG domain, K2 domain, and the transactivation domain (Figure 1.4). It is a member 
of the SOXE subfamily (Wright et al. 1993) and has been shown to be necessary for proper 
neural crest development (Lane and Liu 1984; Herbarth et al. 1998; Southard-Smith et al. 1998). 
While SOX10 is downregulated in many neural crest derived tissues, its expression remains 
consistent in both melanocytes and Schwann cells. Indeed, SOX10 is necessary for all stages of 
Schwann cell development, and conditional loss of SOX10 at any stage results in demyelination 
(Paratore et al. 2001; Finzsch et al. 2010; Bremer et al. 2011). Additionally, SOX10 regulates 
many genes critical for Schwann cell function such as MPZ (Peirano et al. 2000), PMP22 (Jones 
et al. 2011b), and GJB1 (Bondurand et al. 2001). Not surprisingly, mutations within SOX10 
target genes can result in demyelinating peripheral neuropathies such as Charcot-Marie-Tooth 
(CMT) disease (Dyck and Lambert 1968; Lupski et al. 1991; Raeymaekers et al. 1991; Hayasaka 
et al. 1993; Kulkens et al. 1993; Ionasescu and Searby 1994). 
CMT disease is characterized by distal muscle wasting and sensory loss (Dyck and Lambert 
1968; Szigeti and Lupski 2009). One characteristic of CMT is the large amount of clinical 
variability that is observed within patients, such as age of onset from the first to seventh decade 
and severity of sensory loss, often despite identical coding mutations (Thomas et al. 1997; 
Pareyson et al. 2006; Pareyson and Marchesi 2009). Clinical variability of CMT was even 
demonstrated within two sets of identical twins with CMT (Garcia et al. 1995). The cause of the 
clinical variability is unknown, however one potential explanation is rSNPs altering CREs, 
leading to disruption of endogenous gene expression and ultimately modifying disease severity. 
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For example, patients with CMT1A generally harbor a duplication of PMP22, although 
duplication of upstream CREs can cause a mild form of CMT1A (Weterman et al. 2010). If a 
rSNP disrupted CREs that regulate PMP22 and caused a decrease in expression, it may result in 
less severe symptoms relative to a patient who does not have this SNP allele. 
Despite recent technological advances, major challenges remain in both the identification and 
functional assessment of CREs and rSNPs (Chapter 1). In Chapter 2, we developed a novel 
pipeline combining computational predictions with functional assays to discover novel CREs 
harboring a SNP. In this chapter, we modify our pipeline to include SOX10 consensus sequence 
information and ultimately identify four active SOX10 response elements that harbor a SNP, two 
of which demonstrate significant allele-specific differences in activity. We deeply characterized 
one of the two SOX10 elements by deleting it from our model Schwann cell line (S16) using 
CRISPR, which helped develop a hypothesis regarding the target gene of this element. 
Specifically, we performed RNA-Seq experiments on the knockout cells compared to 
unmodified S16 cells and identified one candidate gene, Tubb2b. Both Tubb2b and the rSNP 
identified may give novel insights into Schwann cell function and development, and both 
represent potential modifiers of disease or potentially causative mutations in patients with 
neurocristopathies. 
All of the work presented in this chapter was performed by the author except the DNase-Seq 
experiments which were performed by Dr. Lingyun Song and Dr. Gregory E. Crawford (Duke 
University) and the analysis and peak calling was performed by Weisheng Wu (University of 
Michigan Bioinformatics Core). The human, mouse, and chicken genome alignments were 
performed by Dr. Tony Antonellis and Dr. Arjun Prasad (Antonellis et al. 2006). 
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Methods 
Computational Identification of SOX10 Consensus Sequences 
The human reference genome (hg18) was downloaded from the UCSC genome browser (Kent et 
al. 2002), and a custom Perl script was written to identify all SOX10 consensus sequences within 
the human genome. SOX10 binds to the core consensus sequences (5’-3’): ACAAA, ACACA, 
ACAAT, or ACAAG (Peirano and Wegner 2000; Srinivasan et al. 2012). The reverse 
complement of each sequence was also identified (5’-3’): TTTGT, TGTGT, ATTGT, or CTTGT. 
This identified ~33.5 million SOX10 consensus sequences, and this dataset was overlapped with 
the regions conserved among human, mouse, and chicken (MCS; Chapter 1). SNPs residing 
within a conserved SOX10 consensus sequence were identified, and regions overlapping RefSeq 
exons were excluded as previously described in Chapter 2 - Methods.  
 
PCR, Cloning, and Mutagenesis 
An identical procedure was used to PCR amplify regions surrounding the conserved SOX10 
consensus sequences harboring SNPs as described in Chapter 2. The primers (Appendix 2) all 
contained gateway adapter sequences (Life Sciences) to clone into pDONR221. The regions 
were sequence verified to ensure the presence of the major allele and were then cloned into pE1B 
forward and reverse as described in Chapter 2 - Methods. Regions demonstrating activity were 
mutagenized to the minor allele or to delete the SOX10 consensus site using an identical 
procedure as described in Chapter 2 - Methods. 
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Overexpression Studies 
The S16 and MN-1 cells were cultured at 37°C in 5% CO2 in general media (GM): Dulbecco’s 
Modified Eagle Medium (DMEM; Invitrogen cat no ILT12430054) and supplemented with 10% 
fetal bovine serum (FBS; ThermoFisher cat no 26140-079), 2 mM L-glutamine (Corning cat no 
COR25005CIS), and 1X Penicillin-Streptomycin (ThermoFisher cat no 15070-063). The S16 
and MN-1 cells were plated at 10,000 cells per well of a 96-well plate. The cells were transfected 
the following day using Lipofectamine 2000 (ThermoFisher Cat no 11668-019) (described in 
detail in Chapter 2). 
For overexpression studies, an additional 100 ng (per well) of overexpression plasmid was added 
in addition to the 200 ng of the SOX10 region in pE1B and 2 ng of CMV-renilla. The dominant-
negative SOX10 plasmid harbors a truncated SOX10 cDNA that contains a premature stop codon 
(E189X) driven by a CMV promoter (Inoue et al. 2004). This mutation creates a truncated 
SOX10 protein which has the ability to dimerize with endogenous SOX10, but lacks the 
transactivation domain resulting in the mutant-wildtype dimer to be nonfunctional. The wildtype 
SOX10 overexpression plasmid contains the SOX10 gene with nearly full length 5’ and 3’ UTRs 
driven by a CMV promoter (Inoue et al. 2004). Both the plate reading and statistical analysis 
were identical to Chapter 2. 
 
DNase Hypersensitivity Site Identification 
DNase-Seq was performed with three biological replicates of the S16 cells at passage numbers 
five, eight, and 14. Each replicate contained ~20 million cells frozen into 1 mL of recovery cell 
culture freezing media (Invitrogen Cat no. 12648010). Cells were thawed and DNase-Seq 
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libraries were generated as previously described (Song and Crawford 2010) with the exception of 
adding a 5’ phosphate to linker 1 to increase the ligation efficiency. DNase-Seq libraries from 
three replicates were pooled into one lane of an Illumina Hi-Seq 2000. Raw reads were aligned 
to the rat rn5 genome using Bowtie (Langmead et al. 2009) and mapping allowing up to two 
mismatches. For the three samples, 69.2% (36,295,401), 70.8% (43,564,606), and 67.9% 
(39,579,719) of the reads mapped to rn5. Peaks were called using F-Seq and the default settings 
(Boyle et al. 2008). For the three samples: 502,787 (sample 1), 438,254 (sample 2), and 412,267 
(sample 3) peaks were identified. 149,342 peaks were shared among all three samples. We used 
sample 2 as a representative experiment and compared all genomic regions to sample 2 peaks. 
 
Generation of Homologous Repair Templates (Gibson Assembly) 
The drug resistant repair templates for homologous recombination were generated using Gibson 
assembly (Gibson et al. 2009). All homologous repair templates were cloned into the BamHI 
restriction site of the multiple cloning site of pUC19. Primers were designed to amplify an 
approximately one kilobase pairs 5’ (rn5; chr17:42265085-42266075) and 3’ (rn5; 
chr17:42266727-42267691) arms of homology surrounding rSOX-4 (rn5; chr17:42266012-
42266902) from S16 (rat) genomic DNA using Primer3 (http://bioinfo.ut.ee/primer3/) with the 
default parameters except the primer tm Min = 55°C, Opt = 58°C, and Max = 60°C (Appendix 3). 
Once the primers were designed, 30 base pair adapter sequences were added to the primers that 
were homologous to either the linearized pUC19 backbone or the drug resistance cassette. For 
example on the 5’ arm of homology, the forward primer contained a 30 base pair adapter 
sequence that was homologous to the 30 base pairs immediately upstream (5’) of the BamHI cut 
site, while the reverse primer contained a 30 base pair adapter sequence homologous to the first 
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30 base pairs of either the blasticidin or neomycin resistance cassette and a LoxP site (Appendix 
3). For the 3’ arm of homology, the forward primer contained a 30 base pair adapter sequence 
homologous to the last 30 base pairs of either the blasticidin or neomycin resistance cassette and 
a LoxP site, while the reverse primer contained a 30 base pair adapter sequence that was 
homologous to the 30 base pairs immediately downstream (3’) of the BamHI cut site. Primers 
were also designed to amplify either the blasticidin or neomycin resistance cassettes, however no 
additional adapter sequences were added. The blasticidin resistance cassette was PCR amplified 
from pCMV/Bsd (ThermoFisher - Cat no. V510-20). The neomycin resistance cassette was PCR 
amplified from the hCas9 expression plasmid backbone. The hCas9 expression plasmid was a 
gift from George Church (Addgene plasmid #41815) (Mali et al. 2013). 
Prior to the Gibson assembly reaction, pUC19 was linearized using BamHI: 15 μL pUC19 (~1.5 
μg), 1 μL BamHI (NEB Cat no. R0136S) (20 units), 3 μL NEBuffer 3, 3 μL BSA, and 8 μL 
ultrapure water. The BamHI reaction was incubated at 37°C for 90 minutes and assessed on a 1% 
agarose in 1X TBE (Fisher cat no 50-751-7033) gel. A single Gibson assembly reaction contains 
the following: 10 μL 2X Gibson Assembly Master Mix, 1 μL (50 ng) of BamHI linearized 
pUC19, 1 μL (100 ng) drug resistant PCR template, 1 μL (100 ng) 5’ arm of homology, 1 μL 
(100 ng) 3’ arm of homology, 6 μL ultrapure water. For some reactions, the volume of DNA was 
varied (the mass of each DNA fragment was maintained), and the water volume was modified to 
ensure a total volume of 20 μL. Reactions were incubated at 50°C for 15 minutes and 
transformed into NEB 5-alpha Competent E Coli (NEB Cat no. C2987I) as per manufacturer’s 
protocol: 2 μL of Gibson reaction was added to one tube of NEB 5-alpha Competent E Coli, 
incubated on ice for 30 minutes, heat shocked at 42°C for 45 seconds, 950 μL of SOC media was 
added, and the tubes were placed at 37°C shaking at 900 rpm for one hour. After one hour, all 1 
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mL of bacteria were plated on 100 mg/mL ampicillin selection plates and placed in a 37°C 
incubator overnight. The following day, colonies were picked and placed into 6 mL of 100 
mg/mL ampicillin selection media and placed at 37°C shaking overnight at 225 RPM. Plasmid 
DNA was isolated using the Qiagen miniprep kit as per the manufacturer’s protocol (Qiagen cat 
no 27106). 
The drug resistance template in pUC19 was subjected to a diagnostic EcoRI restriction enzyme 
digest: 1 μL drug resistance template in pUC19 (~300 ng), 1 μL EcoRI (NEB Cat no. R0101S) 
(10 units), 1 μL NEBuffer 2, and 7 μL ultrapure water. The EcoRI reaction was incubated at 
37°C for one hour and assessed on a 1% agarose in 1X TBE (Fisher cat no 50-751-7033) gel. 
Plasmids that digested appropriately were sent for sequencing using custom sequencing primers 
designed using Primer3 (http://bioinfo.ut.ee/primer3/) with the default parameters except the 
primer tm Min = 55°C, Opt = 58°C, and Max = 60°C that tiled the entire insert (spaced ~600 
base pairs apart). Properly recombined plasmids were used in subsequent steps as homologous 
repair templates. 
 
S16 Cell Death Curves 
To determine the effective drug concentrations of blasticidin and G418 on S16 cells, death 
curves were performed. S16 cells were plated in 6-well dishes at 50,000 and 100,000 cells per 
well. Both blasticidin (Thermo Cat no. A11139-03) and G418 (Invitrogen Cat no. ILT10131035) 
were tested individually by adding the drug at the indicated concentration into standard growth 
media. Five drug concentrations of blasticidin and one negative control were tested: 0, 2, 4, 6, 8, 
and 10 μg/mL. Blasticidin effectively prevented all cell growth within five days after addition of 
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selection media at all concentrations, except 0 and 2 μg/mL. Five concentrations of G418 and 
one negative control were tested: 0, 500, 600, 700, 800, 1000 μg/mL. G418 effectively prevented 
all cell growth within 14 days after addition of selection media at concentrations of 700 μg/mL 
and above. Selection media was made that contained standard growth media plus either 4 μg/mL 
blasticidin (blast media) or 4 μg/mL blast and 700 μg/mL G418 (blast-neo media).  
 
CRISPR in S16 Cells 
Guide RNAs (gRNAs) were designed against rSOX-4 by scrutinizing the Sox10 consensus site 
and surrounding sequences for the protospacer adjacent motif (PAM; 5’-NGG-3’) (Mali et al. 
2013). Two gRNAs (Figure 3.9) were identified with cut sites within 30 base pairs of the Sox10 
consensus site and flanked by the PAM. The 20 base pairs immediately 5’ to the PAM were 
ordered as overlapping primers with adapter sequences to perform Gibson assembly (Gibson et 
al. 2009) into the gRNA cloning vector (a gift from George Church; Addgene plasmid #41824). 
An additional 5’-G was added between the adapter sequence and the gRNA. If the gRNA already 
contained a 5’-G, no additional modification was added. The overlapping gRNAs were diluted to 
200 μM and were PCR amplified to generate a double stranded DNA fragment with the gRNA in 
the middle, flanked by 40 base pair homologous sequences for Gibson assembly. One PCR 
reaction contained 5 μL gRNA-1 forward primer, 5 μL gRNA-1 reverse primer, and 40 μL of 
PCR supermix (Invitrogen Cat no. 10572-014). 
The gRNA cloning vector was digested using AflII: 5 μL (~500 ng) gRNA cloning vector, 2 μL 
CutSmart buffer, 2 μL AflII (NEB Cat no. R0520S; 40 units), and 11 μL ultrapure water. The 
reaction was incubated at 37°C for one hour, and the gRNAs were cloned into the AflII cut 
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gRNA expression plasmid using Gibson assembly: 2.5 μL (~50 ng) AflII cut gRNA expression 
plasmid, 1.5 μL (~375 ng) double stranded gRNA insert, 10 μL 2X Gibson Assembly Master 
Mix, and 6 μL ultrapure water. The reaction was incubated at 50°C for 15 minutes before the 
reaction was transformed and plasmids isolated as described above (Gibson Assembly). Plasmids 
were assessed by EcoRI digestion and sent for sequencing with custom sequencing primers. 
S16 cells were plated at 100,000 cells per well in a 6-well dish 24 hours prior to transfection. The 
drug repair templates were linearized by HindIII digestion: 15 μL (~5 μg) of drug repair template, 
3 μL NEBuffer 3, 1 μL HindIII (NEB Cat no. R0104S); 20 units), and 11 μL ultrapure water. 
The reaction was incubated at 37 °C for two hours and purified using the Qiagen PCR 
purification kit (Qiagen Cat no. 28104). The S16 cells were transfected with Lipofectamine 2000 
(ThermoFisher Cat no. 11668-019) and 3 μg of total DNA per well: 1 μg of hCas9 (a gift from 
George Church; Addgene plasmid #41815) (Mali et al. 2013), 1 μg of rSOX-4 targeting gRNA 
expression plasmid, and 1 μg of linearized drug repair template (~1:1:1 molar ratio). For an 
individual well, 5 μL of Lipofectamine 2000 was mixed with 500 μL of Optimem (ThermoFisher 
cat no 31985-062) and incubated for 10 minutes at room temperature (cocktail 1). The 3 μg of 
total DNA was mixed with 500 μL of Optimem and combined with the first cocktail after the 10 
minute incubation (transfection mixture). The transfection mixture was vortexed for 3 seconds 
and incubated for 20 minutes at room temperature. During the final incubation, the S16 cells 
were washed with 2mL of 1X PBS (ThermoFisher Cat no. 10010-023), and 1 mL of the 
transfection mixture was added. The cells were incubated for 4 hours at 37°C in 5% CO2. After 4 
hours, the transfection mixture was removed and replaced with 3 mL of standard growth media. 
The cells were incubated for 72 hours at 37°C in 5% CO2, and then the cells were passaged 1:3 
into a new 6-well dish with standard growth media and incubated overnight at 37°C in 5% CO2. 
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The following morning, the standard growth media was removed and drug selection media (4 
μg/mL blasticidin (blast media) or 4 μg/mL blast and 700 μg/mL G418 (blast-neo media)) was 
added. Selection times varied from 3-5 days for blasticidin and 10-14 days with G418, however 
an untransfected positive control well was used to assess the drug effectiveness. The selection 
media was replaced every three days to maintain appropriate drug concentrations. Once the 
untransfected control cells died, the CRISPR transfected cells were expanded into a T-75 flask 
and maintained in drug selection media. 
 
Flow Cytometry and Cell Expansion 
A confluent T-75 flask of CRISPR-modified S16 cells was prepared for flow cytometry. The 
cells were harvested into a 15 mL conical tube, spun at 2,000 RPMs for two minutes, the media 
was removed, and the cell pellet was resuspended in 2 mL of 1X PBS. Then the cells were 
passed through a 40 μm cell strainer (Falcon Cat no. 352340) by pipetting the solution through 
the filter into a new 15 mL conical tube. Five 96-well tissue culture dishes (Fisher Cat no. 07-
200-565) were filled with 75 μL of drug selection media per well. The cells were flow sorted by 
the University of Michigan flow cytometry core using front and side scatter (or for GFP positive 
cells when transfected with Cre:GFP) to one cell per well of the 96-well plate. 
The cells were incubated at 37°C in 5% CO2 for approximately 14 days. The drug selection 
media was changed every 4-5 days to maintain drug concentrations. The 96-well plates were 
assessed after 14 days for the presence of cell colonies in individual wells. These wells were 
expanded into 48-well plates (BioExpress Cat no. 677180) and incubated at 37°C in 5% CO2 for 
3-5 days until the cells were confluent. Each well was passaged from a 48-well dish into a 6-well 
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dish incubated at 37°C in 5% CO2 for 3-5 days until the cells were confluent. Finally, the cell 
clones were expanded into a T-75 flask and partially harvested for genomic DNA isolation using 
the Wizard Genomic DNA Purification Kit (Promega Cat no. A1120) according to the 
manufacturer’s protocol. The cells were assessed by diagnostic PCR to assess for proper 
recombination of the drug repair template into the rSOX-4 locus (Appendix 4). Intermediate 
expansion vessels were used as necessary depending on cell growth, such as 12-well plates or T-
25 flasks. Additional growth time or media changes were also performed depending on cell 
growth, however throughout clonal expansion, drug selection media was always used.  
 
Cre:GFP Lipofectamine 2000 Transfection into T-75 Flask 
The floxed drug resistance cassettes were removed from the CRISPR modified S16 cells by 
transient transfection with a Cre:GFP plasmid (a gift from Connie Cepko; Addgene plasmid # 
13776). Due to the low transfection efficiency, an approximately 70% confluent T-75 flask was 
transfected with Cre:GFP. An identical method was used as previously described (Chapter 2), 
with increased amounts of reagents: first mixture contained 60 μL Lipofectamine 2000 in 1.5 mL 
OptiMem, second mixture contained 24 μg of Cre:GFP in 1.5 mL OptiMem, and the transfection 
mixture contained a total of 3 mL of mixture one (1.5 mL) and mixture two (1.5 mL). After the 
20 minute room temperature incubation of the transfection mixture, the cells were washed with 
10 mL of 1X PBS, 3 mL of the transfection mixture was added, the cells were incubated for four 
hours at 37°C in 5% CO2, and the transfection mixture was removed and 10 mL of standard 
media was added (no PBS wash between transfection mixture and standard media addition). The 
cells were incubated for 72 hours at 37°C in 5% CO2. After 72 hours, the cells were processed 
for flow cytometry and GFP positive cells were sorted to individual cells within wells of a 96-
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well plate that were gradually expanded into a T-75 flask for subsequent analysis (see above). 
Standard growth media was used for all expansion stages after Cre:GFP transfection. 
 
TRIzol RNA Isolation 
Cells were harvested from a confluent T-75 flask, placed in a 15 mL conical vial, spun at 2,000 
RPM for 2 minutes, and resuspended in 5 mL of TRIzol (ThermoFisher Cat no. 15596-018). 1 
mL of the TRIzol solution was used for RNA isolation, while the rest was stored at -80°C. 200 
μL of chloroform was added to the 1 mL of cells in TRIzol and vortexed for one minute. The 
solution was incubated at room temperature for three minutes and then spun at 12,000g for 15 
minutes at 4°C. The top, aqueous phase was removed (~1 mL) and transferred to a clean tube. 
500 μL of 100% isopropanol was added to the aqueous phase, mixed by inversion 2-3 times, and 
incubated at room temperature for 20 minutes. The tube was then spun at 12,000g for 10 minutes 
at 4°C to pellet the RNA. The supernatant was removed and discarded, and 1 mL of 75% ethanol 
was added. The tube was mixed by inversion 2-3 times, spun at 7,500g for five minutes at 4°C, 
and the supernatant was removed and discarded. The ethanol wash was performed a second time, 
before the RNA pellet was air dried for 5-10 minutes (or until no ethanol remained in the tube). 
The pellet was resuspended in 50 μL of ultrapure water and used in subsequent analyses. 
 
RNA-Sequencing Analysis 
RNA was isolated from the three rSOX-4 mutants and two unmodified S16 cells (one parental 
cell line of the rSOX-4 mutants [passage 9], and one older passage [passage 39]) using TRIzol. 
PolyA selected mRNA libraries were generated using the TruSeq kit (illumina Cat no. RS-122-
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2001) and subjected to 50 base pair single end sequencing on the HiSeq2000 platform. Two 
technical replicates of the five cells were pooled and run across two sequencing lanes which 
resulted in ~21.5 million reads per cell line. The quality of the reads was assessed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The reads were aligned against the 
rat Rnor_5.0 (Ensembl) reference genome downloaded from the illumina iGenomes 
(http://support.illumina.com/sequencing/sequencing_software/igenome.html) using STAR 
(Dobin et al. 2013). Default parameters were used, except only uniquely mapped reads were 
allowed (~82% of total reads mapped uniquely). HTSeq (Anders et al. 2015) was used to count 
the number of reads per gene using default parameters except the stranded reads function was 
disabled. Finally differential gene expression between the rSOX-4 mutants and unmodified S16 
cells was determined using DESeq2 (Love et al. 2014). All programs were run on the ARCTS 
flux servers at the University of Michigan. An identical analysis was performed with the five 
unmodified S16 clones derived from the original parental cell line of the rSOX-4 mutants. 
 
Digital Droplet PCR 
cDNA was synthesized from RNA extracted from the rSOX-4 mutant and wildtype S16 cells 
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems Cat no. 
4368814). A single reaction contained 3.2 μL ultrapure water, 2 μL 10X random primers, 2 μL 
10X RT buffer, 1 μL RNase inhibitor, 0.8 μL dNTPs, 1 μg RNA in 10 μL of water, and 1 μL 
MultiScribe reverse transcriptase. The reaction was incubated for 10 minutes at 25°C, then 2 
hours at 37°C, then 85°C for 5 seconds, and finally held at 4°C.  
The resulting cDNA was diluted 1:333 in ultrapure water prior to the digital droplet PCR 
(ddPCR) reaction. A single ddPCR reaction contained 11.5 μL 2X ddPCR supermix (BioRad Cat 
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no. 1863010), 1 μL FAM probe, 1 μL HEX probe, 6 μL cDNA template (diluted 1:333), and 3.5 
μL water. FAM probes were designed against the gene of interest while HEX probes were 
against the control gene (Gapdh). The probes and primers were ordered from IDT PrimeTime 
predesigned assays for rat except for the FAM probe for Aldh5a1 that was custom designed 
using IDT PrimerQuest tool with default parameters for two primers one probe (Appendix 5). All 
probes and primer sets were diluted to a stock 20X concentration in ultrapure water (500 μL for 
standard size and 100 μL for mini size). Droplets were generated using a droplet generation 
cartridge (BioRad Cat no. 1864008). Only 20 μL of the reaction mixture was used in droplet 
generation to avoid any air bubbles, which was combined with 70 μL of oil for probes (BioRad 
Cat no. 1863005). A gasket (BioRad Cat no. 1863009) was placed over the droplet generation 
cartridge and placed into the droplet generator (BioRad Cat no. 1864002). 40 μL of the resulting 
droplets were carefully transferred to a 96-well semi-skirted PCR plate (Eppendorf Cat no. 
951020346) and the plate was heat-sealed with foil (BioRad Cat no. 1814040). The following 
PCR program used for the ddPCR reactions: 95°C for 10 minutes, 95°C for 30 seconds, 60°C for 
one minute, repeat steps 2 and 3 40 times, 98°C for 10 minutes, and 4°C hold. The plate was then 
transferred to the droplet reader (BioRad Cat no. 1864003), and the results were analyzed using 
the QuantaSoft (BioRad Cat no. 1864011) software to determine the absolute quantification of 
each gene of interest. Significant differences between the rSOX-4 and unmodified S16 cells was 
performed using a Student’s T-test. Each cDNA sample was assessed in four technical replicates, 
and the average was used in subsequent analysis. For rSOX-4, one cDNA sample was used for 
each mutant cell line, and all three were combined for the final analysis. For unmodified S16 
cells, three independent biological replicates were assessed and combined for the final analysis. 
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Transient Transgenic LacZ Mice 
rSOX-4 was PCR amplified with gateway adapter primers to clone the region into the reverse 
orientation of the HSP70:LacZ (Pennacchio et al. 2006) gateway compatible vector (i.e. the 
gateway adapters were put onto the opposite primer). The plasmid was sequence verified with 
custom sequencing primers and maxi-prepped (Zymo Cat no. D4203) according to the 
manufacturer’s protocol. The rSOX-4:LacZ transgene was liberated from the plasmid backbone 
using a SalI digestion: 40 μL (~50 μg) rSOX-4:LacZ plasmid, 5 μL NEB CutSmart buffer, and 5 
μL SalI-HF (NEB Cat no. R3138T); 500 units). The reaction was incubated at 37°C overnight, 
and a small aliquot of the cut product was assessed on a 1% agarose gel. The digested plasmid 
was submitted to the University of Michigan transgenic animal core, the transgene was gel 
purified, and the transgene was injected into mouse zygotes. The zygotes were injected into 
pseudopregnant mice, and embryos were harvested 11 days later (~E11.5). 
The embryos were dissected out and placed into 15 mL of ice cold fixative solution: 0.2% 
glutaraldehyde and 2% formaldehyde in PBS. The embryos were fixed for 20 minutes on ice and 
then washed three times for 10 minutes with wash buffer: 2mM MgCl2, 5mM EGTA, and 0.02% 
NP40 in PBS. After washing, the embryos were transferred to a 50 mL conical vial containing 
~25 mL of LacZ staining solution: 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 
and 1 mg/mL X-gal (Invitrogen Cat no. 15520-034) in wash buffer. The X-gal was diluted to 50 
mg/mL in dimethylformamide prior to addition to the staining solution. The embryos were gently 
rocked at 37°C overnight in the dark. The next morning, the embryos were washed three times 
for 10 minutes each with wash buffer and imaged using a dissecting scope with QImaging 
camera (QICAM FAST1394) and software (Qcapture Pro Version 6). 
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Results 
Computational Identification of Conserved SOX10 Consensus Sites Containing SNPs 
We modified the computational pipeline developed in Chapter 2 to include information about 
SOX10 consensus sites. A custom Perl script was written to identify all SOX10 consensus 
sequences in the human genome (hg18) using the core SOX10 consensus sites (5’ to 3’): 
ACAAA, ACACA, ACAAT, or ACAAG. The reverse complement of each sequence was also 
assessed, and this analysis revealed over 33 million consensus sequences in the human genome 
(Figure 3.1). These regions were overlapped with the multi-species conserved sequences (i.e. 
five base pair long regions identical between human, mouse, and chicken) to identify fully 
conserved SOX10 consensus sites. The conserved regions were overlapped with the same SNPs 
validated ‘by-frequency’ used in Chapter 2, and finally regions with any overlap with RefSeq 
exons were removed (Pruitt et al. 2012) to exclude regions conserved due to gene function. This 
generated a dataset of 224 fully conserved non-coding SOX10 monomers with SNPs. 
This dataset was prioritized for functional studies by using two additional filters. The first filter 
required regions to overlap with in vivo Sox10 ChIP-Seq peaks identified in nuclei from rat 
sciatic nerve, which mainly contains Schwann cell nuclei (Srinivasan et al. 2012). The 224 
regions described above were converted from the human genome to the rat genome using the 
liftOver utility on the UCSC genome browser (Kent et al. 2002), and overlap between the two 
datasets was determined using the UCSC table browser (Karolchik et al. 2004). This analysis 
revealed nine conserved SOX10 consensus sites that overlap with ChIP-Seq peaks. 
We also prioritized the 224 genome-wide SOX10 predictions by identifying dimeric SOX10 
binding sites. A custom Perl script was written to identify dimeric SOX10 binding sites where  
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Figure 3.1 Computational Identification of Conserved SOX10 Consensus Sites. The human 
genome was analyzed for all SOX10 consensus sequences and overlapped with the multi-species 
conserved sequences (five base pairs in length or greater and identical across the human (hg18), 
mouse (mm9), and chicken (gal3) genomes). Overlap between the fully conserved SOX10 
monomers and SNPs validated ‘by-frequency’ from dbSNP130 was determined, and exons were 
excluded using the RefSeq dataset to generate fully conserved non-coding SOX10 monomers 
harboring SNPs. This dataset was further prioritized by identifying regions overlapping Sox10 
ChIP-Seq peaks or that formed a putative dimeric SOX10 binding site with the fully conserved 
SOX10 monomers (intermonomeric spacer varied 1-30 base pairs). Numbers below each dataset 
label represent the number of regions in the dataset. 
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one monomer was from the 224 conserved non-coding SOX10 monomers with a SNP, and the 
other monomeric site was a fully conserved SOX10 binding site (110,561; Figure 3.1). The 
intermonomeric spacer was allowed to vary between one and 30 base pairs to minimize false 
negatives. While both monomers were required to be conserved, the intermonomeric spacer was 
not necessarily conserved. This analysis revealed 13 dimeric SOX10 sites, and combined with 
the nine overlapping ChIP-Seq peaks, resulted in a prioritized dataset of 22 putative SOX10 
binding sites for further analysis. The regions were called rSOX (regulatory SOX) and were 
numbered incrementally from the p- to q-arm of chromosome 1 to 22, X, and Y. The first nine 
regions correspond to the SOX10 consensus sites overlapping ChIP-Seq peaks, while rSOX-10-
22 correspond to the dimeric SOX10 consensus sites. 
 
Identification of Two SOX10 Enhancers Containing rSNPs 
To evaluate the 22 prioritized SOX10 elements, a region surrounding the SOX10 consensus site 
was amplified based on general conservation using the PhastCons 17-way vertebrate alignment 
(Siepel et al. 2005). The regions were amplified from human genomic DNA, cloned into 
pDONR221, and sequence verified to ensure both the presence of the major allele and integrity 
of the sequence. Properly integrated regions were then cloned into the luciferase expression 
plasmid pE1B in both the forward and reverse orientations. All 22 regions were assessed in the 
S16 cell line, which is a rat immortalized cell line that is the best cellular model of a myelinating 
Schwann cell and expresses endogenous Sox10 (Goda et al. 1991; Hai et al. 2002; Hodonsky et 
al. 2012). All regions were compared back to an empty vector that does not contain any 
sequences upstream of the minimal E1B promoter, and its activity has been set to ‘1’. To be 
considered for further analysis, regions were required to display five-fold or higher activity 
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compared to the empty vector. Four of the 22 regions met this criteria in at least one orientation 
(Fwd = forward and Rev = Reverse): rSOX-1 (Fwd = 2.57, Rev = 8.29), rSOX-4 (Fwd = 4.83, 
Rev = 25.96), rSOX-6 (Fwd = 0.33, Rev = 11.01), and rSOX-22 (Fwd = 14.12, Rev = 4.44) 
(Figure 3.2 and Table 3.1). To assess the effect of the SNP, the four active regions were 
mutagenized to the minor allele and reassessed in the S16 cells. Of the four active regions, two 
regions, rSOX-4 and rSOX-22, demonstrated a statistically significant effect between the two 
SNP alleles on luciferase activity in both orientations (Figure 3.3).  
These two regions were further assessed by deleting the SOX10 consensus site. For rSOX-4, the 
monomeric site was deleted; however, since rSOX-22 contains a dimeric SOX10 consensus site, 
both SOX10 monomers and the intermonomeric spacer were deleted. These regions were only 
assessed in the more active orientation, specifically rSOX-4 in the reverse orientation and rSOX-
22 in the forward orientation. For both rSOX-4 and rSOX-22, deleting the SOX10 consensus site 
further reduced luciferase activity compared to the minor allele in Schwann cells (Figure 3.4). 
Additionally, all three alleles were assessed in the MN-1 cells, a mouse motor neuron cell line 
that does not express endogenous Sox10, to determine if these regions may be SOX10 
responsive elements (Salazar-Grueso et al. 1991; Hodonsky et al. 2012). None of the alleles for 
either rSOX-4 or rSOX-22 demonstrated any luciferase activity in the MN-1 cell line, suggesting 
SOX10 may be important for the regulatory activities of both elements. 
To evaluate the necessity of SOX10 protein for the activity of these regions, a plasmid 
expressing a dominant-negative version of SOX10 (Inoue et al. 2004) was co-transfected with 
either rSOX-4 or rSOX-22 in Schwann cells (Figure 3.5). This plasmid contains a premature stop 
codon that results in a truncated form of SOX10 that maintains the dimerization and HMG (DNA  
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Figure 3.2 Four Putative SOX10 Binding Sites Display Strong Activity in Schwann Cells. The 22 
conserved SOX10 consensus sites were cloned upstream of a luciferase reporter gene and tested 
in the forward (A) or reverse (B) orientation in S16 cells. The activity of each genomic segment 
is expressed relative to a control vector with no insert (‘Empty’), which was arbitrarily set to ‘1’. 
Four regions display greater than five-fold activity in at least one orientation. A dashed line is set 
to a five-fold increase in activity over the empty control to indicate ‘strong’ enhancer activity, 
and error bars show standard deviation. 
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Table 3.1 Four Active SOX10 Regions in Schwann Cells. 
 
1Coordinates for conserved SOX10 monomeric site for rSOX-1, -4, and -6 and dimeric site for 
rSOX-22 
2MAF is the minor allele frequency from the 1000 Genomes Project (Altshuler et al. 2012) 
  
Region Forward Reverse Coordinates (hg18)1 rs Number MAF2 
rSOX-1 2.57 8.29 chr2:44834620-44834625 rs3738980 0.3035 
rSOX-4 4.83 25.96 chr6:22818474-22818479 rs16886790 0.2001 
rSOX-6 0.33 11.01 chr6:98692222-98692227 rs17814604 0.1014 
rSOX-22 14.12 4.44 chr16:53169712-53169728 rs1186802 0.4219 
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Figure 3.3 Two SOX10 Regions Display a Significant Effect of the SNP on Luciferase Activity. 
All four active regions were mutagenized to the minor allele and reassessed in both orientations. 
Two regions, rSOX-4 and rSOX-22, demonstrate a significant decrease in activity in the minor 
allele (red and grey bars) relative to the major allele (blue and black bars). The major alleles for 
both orientations have been set to ‘100’, a dashed line indicates the normalized major allele 
activity, and the minor allele activity is relative to the major allele. The error bars represent 
standard deviation. 
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Figure 3.4 SOX10 is Required for Luciferase Activity of Both rSOX-4 and rSOX-22. The SOX10 
consensus site was deleted from both rSOX-4 (monomeric) and rSOX-22 (monomers and 
intermonomeric spacer) and reassessed in Schwann cells (blue bars; S16). The activity is 
compared to an empty control plasmid arbitrarily set to’1’, and only the more active orientation, 
reverse for rSOX-4 and forward for rSOX-22, is assessed. All three alleles for both regions were 
assessed in motor neurons (red bars; MN-1). The error bars for both S16 and MN-1 cells 
represent standard deviation, and ΔSOX represents the region with SOX10 consensus sites 
deleted. 
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Figure 3.5 SOX10 is Necessary and Sufficient for Luciferase Activity of rSOX-4 and rSOX-22. 
(A) rSOX-4 and rSOX-22 were transfected into Schwann cells either independently (blue bars) 
or co-transfected with a dominant-negative SOX10 expression plasmid (red bars). The major 
untreated allele for both rSOX-4 and rSOX-22 has been set to ‘100’, and all other bars represent 
relative activity. (B) rSOX-4 and rSOX-22 were transfected into motor neurons either 
independently (blue bars) or co-transfected with a wildtype SOX10 expression plasmid (red 
bars). The major untreated allele for both rSOX-4 and rSOX-22 has been set to ‘1’, and all other 
bars represent relative activity. The double slashed line and broken red bars represent a break in 
the Y-axis. Error bars represent standard deviation, and ΔSOX represents the region with SOX10 
consensus sites deleted. 
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binding) domains, but lacks the transactivation domain. When this mutant SOX10 interacts with 
the wildtype SOX10, the resulting dimeric complex is not functional, ultimately resulting in a 
depletion of wildtype SOX10 within the cell. For both regions, co-transfection of dominant-
negative SOX10 reduced activity of all three alleles by ~90%. Conversely, when rSOX-4 or 
rSOX-22 was co-transfected with a wildtype SOX10 expression plasmid into the MN-1 cells, all 
three alleles displayed high levels of luciferase activity (Figure 3.5). Taken together, these data 
suggest that SOX10 is both necessary and sufficient for the regulatory activity of rSOX-4 and 
rSOX-22 in our in vitro cell models. 
 
The Genomic Landscape of rSOX-4 and rSOX-22 
Both rSOX-4 and rSOX-22 reside within gene deserts, with the nearest genes approximately one 
megabase pairs away in both the 5’ and 3’ directions with the exception of Hdgfl1 which is ~150 
kilobase pairs 5’ of rSOX-4 (Figure 3.6 and Figure 3.7). To better understand the genomic 
features of both regions and identify potential candidate target genes, DNase-Seq was performed 
on the S16 cell line. Three biological replicates of the S16 cell lines were used, and DNase-Seq 
was performed by Dr. Greg Crawford at Duke University. The data was analyzed at the 
bioinformatics core at the University of Michigan using F-Seq (Boyle et al. 2008). We identified 
approximately 450,000 peaks on average in each of the three cell lines. Using the sample 2 cell 
line as a representative sample, we identified all peaks with an F-Seq score greater than 0.08 
(31,845 peaks, 7.3% of all peaks). Using these high confidence peaks, we observed rSOX-4 
resided within a DNase hypersensitivity site (DHS) (Figure 3.6), while rSOX-22 does not reside 
within a DHS (Figure 3.7). 
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Figure 3.6 rSOX-4 Overlaps Genomic Features Associated with Enhancers. (Top) rSOX-4 (red 
box) overlaps histone 3 lysine 27 acetylation peaks (H3K27Ac; purple track), Sox10 ChIP-Seq 
peaks from rat sciatic nerve (pink track), and S16 DNase hypersensitivity peaks (S16 DNase 
HSS; black track). (Bottom) Zoomed out browser from above to show surrounding RefSeq 
genes. Green bar demonstrates rSOX-4 resides within peaks from all genomic features assessed. 
For both top and bottom, track names are at the left, the scale for each track is indicated, and the 
width of each browser window is indicated at the top (Kb = kilobase pairs and Mb = megabase 
pairs). 
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Figure 3.7 rSOX-22 Does Not Overlaps Genomic Features Associated with Enhancers. (Top) 
rSOX-22 (red box) does not overlap histone 3 lysine 27 acetylation peaks (H3K27Ac; purple 
track), Sox10 ChIP-Seq peaks from rat sciatic nerve (pink track), or S16 DNase hypersensitivity 
peaks (S16 DNase HSS; black track). The Y-axis scale for all tracks was matched to Figure 3.6 
for comparisons. (Bottom) Zoomed out browser from above to show surrounding RefSeq genes. 
Green bar demonstrates rSOX-22 location across all three tracks. For both top and bottom, track 
names are at the left, the scale for each track is indicated, and the width of each browser window 
is indicated at the top (Kb = kilobase pairs and Mb = megabase pairs). 
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Additionally, we scrutinized each region for the presence of histone 3 lysine 27 acetylation 
(H3K27Ac) , which has been shown to correlate with active enhancers (Creyghton et al. 2010). 
We utilized previously published H3K27Ac data (Hung et al. 2015) generated from rat sciatic 
nerve to determine if our regions correlated with H3K27Ac peaks. Similar to the DHS data, 
rSOX-4, but not r-SOX-22, resides within a H3K27Ac peak from sciatic nerve (Anido et al. 
2015). Finally, we examined each region for the presence of a SOX10 ChIP-Seq peak from 
sciatic nerve (Srinivasan et al. 2012). rSOX-4 was prioritized because it overlapped a SOX10 
ChIP-Seq peak, while rSOX-22 had no evidence for SOX10 occupancy. Taken together, rSOX-4 
is associated with many enhancer marks and SOX10 ChIP-seq data (Figure 3.6), while rSOX-22 
is not (Figure 3.7). Based on the overlapping genomic features supporting rSOX-4 as an 
enhancer, we further pursued this region to determine the candidate target gene(s). 
 
CRISPR Deletion of rSOX-4 from S16 Cells 
To identify the candidate target gene(s) regulated by rSOX-4, we used the CRISPR-Cas9 system 
to delete rSOX-4 from S16 cells (Wiedenheft et al. 2012; Mali et al. 2013). Briefly, repair 
templates were generated with approximately one kilobase pair arms of homology flanking 
rSOX-4 with a floxed blasticidin or neomycin resistance cassette. The S16 cells were transfected 
with the blasticidin repair template, human codon optimized Cas9 (hCas9) (Mali et al. 2013), and 
one of two guide RNAs (gRNAs) targeting rSOX-4. Next, the cells were selected for stable 
integration of the blasticidin repair template and flow sorted to generate clonal cell lines. We 
were able to generate two clones, one using gRNA-1 (rSOX-4 Clone 1-B) and one using gRNA-
2 (rSOX-4 Clone 2-B) that had properly recombined in the blasticidin resistance cassette in place 
of rSOX-4. Integration was assessed using a diagnostic PCR with one primer outside the arms of 
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homology and one primer within the drug repair template (Figure 3.8). These PCR products were 
sequence verified to ensure the integrity of the genomic DNA. 
This process was repeated once more using the neomycin resistance template to generate double 
drug resistant clonal cell lines (Figure 3.8); however, the gRNAs had to be reversed due to 
InDels (Figure 3.9) in the remaining wildtype alleles (i.e. gRNA1 was used in rSOX-4 Clone 2-B 
and gRNA2 was used in rSOX-4 Clone 1-B). Additionally, we were unable to amplify the 
blasticidin repair template from rSOX-4 Clone 2 following the second round of clone generation. 
Nevertheless, after two rounds of CRISPR, there were no remaining wildtype alleles as assessed 
by a wildtype specific PCR with both primers within the deleted rSOX-4 region (Figure 3.10). 
The clones were then transiently transfected with a Cre:GFP plasmid to remove the drug 
resistance cassettes, and GFP positive cells were flow sorted to generate clonal populations. A 
final diagnostic PCR was performed to assess for complete removal of the drug resistance 
cassettes, and the products were sequence verified to ensure only a single loxP scar remained 
(Figure 3.10). We were able to generate three clonal cell lines: two cell lines shared a parental 
cell line prior to Cre:GFP transfection (i.e. rSOX-4 Clone 2-1 and 2-2 were derived from rSOX-4 
clone 2) while the other was independently generated (rSOX-4 Clone 1). The generation of 
rSOX-4 deleted cell lines will allow us to profile their gene expression and compare them to the 
gene expression profile of an unmodified S16 cell, to determine the difference between the two 
cells population and ultimately identify the candidate target gene(s) regulated by rSOX-4. 
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Figure 3.8 Blasticidin and Neomycin Resistance Cassettes Stably Replaced rSOX-4 in S16 cells. 
A blasticidin (A) or neomycin (B) repair template was used to delete rSOX-4 from S16 cells. 
Two clones were generated using different gRNAs targeting different sites within rSOX-4. 
rSOX-4 Clone refers to flow sorted clonal cells, rSOX-4 Het are the heterogeneous parental 
populations prior to flow sorting (-B = blasticidin resistant, -B/N = blasticidin and neomycin 
resistant), and WT S16 refers to the unmodified original parental S16 cell line. The 5’ and 3’ 
indicate across which arm of homology the diagnostic PCR was performed, Blast indicates a 
diagnostic PCR for the blasticidin resistance cassette, and Neo indicates a diagnostic PCR for the 
neomycin resistance cassette. 
 110 
Figure 3.9 CRISPR Cuts All Alleles in S16 Cells. A wildtype specific diagnostic PCR was performed on both rSOX-4 Clone 1-B and 
2-B, and the products were sequenced. (A) A single base pair insertion (yellow box) of an adenine was identified in the remaining 
nonrecombined alleles of rSOX-4 Clone 1-B that resides directly within the gRNA-1 cut site. (B) A 79 base pair deletion was detected 
encompassing the gRNA-2 cut site in rSOX-4 Clone 2-B. The yellow box represents the expected 5’ sequence while the blue box 
represents the 3’ sequence. For both A and B, the rn5 sequence is the expected sequence from the rn5 genome, and gRNA-1, Sox10 
consensus site, and gRNA-2 are labeled and indicated by the line under the specific nucleotide sequences. 
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Figure 3.10 No Wildtype Alleles of rSOX-4 Remain in the CRISPR Modified S16 Cells. (A) A 
wildtype specific PCR was performed on the three Cre:GFP transfected clonal cell lines (rSOX-4 
Clone 1, 2-1, and 2-2), the parental cell line prior to Cre:GFP transfection (rSOX-4 Clone 1-B/N 
and -2B/N), and unmodified S16 cells (WT S16). A SOX6 specific PCR was performed as a 
positive control. (B) A diagnostic PCR was performed across the site of integration (rSOX-4) for 
the three rSOX-4 clones, the parental cell lines, and unmodified S16 cells (WT S16). (C) 
Sequencing results from the bands of rSOX-4 Clone 1, 2-1, and 2-2 in B 5’ Cre. The expected 
sequence was generated in silico based on the expected result for proper recombination and Cre 
excision. The 5’ and 3’ arms of homology are labeled above the sequence by the line, and the 
loxP scar is shaded in green. Only the sequencing of the 5’ PCR product from B is shown for 
clarity, however sequencing from the 3’ PCR confirmed these results. 
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Tubb2b is a Candidate Target Gene of rSOX-4 
We performed RNA Sequencing (RNA-Seq) on the rSOX-4 clonal cell lines and two unmodified 
S16 cell lines to determine any gene expression changes genome-wide between the two 
populations. Briefly, RNA was extracted from the three rSOX-4 deleted cell lines and two 
unmodified S16 cell lines (one was the parental cell for all three rSOX-4 clonal cell lines). The 
RNA was subjected to 50 base pair single end reads, aligned to the rn5 genome using STAR 
(Dobin et al. 2013), and reads were counted for each gene using HTSeq (Anders et al. 2015). We 
then used DESeq2 (Love et al. 2014) to analyze differential gene expression between the mutant 
rSOX-4 cells and the unmodified S16 cells. This analysis identified 197 genes significantly 
differentially expressed between the two cell populations (Figure 3.11). We decided to filter 
these genes based on two criteria: (1) the target gene likely resides on the same chromosome as 
rSOX-4. While it is possible the target gene(s) reside on an different chromosome (Spilianakis et 
al. 2005), the vast majority of described CREs act in cis (Chapter 1). (2) The target gene(s) will 
demonstrate decreased expression in the rSOX-4 deleted cell lines compared to the unmodified 
S16 cells. Based on our luciferase data, we anticipate rSOX-4 acts as a transcriptional activator 
(enhancer) and deletion of this element would result in decreased gene expression. Of the 197 
genes, only six genes were on the same chromosome (Chr 17) as rSOX-4, and only two genes 
showed decreased expression in the rSOX-4 mutants relative to unmodified S16 cells (fold 
change shown is relative to unmodified S16 cells): Tubb2b (-7.41) and Gmnn (-1.61) (Table 3.2).  
To validate the RNA-Seq results, we performed digital droplet PCR (ddPCR) (Figure 3.12). 
While we were able to recapitulate the RNA-Seq results for Tubb2b, we were unable to validate 
the decrease in Gmnn expression. Across three independent experimental replicates, the 
expression of Gmnn in the rSOX-4 deleted cells relative to the unmodified S16 cells  
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Figure 3.11 Gmnn and Tubb2b are Significantly Decreased in Expression in the rSOX-4 Mutant 
Cells. MA plot of the mean expression of every gene (dots) against the log 2 fold change. The 
mean expression is calculated as the mean of the normalized counts across all samples, and the 
log 2 fold change is relative to the unmodified S16 cells. Any gene above the red line (‘0’) 
indicates higher expression in the rSOX-4 mutant cells, and any gene below the red line indicates 
lower expression in the rSOX-4 mutant cells. The red dots indicate genes significantly 
differentially expressed between rSOX-4 and the unmodified S16 cells (p < 0.05). Gmnn and 
Tubb2b are labeled and indicated by the blue circles. 
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Table 3.2 Six Genes are Significantly Differentially Expressed on Chromosome 17. 
Gene p-value1 Mean Expression2 Fold Change3 Distance4 
Tubb2b 1.48E-10 355.60 (51.5%) -7.41 8.9 
Rbm24 0.025 111.63 (44.2%) 2.63 23 
Gmnn 0.042 2,309.92 (75.8%) -1.61 1.9 
Etl4 0.044 376.98 (52.0%) 1.73 47 
Mylip 0.044 1,059.61 (63.2%) 1.59 20.5 
Akr1c19 0.045 103.36 (43.8%) 2.50 29 
Aldh5a1 0.949 494.33 (54.5%) -1.09 1.7 
1Benjamini-Hochberg adjusted p-value for multiple testing. 
 
2Mean expression is the average of total counts across all cell lines. Number in parentheses is 
percentile rank of these genes relative to genes expressed in S16 cells (i.e. at least one read 
counted for the gene to be included). 
 
3Fold change calculated relative to wild type cells. Negative value means lower expression in 
rSOX-4 mutant cells, and positive values means higher expression in rSOX-4 mutant cells. 
 
4Distances from rSOX-4 to the gene are given in millions of base pairs (Mb). 
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demonstrated a significant increase, significant decrease, and no significant difference. This may 
be due to role of Gmnn in cell cycle regulation (McGarry and Kirschner 1998) which is 
confounding our results (discussed below); however, because we could not validate the RNA-
Seq results for Gmnn we focused our efforts on Tubb2b as the likely candidate target gene of 
rSOX-4. As a control, Aldh5a1 was included because it was not expected to display a difference 
based on RNA-Seq results, is expressed at approximately the same level as Tubb2b, and resides 
between rSOX-4 and both Tubb2b and Gmnn. In our ddPCR assay, Aldh5a1 did not display 
significant differences in gene expression between the two cell populations. 
One potential confounding variable in our experimental design is the affects of clonal expansion 
from single cells on gene expression. To account for this, we performed RNA-Seq and 
differential gene expression analysis using five additional unmodified S16 clones. The original, 
unmodified parental S16 cell line was flow sorted to generate clonal populations using front and 
side scatter. Five clones were selected, expanded into T-75 flasks, and RNA was isolated and 
sent for RNA-Seq. Identical procedures were used for RNA-Seq, mapping the reads, and 
determining differential gene expression as were used for the rSOX-4 mutants. We included 
these five clones with the previous unmodified S16 RNA-Seq dataset and reanalyzed the 
differential gene expression between the rSOX-4 mutants and all unmodified S16 cell lines. In 
agreement with the ddPCR results, Tubb2b, but not Gmnn, was significantly decreased in 
expression in the rSOX-4 mutants compared to all unmodified S16 samples (Figure 3.13 and 
Table 3.3). Combined, these results reveal Tubb2b as a candidate target gene of rSOX-4. 
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Figure 3.12 Tubb2b is Significantly Decreased in Expression in ddPCR Assays. Digital droplet 
PCR (ddPCR) was used to validate the results obtained from the RNA-Seq analysis. The 
expression of Tubb2b and Aldh5a1 in unmodified S16 cells has been set to ‘1’, and the relative 
expression of the gene in the rSOX-4 mutant cells is displayed. Aldh5a1 was used as a negative 
control. The blue bars are the unmodified S16 cells, red bars are the rSOX-4 mutant cells, and 
error bars represent standard deviation. Each bar represents four technical replicates of three 
biological replicates. ** = p < 0.05, and N.S. = not significant. 
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Figure 3.13 Tubb2b is Significantly Decreased in Expression in the rSOX-4 Mutant Cells 
Compared to All Unmodified S16 Cells. MA plot of the mean expression of every gene (dots) 
against the log 2 fold change. The mean expression is calculated as the mean of the normalized 
counts across all samples, and the log 2 fold change is relative to the unmodified S16 cells. Any 
gene above the red line (‘0’) indicates higher expression in the rSOX-4 mutant cells, and any 
gene below the red line indicates lower expression in the rSOX-4 mutant cells. The red dots 
indicate genes significantly differentially expressed between rSOX-4 and the unmodified S16 
cells (p < 0.05). Gmnn and Tubb2b are labeled and indicated by the blue circles. 
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Table 3.3 Tubb2b is Significantly Decreased in Expression in rSOX-4 Mutants Compared to All 
Unmodified S16 Cells. 
Gene p-value1 Mean Expression2 Fold Change3 Distance4 
Tubb2b 1.33E06 738.43 (65.3%) -9.62 8.9 
Gmnn 0.93 1,495.23 (74.2%) -1.06 1.9 
 
1Benjamini-Hochberg adjusted p-value for multiple testing. 
 
2Mean expression is the average of total counts across all cell lines. Number in parentheses is 
percentile rank of these genes relative to genes expressed in S16 cells (i.e. at least one read 
counted for the gene). 
 
3Fold change calculated relative to wild type cells. Negative value means lower expression in 
rSOX-4 mutant cells, and positive values means higher expression in rSOX-4 mutant cells. 
 
4Distances from rSOX-4 to the gene are given in millions of base pairs (Mb). 
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rSOX-4 Directs LacZ Expression In Vivo in Mice at E11.5 
To determine the physiological relevance of rSOX-4 in an in vivo mouse model, we assessed its 
ability to direct LacZ expression. Because the regulatory activity of rSOX-4 is dependent on 
SOX10, we anticipated rSOX-4 would demonstrate activity in tissues which express SOX10. 
Additionally, based on the RNA-Seq data suggesting Tubb2b as a candidate target gene, we 
selected embryonic day 11.5 (E11.5). This was due to the known role of Tubb2b in neuronal 
migration (Jaglin et al. 2009), and we reasoned it may be performing a similar role in migratory 
neural crest cells and their derivatives. By E11.5 in mice, the neural tube has closed, and neural 
crest cells and derivative cells have begun to migrate (Serbedzija et al. 1990; Serbedzija et al. 
1992; Osumiyamashita et al. 1994; Wilson et al. 2004). 
Primers were designed to amplify and clone rSOX-4 into pDONR221 in the reverse orientation 
because this was the more active orientation. The region was sequence verified to ensure the 
presence of the major allele and then LR cloned upstream of the minimal Hsp68 promoter 
directing LacZ expression (Pennacchio et al. 2006). The rSOX-4:LacZ transgene was liberated 
from the plasmid backbone, gel purified, and injected into mouse zygotes. The zygotes were 
implanted into pseudopregnant mice and grown to embryonic day 11.5 (E11.5). The embryos 
were then harvested, and LacZ expression was detected. We isolated 54 embryos from ten mice 
and identified six LacZ positive mice (Figure 3.14). 
Of the six embryos, one displayed blue expression throughout the embryo and most likely 
represents the transgene integrating into a ubiquitously expressed locus. The remaining five 
embryos all demonstrated LacZ staining in the dorsal root ganglia and migrating melanoblasts, 
both tissues which express SOX10 at this developmental timepoint (Britsch et al. 2001; 
Sonnenberg-Riethmacher et al. 2001). In addition, three of the five embryos displayed staining in 
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Figure 3.14 rSOX-4 Demonstrates Enhancer Activity in vivo in Melanoblasts and the Dorsal Root Ganglia in Mice at E11.5. Five 
of six mice displayed LacZ expression in a tissue-specific manner. One mouse (C) demonstrated near ubiquitous expression. All 
five tissue-specific expression mice demonstrated expression in the migrating melanoblasts (M) and dorsal root ganglia (DRG) 
indicated by the arrow. An enlarged section of the melanoblasts is shown in the upper right for each of the five mice. 
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the head and brain regions (Figure 3.14 - A, B, E, and F). These experiments demonstrate rSOX-
4 is active in vivo in mice and combined with the CRISPR RNA-Seq data, suggest that rSOX-4 is 
regulating Tubb2b, which is playing an important role in neural crest cells and melanoblast 
migration. 
 
Discussion 
While utilizing an unbiased approach can identify many CREs important for relevant tissues, as 
was demonstrated in Chapter 2, the incorporation of transcription factor binding site information 
allows for a more focused approach to generate transcriptional hierarchies. A transcription factor 
centric approach also allows for the use of genome-wide datasets such as ChIP-Seq, which 
ultimately revealed rSOX-4 and Tubb2b as strong candidate enhancers and genes relevant for 
SOX10 expressing tissues, respectively. We therefore modified our computational pipeline from 
Chapter 2 to incorporate the well-characterized TFBS for SOX10. SOX10 was selected due to its 
importance in Schwann cells, the identification of mutations within characterized SOX10 
binding sites causing peripheral neuropathies (Houlden et al. 2004; Jones et al. 2011a), and the 
identification of regulatory SNPs within SOX10 binding sites that alter disease severity (Emison 
et al. 2005; Emison et al. 2010). We identified 224 conserved SOX10 binding sites harboring a 
SNP. These were prioritized for analysis by using SOX10 ChIP-Seq data (Srinivasan et al. 2012) 
and dimeric SOX10 binding sites to generate 22 prioritized regions. Surprisingly, of the 22 
assessed, only four regions demonstrated strong luciferase activity, despite all 22 regions 
harboring a conserved SOX10 monomer or dimer.  
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There are several possible explanations for this observation, such as the role of SOX10 in other 
tissue types. Indeed, SOX10 is critical for neural crest development, and mutations within 
SOX10 target genes can affect multiple tissues including Schwann cells (i.e PMP22; CMT1) 
(Jones et al. 2011a), enteric neurons (i.e. RET; Hirschsprung’s disease) (Emison et al. 2010), and 
melanocytes (i.e. MITF; Waardenburg syndrome) (Bondurand et al. 2000). These 18 regions may 
be functional, but the S16 cells are missing additional co-factors necessary for activity such as 
PAX3 in melanocytes (Bondurand et al. 2000). One caveat to this explanation is that seven of the 
18 regions overlap a Sox10 ChIP-Seq peak generated from rat sciatic nerves (Srinivasan et al. 
2012). While this discrepancy may be a limitation of our in vitro Schwann cell model compared 
to the in vivo dataset, ChIP-Seq peaks do not necessarily predict a functional regulatory element 
(Fisher et al. 2012; Kvon et al. 2012; Leonid et al. 2013). Indeed, rSOX-22 displayed strong 
luciferase activity and was validated as a SOX10 response element despite not overlapping a 
SOX10 ChIP-Seq peak. 
Another possible explanation for the lack of activity observed in the 18 regions is that they 
function at a different developmental time point in Schwann cell maturation. For example, these 
regions may only be active in neural crest cells or early Schwann cell precursors and require 
additional co-factors such as AP2α (Stewart et al. 2001; Jessen and Mirsky 2005; Wahlbuhl et al. 
2012). Additional studies will be necessary to understand and characterize the roles (if any) of 
these 18 less active regions. 
From the four active regions identified, we focused on two regions, rSOX-4 and rSOX-22, 
because of the significant differences in allele-specific regulatory activity. Through 
overexpression studies using dominant-negative SOX10 in the S16 cells and wildtype SOX10 in 
the MN-1 cells, as well as deletion of the SOX10 consensus site, we were able to show that 
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SOX10 is both necessary and sufficient for luciferase activity of both regions in our cell culture 
models. Interestingly, upon deletion of the SOX10 consensus site in rSOX-4, there was still 
significant (~4.5 fold increase relative to empty) activity suggesting there may be additional 
SOX10 binding sites. Indeed, there are two additional SOX10 consensus sites conserved among 
human, mouse, and chicken; however deletion of these sites independently or in tandem did not 
further reduce luciferase activity compared to the single deletion of the original rSOX-4 SOX10 
consensus site (Figure 3.15). These data suggest there may be additional TFBSs that are 
responsible for the residual activity observed in the SOX10 deletion constructs. Using the 
TRANSFAC Match tool (Kel et al. 2003) to analyze the rSOX-4 region, binding sites for two 
transcription factors critical for early Schwann cell development were identified: two AP2α 
(Stewart et al. 2001; Jessen and Mirsky 2005; Wahlbuhl et al. 2012) and one YY1 (He et al. 
2010). Deletion of these predicted TFBS individually and in tandem with the SOX10 binding site 
may explain the residual activity observed in the SOX10 deleted rSOX-4 construct. 
Based on the additional support of genomic features (i.e. ChIP-Seq, DNase HSS, and H3K27Ac 
peaks) we focused our efforts on identifying the target gene of rSOX-4. To do this, we utilized 
CRISPR to delete the region in S16 cells. We performed two rounds of drug selection to target 
all wildtype alleles, but we observed that all wildtype alleles were cut by Cas9 in a single round 
of transfection, despite not necessarily being repaired by homologous recombination. This 
suggests that simultaneous targeting of all wildtype alleles could be performed in a single 
experiment by transfecting both the blasticidin and neomycin repair templates. This strategy may 
be hampered by multiple factors including the efficiency of transfection, Cas9 DNA editing, 
homologous recombination rates, and the actual number of wildtype alleles in a polyploid 
immortalized cell line. In fact, while the karyotype of our S16 cells is unknown, we did perform 
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Figure 3.15 Deleting Additional SOX10 Consensus Sites in rSOX-4 has No Effect on Luciferase 
Activity. (Top) A schematic of the three SOX10 consensus sites (black boxes) with each site 
deleted (indicated by the red Xs). The name of each construct is shown at the left, and a scale bar 
is shown at the top. (A) The four SOX10 deletion constructs were assessed in the reverse 
orientation only in the S16 cells either untreated (left side; blue bars) or co-transfected with 
dominant-negative SOX10 (right side; red bars). All activity is relative to the untreated major 
activity which as been set to ‘100’. (B) The four SOX10 deletion constructs were assessed in the 
reverse orientation only in the MN-1 cells either untreated (left side; blue bars) or co-transfected 
with wildtype SOX10 (right side; red bars). All activity is relative to the untreated major activity 
which as been set to ‘1’. 
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metaphase spreads and observed approximately triploid chromosome counts (data not shown). 
This is in agreement with spectral karyotyping (SKY) (Schröck et al. 1996) of different 
subcultures of S16 cells (unpublished data) which detected near triploid chromosome counts. 
Interestingly, one of the more common structural abnormalities observed was complete loss of 
chromosome 17 (where rSOX-4 resides). Our S16 subcultures do not appear to be missing 
chromosome 17, since two rounds of CRISPR targeting and drug selection were required to 
modify all alleles present. Regardless, we were able to target all wildtype alleles in the S16 cells 
to remove rSOX-4 and leave only a single loxP scar behind. 
One major problem of using CRISPR in cell lines is the potential for off-target effects (Fu et al. 
2013; Pattanayak et al. 2013). This was partially mitigated in our analysis by the independent 
generation of two clonal cell lines; however due to the InDels generated in the non-recombined 
alleles, we were unable to use a single gRNA for each clone throughout both rounds of targeting. 
Because of this, it is possible the two clonal cell lines share similar off target affects. Current 
methods to detect off target effects such as GUIDE-Seq (Tsai et al. 2015) are only able to predict 
candidate off target sites prior to CRISPR editing and would be unable to determine off target 
effects in our edited cell lines. This procedure could be employed to assess candidate sites which 
could be screened in our modified cells. 
A different method to detect off target effects could employ a modified version of L1-Seq (Iskow 
et al. 2010). L1-Seq was developed to detect novel integration sites of LINE1 elements in cell 
lines and could potentially identify off target sites where the repair template integrated. This 
method, however, would be unable to detect small InDels similar to what we observed in the 
non-recombined alleles of the rSOX-4 cell lines between rounds of CRISPR editing. A final 
method to detect off target effects would be whole genome sequencing of our CRISPR modified 
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cell lines. This is currently limited in three ways: (1) the S16 cells are immortalized cells with 
unknown genomic rearrangements and an unknown karyotype (2) the rat genome is poorly 
annotated making distinctions between SNPs and novel mutations caused by CRISPR 
challenging and (3) the prohibitive cost of sequencing the rSOX-4 cells to identify novel InDels. 
The second issue could be partially mitigated by sequencing the unmodified parental cells, but 
significant problems still arise when mapping the reads back to the rat reference genome, due to 
unknown genomic rearrangements. In this study, we attempted to minimize false positive target 
genes by leveraging two independent rSOX-4 mutant cell lines. Future studies should use unique 
gRNAs for each clonal cell line, potentially designing additional unique gRNAs for every clonal 
line as necessary. 
To detect any gene expression changes based on the loss of rSOX-4, we performed RNA-Seq 
analysis on the three rSOX-4 mutant clones and two unmodified S16 cell lines. One of the 
unmodified S16 cell lines was the original founder for all three rSOX-4 mutant clones, while the 
other was an older passage (passage 39) stock. The older passage stock was chosen to account 
for potential effects of additional passages on gene expression. After mapping, read counting, 
and using DeSeq2 to determine gene expression differences, we identified 197 genes that were 
significantly differentially expressed between the two groups. These 197 differentially expressed 
genes may be the result of off target effects. Indeed, we observed three distinct clusters of genes 
(genes that are either direct neighbors or separated by a single gene) that were significantly 
differentially expressed. Interestingly, all genes within a cluster demonstrated the same direction 
of the fold change (i.e. all were either upregulated or downregulated), and for two of the three 
clusters this resulted in increased gene expression in the rSOX-4 mutants relative to the 
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unmodified S16 cells (Table 3.4). This may suggest a nearby insertion of the CMV promoter, 
that was used to direct blasticidin or neomycin expression, is affecting nearby gene expression.  
Conversely, 35 of the 197 genes were also significantly differentially expressed between the five 
unmodified S16 clones. Within the five modified clones, RNA was isolated from three actively 
dividing cell lines while the other two were isolated from fully confluent flasks (i.e. not actively 
dividing). This suggests that these 35 genes may depend on the cell cycle and are confounding 
interpretation of the RNA-Seq results. For example, Ube2c is a known cell cycle regulator 
(Townsley et al. 1997), and is one of the 35 genes significantly differentially expressed in both 
the rSOX-4 compared to unmodified S16 dataset and the S16 clone dataset. Another gene 
common to both datasets is S100a6 which is also involved in cell cycle progression and 
senescence (Słomnicki and Leśniak 2010; Bao et al. 2012). 
Despite potential disruption of cell cycle regulators, and other unknown variables, we anticipated 
the deletion of rSOX-4 would result in decreased gene expression in the rSOX-4 mutant cell 
lines relative to the unmodified S16 cells based on the luciferase data that rSOX-4 is acting as an 
enhancer. In addition, while it is possible that the target gene of rSOX-4 resides on a different 
chromosome, we focused our efforts on downregulated genes in cis with rSOX-4. Only two 
dysregulated genes met this criteria: Gmnn and Tubb2b. Upon further examination, only Tubb2b 
could be validated using ddPCR with independent cDNA samples and by additional RNA-Seq 
results using five clonal unmodified S16 cell lines.  
Interestingly, Gmnn is a known cell cycle regulator (McGarry and Kirschner 1998), and although 
it was not one of the 35 genes discussed above, it may explain why Gmnn was a false positive. It 
is important to note that Gmnn has additional roles that make it an attractive candidate target  
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Table 3.4 Tubb2b is Significantly Decreased in Expression in rSOX-4 Mutants Compared to All 
Unmodified S16 Cells. 
Gene p-value1 Mean Expression2 Fold Change3 Distance4 
Tubb2b 1.33E06 738.43 (65.3%) -9.62 8.9 
Gmnn 0.93 1,495.23 (74.2%) -1.06 1.9 
 
1Benjamini-Hochberg adjusted p-value for multiple testing. 
 
2Mean expression is the average of total counts across all cell lines. Number in parentheses is 
percentile rank of these genes relative to genes expressed in S16 cells (i.e. at least one read 
counted for the gene). 
 
3Fold change calculated relative to wild type cells. Negative value means lower expression in 
rSOX-4 mutant cells, and positive values means higher expression in rSOX-4 mutant cells. 
 
4Distances from rSOX-4 to the gene are given in millions of base pairs (Mb). 
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gene of rSOX-4. Recent studies where Gmnn expression was decreased in mice resulted in 
inhibition of the epithelial to mesenchymal transition required for neural crest delamination 
(Emmett and O'Shea 2012). Additionally, when Gmnn is specifically deleted in neural crest cells 
of mice, the enteric nervous system fails to develop, and the mice exhibit severe Hirschprung’s 
disease phenotypes (Stathopoulou et al. 2016). While further experiments such as deletion of 
rSOX-4 in vivo in mice may be necessary to conclusively exclude Gmnn as the target gene of 
rSOX-4, our data at present were unable to validate the initial RNA-Seq results. 
Tubb2b is a critical component of microtubules, and mutations of this gene can result in 
polymicrogyria (Jaglin et al. 2009). There is no known role of Tubb2b in either the neural crest 
nor Schwann cells; however, Tubb2b expression is highest in migratory neurons (Jaglin et al. 
2009; Breuss et al. 2015). Since rSOX-4 directed LacZ expression in migratory melanoblasts, 
this may suggest that Tubb2b has a similar, uncharacterized role in these and other neural crest 
derived cells; specifically, in cell migration. A mouse harboring a GFP transgene reporter 
inserted into the endogenous Tubb2b locus has been generated (Breuss et al. 2015). The earliest 
time point the authors looked at was E14.5, which is after melanoblast migration has completed 
(Mort et al. 2015); however, the expression patterns are strikingly similar, as the authors observe 
GFP expression within the presumptive spinal cord and GFP expression in the head and brain 
region. Using this mouse to investigate earlier time points, such as E11.5 when melanoblasts are 
migrating, may uncover a novel role for Tubb2b.  
Interestingly, in the most recent release of the human genome (GRCh38), rSOX-4 resides within 
the first intron of a long non-coding RNA (lncRNA), LOC105374972. At this time there is no 
known function of the lncRNA, but it has been classified as ‘validated’. Converting the 
coordinates of the lncRNA from human to rat, we were unable to detect any RNA-Seq reads 
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corresponding to the lncRNA exons. This may be due to generating a polyA selected RNA 
library for RNA-Seq, and being unable to capture this lncRNA because it may not be 
polyadenylated (Yang et al. 2011). Another reason for the lack of RNA-Seq reads is that the 
lncRNA may also not be present in Schwann cells. Based on our in vivo rSOX-4:LacZ mice 
which demonstrated that rSOX-4 is active in the dorsal root ganglia and melanoblasts, the 
lncRNA may play a role in these other tissues. Additional studies will be necessary to elucidate 
any functional role of the lncRNA and determine if rSOX-4 regulates the lncRNA. 
In this chapter, we modified the unbiased rSNP computational identification program developed 
in Chapter 2 to include specific TFBS information. We used SOX10 because it has a well 
characterized binding site (Peirano and Wegner 2000; Srinivasan et al. 2012), and it is critical for 
Schwann cell function (Chapter 1). While we were able to successfully identify two SOX10 
response elements with rSNPs, the pipeline outlined here is very modular and can be used for the 
identification of other TFBSs. Indeed, we modified our pipeline to predict THAP1 binding sites 
by including information about THAP1 binding sites, removing the SNP filter, and using 
conservation among human, mouse, and dog at candidate genes identified through additional 
experiments. THAP1 is a transcription factor that, when mutated, causes torsion dystonia in 
humans (Fuchs et al. 2009). In collaboration with Dr. William Dauer, we were able to use this 
modified pipeline to quickly identify and functionally assess 13 regions near the candidate genes. 
One of these regions demonstrated decreased expression when the THAP1 consensus site was 
deleted, and additional experiments are being performed to determine the functional role of this 
response element. 
The pipeline established in this chapter also allows for the rapid characterization of variants of 
unknown significance identified in patients. Recently we were contacted by a physician 
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regarding a variant of unknown significance identified in a 13-year-old boy with CMT1. The 
variant resides in the intron of MPZ, and the patient had no coding mutations in any other known 
CMT disease genes. This variant converted one predicted SOX10 monomer to a different SOX10 
monomer, and was located 117 base pairs downstream (3’) of a previously characterized SOX10 
element (Antonellis et al. 2010). Upon testing the wildtype allele, patient variant, and a deleted 
SOX10 consensus site in our luciferase assays in S16 cells, we observed a large increase in 
activity of the patient variant compared to the wildtype allele in Schwann cells (Figure 3.16). We 
also observed low luciferase activity in motor neurons consistent with this being is a SOX10 
response element. Interestingly, increased MPZ expression has been shown to cause CMT1 in 
patients (Maeda et al. 2012). Additional studies will be necessary to demonstrate that this variant 
is causative, however the functional pipeline developed in this chapter allowed rapid assessment 
of this variant and can be used for similar studies in the future. 
As demonstrated in this chapter and in Chapter 2, our computational pipeline can successfully 
identify TFBSs harboring SNPs. We were able to identify 224 fully conserved SOX10 binding 
sites and prioritized 22 using additional genomic datasets. We rapidly functionally evaluated the 
regions using luciferase assays to identify two novel rSNPs within SOX10 response elements. 
We focused on one region, rSOX-4, and deeply characterized the region through CRISPR knock 
out and in vivo transient transgenic mouse reporter experiments. Through these (and other) 
experiments, Tubb2b was identified as a strong candidate target gene of rSOX-4. While 
additional experiments will be necessary to confirm our results the rSNP within rSOX-4, rSOX-4 
itself, and Tubb2b represent excellent candidate modifiers of neurocristopathies. Additionally, 
understanding and characterizing the role of Tubb2b in neural crest cells and in particular 
melanoblasts will give novel insight into the development of these cell populations. 
 132 
  
Figure 3.16 A Variant Allele Identified in a Patient with CMT1 Increases Luciferase Activity 
Compared to the Wildtype Allele. (A) The sequence surrounding the patient variant (red letter; 
purple box) within a SOX10 consensus site indicated by the line at the top. The other line 
(labeled with ‘?’) indicates another potential SOX10 monomeric or dimeric site. Only changes in 
sequence between the indicated species and humans is display. The ‘.’ Indicates identical base 
pair as in humans and ‘=’ indicates no sequence alignment. (B) A region surrounding the patient 
variant was amplified and assessed in luciferase assays. Three constructs were generated 
harboring either the wildtype, patient variant, or deletion of the SOX10 monomer (ΔSOX). The 
regions were assessed in either the forward (left bars; Forward) or reverse (right bars; Reverse) 
in both Schwann cells (S16; blue bars) or motor neurons (MN-1; red bars). The activity of each 
allele is compared back to a control plasmid that contains no insert (‘Empty’) that has been set to 
‘1’, and error bars represent standard deviation. 
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In the next chapter, we will utilize the modularity of our computational pipeline to remove the 
SNP filter and identify novel dimeric SOX10 binding sites within known genes associated with 
Schwann cell function. We also identify a subset of SOX10 response elements near genes 
implicated as negative regulators of myelination and start to address how SOX10 expression 
remains constant even in non-myelinating Schwann cells. 
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Stringent Comparative Sequence Analysis Reveals SOX10 as a Putative 
Inhibitor of Glial Cell Differentiation 
Introduction 
Schwann cells produce the myelin sheath in the peripheral nervous system (PNS), which allows 
rapid saltatory conduction and long-range communication between the central nervous system 
and innervated muscles and sensory organs. Schwann cell development is directed by a 
transcriptional hierarchy that promotes the expression of proteins important for migration along 
peripheral nerves, radial sorting of axons, and the initiation of myelination (Jessen and Mirsky 
2005; Stolt and Wegner 2015). Atop this hierarchy sits the transcription factor SOX10, which is 
critical for the development and long-term function of Schwann cells (Kuhlbrodt et al. 1998) and 
is expressed during all stages of Schwann cell development (Kuhlbrodt et al. 1998; Britsch et al. 
2001).  
Three major lines of evidence underscore the importance of SOX10 for the function of Schwann 
cells. First, loss of Sox10 at any developmental stage results in dramatic phenotypes in mice: 
ablation of Sox10 activity during early development results in a lack of Schwann cells (Britsch et 
al. 2001), conditional deletion of Sox10 in the immature Schwann cell stage results in lethality in 
mice (Finzsch et al. 2010), and conditional deletion of Sox10 in terminally differentiated 
myelinating Schwann cells results in demyelination of the peripheral nerves (Bremer et al. 2011). 
Second, dominant-negative SOX10 mutations cause an autosomal dominant disease characterized 
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by peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg-
Shah syndrome, and Hirschsprung disease (PCWH) (Inoue et al. 1999; Inoue et al. 2004); the 
non-PNS phenotypes reflect the role of SOX10 in other neural crest derivatives (e.g. 
melanocytes and enteric neurons) and in oligodendrocytes. Finally, mutations in SOX10 target 
genes, including those encoding peripheral myelin protein 22 (PMP22) (Lupski et al. 1991; 
Raeymaekers et al. 1991), myelin protein zero (MPZ) (Kulkens et al. 1993), early growth 
response 2 (EGR2) (Warner et al. 1998), and gap junction beta 1 (GJB1) (Ionasescu and Searby 
1994), cause demyelinating peripheral neuropathy.  
The identification of additional SOX10 response elements and target loci will provide important 
information on the process of myelination in the peripheral nerve as well as novel target 
sequences to scrutinize for mutations and modifiers of peripheral neuropathy. Indeed, genome-
wide analyses have been essential for characterizing SOX10 biology in Schwann cells (Lee et al. 
2008; Srinivasan et al. 2012); Chapter 3); however, these efforts have primarily focused on 
identifying positive regulators of myelination by examining tissues or cells in a myelinating state. 
Less-biased approaches are needed to complement the above studies and to identify functions of 
SOX10 outside of the regulation of promyelinating loci. 
Here, we modify our stringent computational strategy developed in the previous chapters to 
rapidly identify SOX10 response elements in the human genome. Combined with molecular 
functional studies, this strategy revealed SOX10 response elements residing near SOX5, SOX6, 
NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2. Interestingly, each of these genes has a known 
role in the negative regulation of glial cell differentiation. As such, we have identified a 
potentially novel role for SOX10 in Schwann cells and present a model where SOX10 activates 
the expression of negative regulators of myelination to temper the pro-myelinating program 
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during non-myelinating stages of Schwann cell development; however additional in vivo 
functional studies will be necessary to test this proposed model.  
All the work in this chapter was performed by the author with the exception of the following. A 
portion of the computational analyses were performed by Tony Antonellis and Arjun Prasad 
(NIH/NCBI). A portion of the cloning and functional assessment of the 65 regions presented in 
this chapter were performed by Chetna Gopinath. The follow-up studies focusing on the 
alternative promoter at Sox6 (i.e. RT-PCR, 5’-RACE, ect.) was performed by Chetna Gopinath 
as part of her thesis research.  The work presented in this chapter resulted in a co-first author 
(Law and Gopinath) manuscript, which is currently under review. Finally, the siRNA 
experiments in S16 cells (Figure 4.9 A), the mRNA expression analysis at multiple 
developmental timepoints from sciatic nerves in rat (Figure 4.9 B), and the siRNA experiments 
using primary Schwann cells (Figure 4.10) were performed by José F. Rodríguez-Molina in John 
Svaren’s laboratory (University of Wisconsin-Madison). 
 
Methods 
Computational Identification and Prioritization of SOX10 Consensus Sequences 
To identify all SOX10 consensus sequences in the human genome, we downloaded individual 
text files for each human chromosome (hg18) from the UCSC Human Genome Browser (Kent et 
al. 2002) and wrote a Perl script (available upon request) that examines each file for the SOX10 
consensus sequences (using a regular expression analysis; 5’-3’): ACACA, ACAAA, ACAAT, 
ACAAG. To identify two SOX10 consensus sequence monomers that are oriented in a head-to-
head manner (and that may represent a dimeric SOX10 binding site), we wrote a second Perl 
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script that examines the human chromosome text files and reports each ACACA, ACAAA, 
ACAAT, or ACAAG consensus sequence that is five to 10 base pairs 5’ to the reverse 
complement of this consensus sequence (5’-3’): TGTGT, TTTGT, ATTGT, or CTTGT.  
To identify genomic sequences that are identical between human, mouse, and chicken, we 
downloaded the vertebrate (44 species) multiz alignment (maf) files from the UCSC Human 
Genome Browser (hg18) and extracted the alignments for human, mouse, and chicken. Next, we 
utilized the program ExactPlus (Antonellis et al. 2006) to identify all human sequences that are at 
least five base pairs long and identical across all three species. All subsequent computational 
analyses that assess for overlap between these and other datasets were performed using the 
UCSC Table Browser (Karolchik et al. 2004) and the ‘intersection’ tool. For these analyses we 
employed UCSC Genome custom tracks containing each: (1) human RefSeq (hg18) protein-
coding sequence to exclude coding sequences; (2) human RefSeq entry (hg18) plus 2.5 kb 
upstream and 2.5 kb downstream of the transcriptional unit to identify regions that map to known 
genes; (3) SOX10 ChIP-Seq peak in the rat genome (rn5) using HOMER analysis (Heinz et al. 
2010) of previously described P15 sciatic nerve datasets; and (4) DNase-Seq peak in the rat 
genome (rn5) that has an F-Seq (Boyle et al. 2008) score of at least 0.08 (see below). 
To identify the 57 loci (Appendix 6) with a known or predicted role in peripheral nerve 
myelination, we performed the following PubMed searches in September 2014: (1) each gene 
name plus ‘Schwann’; and (2) each gene name plus ‘Myelin’. We also searched for each gene 
name plus ‘Schwannoma’ in the GEO Profiles database at NCBI to determine if gene expression 
is depleted upon treatment with SOX10 siRNA (Lee et al. 2008).  
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Standard and Quantitative RT-PCR 
Total RNA was isolated from S16 and MN-1 cells. 100,000 cells were plated in a 6-well plate 
and incubated overnight at 37°C in 5% CO2. For an individual well, 5 μL of Lipofectamine 2000 
was mixed with 500 μL of Optimem (ThermoFisher cat no 31985-062) and incubated for 10 
minutes at room temperature (cocktail 1). 4 μg of wildtype SOX10 or E189X SOX10 (Inoue et al. 
2004) plasmid DNA was mixed with 500 μL of Optimem and combined with the first cocktail 
after the 10 minute incubation (transfection mixture). The transfection mixture was vortexed for 
three seconds and incubated for 20 minutes at room temperature. During the final incubation, the 
S16 cells were washed with 2 mL of 1X PBS (ThermoFisher Cat no. 10010-023), and 1 mL of 
the transfection mixture was added. The cells were incubated for four hours at 37°C in 5% CO2. 
After four hours, the transfection mixture was removed and replaced with 3 mL of standard 
growth media (Chapter 2). The cells were incubated for 72 hours at 37°C in 5% CO2. Mock 
transfections were performed in the absence of DNA.  
After 72 hours, total RNA was isolated from the transfected cells using the RNeasy kit (Qiagen 
Cat no. 74104). The cells were harvested, centrifuged for two minutes at 2,000 RPMs, the 
supernatant was discarded, and the cells were resuspended in 350 μL RLT buffer plus beta-
mercaptoethanol (BME; 1 mL of RLT buffer add 10 μL BME). Next, 350 μL of 70% ethanol 
was added and the mixture was vortexed for 30 seconds. The entire mixture (including 
precipitate) was transferred to the spin column, centrifuged at 15,000 RPMs for 30 seconds, and 
the flowthrough was discarded. Subsequently, 700 μL of RW1 buffer was added to the sample, 
centrifuged at 15,000 RPMs for 30 seconds, and the flowthrough was discarded. The sample was 
washed by added 500 μL of RPE buffer, centrifuged at 15,000 RPMs for 30 seconds, and the 
flowthrough was discarded. A second wash was performed, but the sample was centrifuged at 
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15,000 RPMs for two minutes for the second wash step. The sample was then centrifuged at 
15,000 RPMs for one minute to remove any remaining liquid (dry spin). The column was then 
transferred to a clean collection tube, 50 μL of ultrapure water was added, and the column was 
centrifuged at 15,000 RPMs for one minute. The flowthrough was added back to the column, the 
column was placed into the same collection tube, and centrifuged a second time at 15,000 RPMs 
for one minute to increase the RNA yield. The RNA was then quantified using the Nanodrop 
Lite and used in subsequent experiments. 
cDNA was synthesized using 1 μg of total RNA and the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems Cat no. 4368814). A single reaction contained 3.2 μL 
ultrapure water, 2 μL 10X random primers, 2 μL 10X RT buffer, 1 μL RNase inhibitor, 0.8 μL 
dNTPs, 1 μg S16 RNA in 10 μL of water, and 1 μL MultiScribe reverse transcriptase. The 
reaction was incubated for 10 minutes at 25°C, then two hours at 37°C, then 85°C for 5 seconds, 
and finally held at 4°C. RT-PCR was performed on isolated cDNA using gene specific primers 
(Appendix 7). A PCR for β-actin served as a positive control. All PCR products were subjected 
to DNA sequencing to confirm specificity.  
RNA was purified from three independent rat sciatic nerves at the P1, P15, and adult timepoints 
using the RNeasy Lipid kit (Qiagen Cat no. 74804), and quantitative RT-PCR was performed by 
our collaborator Dr. John Svaren as previously described (Gokey et al. 2012).  
 
5’ Rapid Amplification of cDNA Ends 
First strand cDNA libraries were synthesized using total RNA isolated from S16 cells (see 
above) and a primer designed within exon 5 of Sox6 (Appendix 8): 1.25 μL rnSOX6 GSP1 (2 
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μM), 6.3 μL (~5 μg) S16 RNA, and 7.95 μL ultrapure water were added. The reaction was 
incubated at 70°C for 10 minutes, chilled on ice for one minute, briefly centrifuged, and the 
following components were added (in order): 2.5 μL 10X PCR buffer, 2.5 μL 25mM MgCl2, 1 
μL 10 mM dNTP mix, and 2.5 μL 0.1 M DTT. The reaction was gently mixed, briefly 
centrifuged, incubated for one minute at 42°C, and 1 μL of SuperScript II RT was added. The 
reaction was incubated for 50 minutes at 42°C, and then incubated at 70°C for 15 minutes to 
terminate the reaction. The mixture was briefly centrifuged and placed at 37°C for 30 minutes.  
The cDNA was then purified using S.N.A.P. column purification. First, 120 μL of binding 
solution (6M NaI) was added to the cDNA mixture (see above). Next, the entire mixture was 
transferred to a S.N.A.P. column, centrifuged at 13,000g for 20 seconds, and the flowthrough 
was saved until the recovery of the cDNA was ensured. The cDNA was washed by adding 400 
μL of 4°C 1X wash buffer to the column, centrifuged at 13,000g for 20 seconds, and the 
flowthrough was discarded. The wash step was repeated three additional times. After washing, 
400 μL of 4°C 70% ethanol was added, centrifuged at 13,000g for 20 seconds, and the 
flowthrough was discarded. The ethanol wash step was repeated one additional time (two total 
ethanol washes). Finally, the column was transferred to a clean recovery tube, 50 μL of 65°C 
ultrapure water was added, and the column was centrifuged at 13,000g for 20 seconds. 
The cDNA was TdT-tailed using the 5’RACE System (Invitrogen Cat no. 18374058) by adding 
6.5 μL ultrapure water, 5 μL 5X tailing buffer, 2.5 μL 2mM dCTP, and 10 μL S.N.A.P.-purified 
cDNA. No additional quantification was performed on the S.N.A.P.-purified cDNA prior to the 
TdT-tailing reaction. The reaction was incubated for three minutes at 94°C, chilled on ice for one 
minute, and briefly centrifuged. Next, 1 μL TDT was added, gently mixed, and incubated at 
37°C for 10 minutes. Finally, the reaction was quenched by incubation at 65°C for 10 minutes. 
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Subsequently, two nested PCRs were performed first using a reverse primer designed within 
exon 4 of Sox6 (Appendix 8): 31.5 μL ultrapure water, 5 μL 10X PCR buffer, 3 μL 25 mM 
MgCl2, 1 μL 10 mM dNTPmix, 2 μL 10 μM rnSOX6 GSP2, 2 μL Abridged anchor primer, 5 μL 
dC-tailed cDNA, and 0.5 μL Taq polymerase (NEB Cat no. M0273S). A second nested PCR was 
performed using a reverse primer designed within exon 3 of Sox6 (Appendix 8): 33.5 μL 
ultrapure water, 5 μL 10X PCR buffer, 3 μL 25 mM MgCl2, 1 μL 10 mM dNTPmix, 1 μL 10 μM 
rnSOX6 GSP3, 1 μL 10 μM AUAP primer, 5 μL of PCR product from first nested reaction, and 
0.5 μL Taq polymerase (NEB Cat no. M0273S). The nested PCR products were separated on a 
1% agarose gel, excised, and purified using the QIAquick gel extraction kit (Qiagen Cat no. 
28704). Gel purified PCR products were TA cloned (Invitrogen Cat no. 450071): 1 μL 5’ RACE 
PCR product, 1 μL Salt solution (1.2 M NaCl2 and 0.06 M MgCl2), 1 μL (10ng) pCR4 TOPO 
vector, and 3 μL ultrapure water. The resulting plasmids were transformed into E. coli, plated on 
kanamycin selective plates, colonies were selected and grown, and plasmid DNA was isolated 
(see Chapter 2 for details). 48 clones were subjected to Sanger sequencing; 44 of the resulting 
sequences correctly mapped to the rat Sox6 locus.  
 
siRNA-mediated Depletion of SOX10  
Control siRNA (siControl 1, Ambion Cat no. AM4611) or Sox10 siRNA (siSox10 1, Life 
Technologies Cat no. s131239) were transfected into S16 cells as described using the Amaxa 
Nucleofection system following the manufacturer’s instructions. At 48 hours post-transfection, 
RNA was isolated using Tri-Reagent (Ambion) and analyzed by quantitative RT-PCR as 
described (Gokey et al. 2012). 
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DNase Hypersensitivity Site Identification 
DNase-Seq was performed with three biological replicates of the S16 cells at passage numbers 
five, eight, and 14. Each replicate contained ~20 million cells frozen into 1 mL of recovery cell 
culture freezing media (Invitrogen Cat no. 12648010). Cells were thawed, and DNase-Seq 
libraries were generated as previously described (Song and Crawford 2010) with the exception of 
adding a 5’ phosphate to linker 1 to increase the ligation efficiency. DNase-Seq libraries from 
three replicates were pooled into one lane of an Illumina Hi-Seq 2000. Raw reads were aligned 
to the rat rn5 genome using Bowtie (Langmead et al. 2009) and mapped allowing up to two 
mismatches. For the three samples, 69.2% (36,295,401), 70.8% (43,564,606), and 67.9% 
(39,579,719) of the reads mapped to rn5. Peaks were called using F-Seq and the default settings 
(Boyle et al. 2008). For the three samples: 502,787 (sample 1), 438,254 (sample 2), and 412,267 
(sample 3) peaks were identified. 149,342 peaks were shared among all three samples. We used 
sample 2 as a representative experiment and extracted all DNase-Seq peaks with an F-Seq score 
of at least 0.08. This revealed a set of 31,845 peaks (7.3%) that were used to prioritize SOX10 
response elements. 
 
Results 
Genome-wide Prediction of SOX10-responsive Transcriptional Regulatory Elements 
SOX10 binds to a well-defined consensus sequence (5’-3’; ACACA, ACAAA, ACAAT, or 
ACAAG) as a monomer or as a dimer when two consensus sequences are oriented in a head-to-
head fashion (Peirano and Wegner 2000; Srinivasan et al. 2012). To identify all putative SOX10 
binding sites in the human genome, we wrote a Perl script to scan each human chromosome and 
report all occurrences of the above SOX10 consensus sequence (Chapter 3). This revealed over 
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33 million monomeric consensus sequences and ~549,000 dimeric consensus sequences with an 
intermonomeric sequence of five to 10 base pairs. 
Multiple-species conservation analysis is an effective approach for predicting non-coding DNA 
sequences with a role in transcriptional regulation (See Chapters 2 and 3). Importantly, 
functionally validated SOX10 binding sites have been identified in non-coding genomic 
sequences that are conserved between human and chicken (Antonellis et al. 2008; Gokey et al. 
2012; Hodonsky et al. 2012); Chapter 3). To prioritize the large dataset of SOX10 consensus 
sequences, we aligned the human, mouse, and chicken genomes and identified all genomic 
sequences that are five base pairs or longer (the length of the monomeric SOX10 consensus 
sequence) and that are identical between these three species. This revealed over two million 
conserved coding and non-coding genomic segments.  
To develop a panel of prioritized SOX10 consensus sequences for functional studies, we used the 
rationale that focusing on: (1) conserved dimeric SOX10 consensus sequences will enrich for 
bona fide SOX10 binding sites; (2) non-coding sequences will deprioritize sequences that are 
conserved due to the function of the gene product; and (3) proximal promoter and intronic 
sequences will provide a candidate target gene for further studies. Thus, we compared the above 
datasets to identify dimeric SOX10 consensus sequences that are conserved between human, 
mouse, and chicken (including the intermonomeric sequence), reside in non-coding sequences, 
and map to an intron or 2.5 kb upstream or downstream of a known (RefSeq) human gene. This 
revealed 238 genomic sequences at 160 loci for further study. To determine the efficacy of our 
modified approach, we further prioritized the above 238 genomic segments by identifying the 
subset that map to loci with a known or predicted role in myelination (see methods for details). 
This revealed 57 genomic sequences at 32 loci with a conserved, dimeric SOX10 consensus 
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sequence that resides within an intron or directly upstream of a myelin-related transcriptional 
unit; we named these elements SOX10 Conserved Consensus Sequences (SOX10-CCS; 
Appendix 6).  
 
Seven Conserved SOX10 Consensus Sequences Display Regulatory Activity in Schwann Cells 
Using our computational pipeline, we identified 57 regions that harbor conserved head-to-head 
SOX10-CCSs at loci with a known or predicted role in myelination. To test if these sequences 
are active in Schwann cells in vitro, a region surrounding each consensus sequence (Appendix 6) 
was amplified from human genomic DNA and cloned upstream of a minimal promoter directing 
the expression of a luciferase reporter gene in the same orientation as the direction of 
transcription of the gene. The regulatory activity of each genomic segment was tested in cultured 
rat Schwann cells (S16) (Goda et al. 1991), which express endogenous Sox10 (Hodonsky et al. 
2012). The luciferase expression directed by each genomic segment was determined in luciferase 
activity assays relative to a control vector with no genomic insert (‘Empty’), with the activity 
arbitrarily set to ‘1’. Seven of the 57 genomic segments demonstrated a greater than 2.5-fold 
(differs from five-fold increase used in previous chapters) increase in luciferase activity 
compared to the empty vector in S16 cells (Figure 4.1): SOX10-CCS-01 (3.7-fold increase; maps 
to PAX7), SOX10-CCS-13 (54-fold increase; maps to SOX6), SOX10-CCS-18 (82-fold increase; 
maps to SOX5), SOX10-CCS-19 (49-fold increase; maps to SOX5), SOX10-CCS-39 (5.9-fold 
increase; maps to TCF7L2), SOX10-CCS-43 (25-fold increase; maps to BCAS3), and SOX10-
CCS-51 (2.6-fold increase; maps to NFIB). These data suggest that these seven genomic 
sequences (Table 4.1) are potential SOX10 response elements. 
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Figure 4.1 Seven Regions Demonstrate Regulatory Activity in Schwann Cells. Each of the 57 genomic segments containing prioritized 
SOX10 consensus sequences were cloned upstream of a luciferase reporter gene in the same orientation as the gene and tested for 
enhancer activity in cultured Schwann (S16) cells. Luciferase data are expressed relative to a control vector that does not harbor a 
genomic insert (‘Empty’) with activity arbitrarily set to ‘1’. Regions that demonstrated a greater than 2.5-fold increase (dashed black 
line) in luciferase activity are indicated in red text, and error bars indicate standard deviations.
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Table 4.1 Seven Genomic Segments with Regulatory Activity in Schwann Cells. 
Element ID Locus UCSC Coordinates1 SOX10 Consensus Sequence2 
SOX10-CCS-01 PAX7 chr1:18854774-18854793 ACAAACTCATTAAACTTGT 
SOX10-CCS-13 SOX6 chr11:16334769-16334784 ACAATCAAGCATTGT 
SOX10-CCS-18 SOX5 chr12:24059368-24059383 ACAAAAATGTATTGT 
SOX10-CCS-19 SOX5 chr12:24059689-24059706 ACACAGAACATTATTGT 
SOX10-CCS-39 TCF7L2 chr10:114895622-114895642 ACAATCCCCAAGATTTTTGT 
SOX10-CCS-43 BCAS3 chr17:56684299-56684319 ACACATTAATAACGTTTTGT 
SOX10-CCS-51 NFIB chr9:14299587-14299605 ACAATCTGTTCTTTGTGT 
 
1Coordinates refer to the March 2006 UCSC Genome Browser Human assembly (hg18). 
 
2SOX10 consensus sequences are indicated in red letters and bold text. 
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The SOX10 Consensus Sequence is Required for the Orientation-Independent Activity of Three 
Regulatory Elements at SOX5, SOX6, and NFIB  
To determine if the regulatory activity of the seven genomic segments is dependent on the 
orientation of the DNA sequence, we retested the activity of each segment in both the ‘forward’ 
and ‘reverse’ orientation relative to the minimal promoter within our reporter gene construct in 
S16 cells. This revealed three genomic segments that enact a greater than 2.5-fold increase in 
luciferase activity in both orientations (Figure 4.2): SOX10-CCS-13 (72-fold forward and 9-fold 
reverse), SOX10-CCS-19 (70-fold forward and 33-fold reverse), and SOX10-CCS-51 (4-fold 
forward and 9-fold reverse). To assess the specificity of these results to Schwann cells, we tested 
each of the seven genomic segments in both orientations in cultured mouse motor neurons (MN-
1 cells) (Salazar-Grueso et al. 1991), which do not express endogenous SOX10 (Hodonsky et al. 
2012). None of the genomic segments enact a greater than 2.5-fold increase in luciferase activity 
in both orientations in MN-1 cells suggesting that our data in S16 cells is Schwann-cell specific; 
however, three genomic segments displayed low levels of activity in only the forward orientation 
in MN-1 cells (Figure 4.2): SOX10-CCS-39 (5.5-fold), SOX10-CCS-43 (6.7-fold), and SOX10-
CCS-51 (4-fold). 
To test the necessity of the conserved SOX10 consensus sequence for the observed activity 
associated with the seven genomic segments described above, we deleted the dimeric SOX10 
consensus sequence along with the intervening sequence in each construct (ΔSOX10) and 
compared the activity to the wildtype genomic segment using the more active orientation. This 
revealed three genomic segments that display at least a 50% reduction in activity upon deleting 
the SOX10 consensus sequence (Figure 4.3): SOX10-CCS-13, SOX10-CCS-19, and SOX10-
CCS-51. Combined, our data are consistent with these three genomic segments—at the SOX6,  
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Figure 4.2 Three Genomic Segments Demonstrate Orientation-independent Luciferase Activity 
in Schwann Cells but Not Motor Neurons. The seven active regions from Figure 4.1 were tested 
in forward (grey bars) and reverse (white bars) orientation in rat Schwann cells (S16; Top) or 
motor neurons (MN-1; Bottom). Luciferase data are expressed relative to a control vector 
without a genomic segment (‘Empty’) with activity arbitrarily set to ‘1’ and error bars indicate 
standard deviations. 
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Figure 4.3 Three Genomic Segments Require the SOX10 Consensus Sequence for Luciferase 
Activity in Schwann Cells. Luciferase reporter gene constructs containing either the wildtype 
sequence (WT) or the sequence lacking the SOX10 consensus sequence(s) (ΔSOX10) were 
transfected into S16 cells and assessed by luciferase assays. The luciferase activity associated 
with each ΔSOX10 construct (red bar) is expressed relative to the respective wildtype construct 
(blue bar), with activity arbitrarily set to ‘100’ and error bars indicate standard deviations. 
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SOX5, and NFIB loci, respectively—representing Schwann cell enhancers that harbor required 
SOX10 consensus sequences. 
 
SOX10 is Necessary and Sufficient for the Activity of the Three Regulatory Elements at SOX5, 
SOX6, and NFIB  
To test if SOX10 is sufficient for the activity of SOX10-CCS-13, SOX10-CCS-19, and SOX10-
CCS-51, we co-transfected each reporter gene construct with or without a construct to express 
wildtype SOX10 (Inoue et al. 2004) in MN-1 cells. Subsequently, we compared the activity of 
each region in the presence or absence of SOX10 expression. There was a ~1,000-fold increase 
in the activity of SOX10-CCS-13 and a ~200-fold increase in the activity of SOX10-CCS-19 and 
SOX10-CCS-51 in the presence of SOX10 (Figure 4.4). 
To determine if SOX10 is necessary for the activity of SOX10-CCS-13, SOX10-CCS-19, and 
SOX10-CCS-51 in Schwann cells, S16 cells were transfected with each SOX10-CCS luciferase 
reporter gene construct along with a construct to express a dominant-negative mutant of SOX10 
(E189X), which interferes with the function of endogenous SOX10 (Inoue et al. 2004). 
Importantly, E189X SOX10 has been shown to specifically reduce the activity of genomic 
segments harboring SOX10 binding sites in luciferase assays (Brewer et al. 2014). We observed 
a greater than 85% reduction in the activity of all three genomic segments upon co-transfection 
with E189X SOX10 (Figure 4.4). Combined, our data indicate that SOX10 is both necessary and 
sufficient for the in vitro enhancer activity of SOX10-CCS-13, SOX10-CCS-19, and SOX10-
CCS-51. 
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Figure 4.4 SOX10 is Required for the Regulatory Activity of SOX10-CCS-13, SOX10-CCS-19 
and SOX10-CCS-51. (A) Luciferase reporter gene constructs harboring SOX10-CCS-13, 
SOX10-CCS-19 or SOX10-CCS-51 were transfected into mouse motor neurons (MN-1) with or 
without a construct to express wildtype SOX10. The luciferase activity associated with each 
construct in the presence of SOX10 is expressed relative to that of the construct in the absence of 
SOX10 with activity set arbitrarily to ‘1’. (B) Luciferase reporter gene constructs harboring 
SOX10-CCS-13, SOX10-CCS-19 or SOX10-CCS-51 were transfected into rat Schwann (S16) 
cells with or without a construct to express dominant-negative (E189X) SOX10. The luciferase 
activity associated with each construct in the presence of E189X SOX10 is expressed relative to 
that of the construct in the absence of E189X SOX10 with activity arbitrarily set to ‘100’. Error 
bars indicate standard deviations in both panels. 
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SOX10-CCS-13 is a Previously Unreported, Alternative Promoter at Sox6 
Examination of SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51 on the UCSC Genome 
Browser revealed that the SOX10 consensus sequence within SOX10-CCS-13 and SOX10-CCS-
19 are also conserved between human and zebrafish (Figure 4.5) further suggesting the these 
sequences may be important in jawed vertebrates. Additionally, analysis of published SOX10 
ChIP-Seq data generated from rat sciatic nerve nuclei (Srinivasan et al. 2012) and our own 
DNase hypersensitivity site (HSS) data generated from S16 cell nuclei (Chapter 3) revealed 
evidence of SOX10 occupancy and open chromatin at each region with the highest peaks for 
both datasets at SOX10-CCS-13 relative to the two other active SOX10-CCS regions (Figure 
4.5). Thus, to validate the efficacy of our approach, we pursued additional analyses of SOX10-
CCS-13, which resides at the SOX6 locus. 
Closer scrutiny of the SOX6 locus on the UCSC Genome Browser revealed seven unique SOX6 
mRNA isoforms in human, mouse, or rat, distinguished by alternative, non-coding first exons. 
Interestingly, SOX10-CCS-13 maps directly upstream of the 3’-most alternative first exon, 
which we named SOX6 exon 1G (Figure 4.6). We therefore hypothesized that SOX10-CCS-13 
acts as an alternative promoter at SOX6. To test this, we performed 5’-rapid amplification of 
cDNA ends (5’-RACE). Briefly, a cDNA library was generated using RNA isolated from 
cultured rat Schwann (S16) cells and a reverse primer in exon 5 of rat Sox6. Subsequently, nested 
PCR was performed using reverse primers in exon 4 and then exon 3 of rat Sox6 (see Appendix 8 
for primer sequences). The PCR products were cloned, sequenced, and aligned to the rat Sox6 
locus. These analyses revealed the presence of five unique Sox6 transcription start sites in 
cultured Schwann cells with 14 of the 44 Sox6-specific sequences mapping directly downstream 
of SOX10-CCS-13 (Figure 4.6). Analysis of RNA-Seq data generated in S16 cells (Chapter 3)  
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Figure 4.5 SOX6, SOX5, and NFIB Harbor Intronic SOX10 Response Elements. (A) Multiple-
species sequence analysis was performed using human, mouse, rat, chicken, and zebrafish 
genomic sequences surrounding the SOX10 consensus sequence (red text) within SOX10-CCS-
13, SOX10-CCS-19, and SOX10-CCS-51. Uppercase text indicates a nucleotide identical to the 
human sequence while lowercase text indicates a non-conserved nucleotide. Dashes indicate the 
absence of a detectable orthologous sequence in zebrafish. (B) SOX10 ChIP-seq and DNase-seq 
peaks are shown at SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51. Y-axes represent 
normalized sequence read depth (SOX10 ChIP-seq) and F-Seq score (DNase-seq). Black bars 
indicate the position of the SOX10 consensus sequence in each genomic segment (not to scale). 
The associated RefSeq intron and base pair size of each genomic segment is indicated along the 
bottom. Arrowheads indicate the direction of transcription. 
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Figure 4.6 SOX10-CCS-13 is an Alternative Promoter at the Sox6 Locus. The ~579 kb rat Sox6 
locus is shown on the UCSC Rat Genome Browser. SOX10-CCS-13 is indicated in red along 
with the seven human, mouse, and rat SOX6 RefSeq mRNAs (blue). Sox6-specific 5’ RACE was 
performed on RNA from S16 cells, and the five distinct Sox6 sequences were mapped to the rat 
genome. Please note that SOX10-CCS-13 maps to both the 5’ end of the seventh Sox6 mRNA 
and the fifth unique 5’ RACE-generated sequence. RNA-Seq data from S16 cells were mapped 
to Sox6 (the y-axis indicates sequence read depth) as was a PCR-amplified, full-length mRNA 
that contains Sox6 exon 1G. Genome-wide regulatory marks were also mapped to Sox6 with the 
Y-axes indicating normalized sequence read depths (both SOX10 ChIP-seq data sets) and F-Seq 
scores (DNase-seq). 
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also revealed reads that map to Sox6 exon 1G, with split reads into downstream exons, but no 
split reads into upstream exons. Additionally, we were able to amplify and sequence-verify a full 
length Sox6 mRNA that originates at exon 1G in S16 cells and contains all the expected exons 
with the exception of one alternatively spliced exon (Figure 4.6). Combined, our data indicate 
that SOX10-CCS-13 represents an internal, alternative promoter at Sox6. 
 
SOX10 is Necessary and Sufficient for the Expression of Sox6 Transcripts Harboring Exon 1G 
To determine if SOX10 is sufficient to direct the expression of Sox6 transcripts, we performed 
RT-PCR using primers designed in Sox6 exon 1G and exon 2 in regions conserved between rat 
and mouse (see Appendix 7 for primer sequences). While these primers amplify Sox6 transcripts 
containing exon 1G from a cDNA library generated from S16 RNA, we were not able to amplify 
these transcripts from a cDNA library generated from cultured mouse motor neurons (MN-1 
cells), which do not express endogenous SOX10 (Figure 4.7). However, when MN-1 cells were 
transfected with a construct to express wildtype SOX10, Sox6 transcripts containing exon 1G 
were detected and verified by DNA sequence analysis. Mock transfection or transfection with a 
construct to express a non-functional mutant version of SOX10 (E189X) (Inoue et al. 2004) did 
not allow amplification of Sox6 transcripts containing exon 1G (Figure 4.7). Thus, SOX10 is 
sufficient to activate the expression of Sox6 transcripts harboring exon 1G in MN-1 cells. 
To determine if SOX10 is necessary for the expression of Sox6 transcripts containing exon 1G in 
Schwann cells, we treated S16 cells with a previously validated siRNA against Sox10 (Gokey et 
al. 2012; Anido et al. 2015) and tested for an effect on total Sox6 mRNA levels and for an effect 
on the level of transcripts containing exon 1G. This analysis revealed a ~70% decrease in both 
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Figure 4.7 SOX10 is Necessary and Sufficient for SOX6 Expression. (A) RT-PCR was 
performed to detect the expression of Sox6 transcripts harboring exon 1G using cDNA isolated 
from S16 cells, MN-1 cells, or MN-1 cells transfected with no expression construct (mock), a 
construct to express wildtype SOX10, or a construct to express dominant-negative (E189X) 
SOX10. Base pair ladders are indicated on the left. RT-PCR for β-actin and samples including 
no cDNA (‘Blank’) were employed as positive and negative controls respectively. Please note 
that while the same primers were used for each reaction, the rat (S16) PCR product was 402 base 
pairs and the mouse (MN-1) PCR product was 349 base pairs; the rat genome harbors a 53 base 
pair rat-specific insertion, which we confirmed via DNA sequence analysis. (B) Rat Schwann 
(S16) cells were treated with a control siRNA (left side) or a siRNA targeted against Sox10 (right 
side). Quantitative RT-PCR was used to measure expression levels of total Sox6 (green bars) or 
Sox6 exon 1G-containing (purple bars) transcripts. Error bars indicate standard deviations. Data 
for panel B was collected by our collaborator Dr. John Svaren at the University of Wisconsin. 
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total Sox6 expression and in the expression of transcripts containing exon 1G (Figure 4.7), 
consistent with SOX10 regulating the promoter activity of SOX10-CCS-13 in Schwann cells. 
Combined, our data indicate that SOX10 is both necessary and sufficient for the expression of 
Sox6 mRNA isoform 7 (Figure 4.6) in our in vitro cell culture model systems.  
 
SOX10 Activates the Expression of Genes that Inhibit Myelination 
Our stringent computational and functional analyses rapidly identified a previously unreported 
SOX10-responsive promoter at the SOX6 locus. Importantly, this finding was facilitated by the 
knowledge of a well-defined SOX10 consensus sequence and reports that SOX10 binding sites 
can be conserved among vertebrate species including human and chicken (Antonellis et al. 2008; 
Gokey et al. 2012; Hodonsky et al. 2012); Chapter 3). While our computational analysis was 
successful, one limitation of our first approach was only identifying conserved SOX10 consensus 
sites near genes previously implicated in myelination. Utilizing a less-biased approach may 
uncover novel functions of SOX10 in Schwann cells. We therefore removed the requirement of 
the SOX10 consensus site residing near genes involved in myelination and converted our 
conserved non-coding SOX10 monomers using the liftOver utility from the UCSC genome 
browser (Kent et al. 2002) from the human (hg18) genome to the rat (rn5) genome 
(61,133/67,482 were successfully converted) and overlayed them with two datasets: (1) 
previously generated SOX10 ChIP-Seq from rat Schwann cell nuclei in vivo (Srinivasan et al. 
2012); (2) DNase-Seq on cultured rat Schwann (S16) cell nuclei (Chapter 3). Intersecting these 
three datasets revealed 214 rat genomic segments that harbor conserved SOX10 consensus 
sequences and map to both SOX10 ChIP-Seq and S16 DNase-Seq peaks. To determine if this 
approach enriches for loci important for myelination, we identified the rat RefSeq gene closest to 
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each region—the 214 genomic segments map to 191 known genes—and performed a gene 
ontology (Ashburner et al. 2000) search using the overrepresentation test for biological processes. 
This analysis revealed 183 biological processes with a p-value less than 0.05 and 37 biological 
processes that showed a greater than five-fold enrichment compared to the human genome. Ten 
of the identified biological processes directly relate to myelinating glia, which all resided in the 
top 14 enriched terms (Table 4.2). Therefore, this combined strategy provided a highly confident 
set of 214 SOX10-response elements at 191 loci for future functional studies aimed at better 
understanding the biological process of myelination. 
Interestingly, three of the 10 gene ontology biological processes that relate to myelination 
specifically relate to negative regulation of gliogenesis, which was due to the presence of six 
genes: NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2 (Table 4.2). Computational analyses 
revealed eight SOX10 consensus sequences at these six loci (Table 4.3). To determine if 
NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2 harbor bona fide SOX10 response elements, we 
amplified genomic regions surrounding the SOX10 consensus sequences using rat genomic DNA 
and cloned each genomic segment in both the forward and reverse orientation upstream of a 
minimal promoter directing luciferase expression. The regulatory activity of each genomic 
segment was tested in S16 cells as described above. This revealed five genomic segments that 
directed reporter gene activity at least 2.5-fold higher than the empty control vector in both 
orientations: Notch1-R1 (4.7-fold forward and 56-fold reverse), Hmga2-R2 (93.7-fold forward 
and 87-fold reverse), Hes1-R1 (22-fold forward and 7.6-fold reverse), Mycn-R1 (28-fold forward 
and 16-fold reverse) and Id2-R1 (8.9-fold forward and 4.1-fold reverse) (Figure 4.8). In the 
nomenclature for these regions, R refers to the number of regions identified at each locus, and 
does not reflect the orientation. Regions Notch1-R2 (7.6-fold) and Id4-R1 (8.6-fold) directed
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Table 4.2 Gene Ontology Annotations of Loci Harboring Conserved SOX10 Consensus Sites. 
GO Biological Process Human1 Our List2 Expected3 P-value Loci4 
Negative regulation of 
oligodendrocyte differentiation 
12 4 0.1 2.74E-02 HES1, ID2, NOTCH1, ID4 
Negative regulation of glial cell 
differentiation 
25 6 0.21 6.34E-04 
HES1, ID2, NOTCH1, HMGA2, MYCN, 
ID4 
Regulation of astrocyte differentiation 25 6 0.21 6.34E-04 
HES1, ID2, NOTCH1, HMGA2, MYCN, 
ID4 
Regulation of oligodendrocyte 
differentiation 
28 5 0.23 3.29E-02 HES1, TCF7L2, ID2, NOTCH1, ID4 
Negative regulation of gliogenesis 34 6 0.28 3.77E-03 
HES1, ID2, NOTCH1, HMGA2, MYCN, 
ID4 
Oligodendrocyte differentiation 60 10 0.5 9.43E-07 
SOX6, NTRK2, PTPRZ1, SOX8, SOX10, 
TCF7L2, ID2, NOTCH1, SOX5, ID4 
Regulation of gliogenesis 74 10 0.61 6.96E-06 
PTPRZ1, SOX8, HES1, SOX10, TCF7L2, 
ID2, NOTCH1, HMGA2, MYCN, ID4 
Regulation of glial cell differentiation 54 7 0.45 3.23E-03 
HES1, TCF7L2, ID2, NOTCH1, HMGA2, 
MYCN, ID4 
Glial cell differentiation 135 13 1.12 1.22E-06 
SOX6, PTPRZ1, NTRK2, SOX8, HES1, 
SOX10, TCF7L2, ID2, NOTCH1, 
PPAP2B, SOX5, ID4, PARD3 
Gliogenesis 168 13 1.39 1.66E-05 
SOX6, PTPRZ1, NTRK2, SOX8, HES1, 
SOX10, TCF7L2, ID2, NOTCH1, 
PPAP2B, SOX5, ID4, PARD3 
 
1Number of genes from the human genome (hg19) that correspond to the biological process (column 1). 
2Number of genes from our list of 191 genes harboring conserved SOX10 consensus sites overlapping SOX10 ChIP-Seq(Srinivasan et 
al. 2012) and S16 DNase-Seq peaks. 
3Number of genes expected by chance for each biological process (column 1). 
4The names of the genes identified from our list (column 4) that and involved in each biological process (column 1). 
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Table 4.3 Eight Genomic Segments Within Loci that Inhibit Glial Cell Differentiation. 
Element ID UCSC Coordinates1 SOX10 Consensus Sequence2 
Notch1-R1 chr3:9307946-9307962 ACAATGGGGCCTCTGT 
Notch1-R2 chr3:9308648-9308662 ACAATCGGCTTTGT 
Hmga2-R1 chr7:65390829-65390834 CTTAGACACAGCACTT 
Hmga2-R2 chr7:65428331-65428349 ACACAGGCCCCTCTTTGT 
Hes1-R1 chr11:77415711-77415729 TGTGTGAGCGCCATGTGT 
Mycn-R1 chr6:51230285-51230310 ACAATGGCCTCTTTCTACAGACAAT 
Id4-R1 chr17:18701782-18701812 ACAAAAACAGCAGTAAATGGAGGCCTTTGT 
Id2-R1 chr6:53091198-53091214 ACAAGAAACACATTGT 
 
1Coordinates refer to the March 2012 UCSC Genome Browser Rat assembly (rn5). 
2SOX10 consensus sequences are indicated in red letters and bold text. 
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reporter gene activity at least 2.5-fold higher than the empty control vector only in the forward 
orientation (Figure 4.8). Hmga2-R1 was not active in either orientation and was excluded from 
further analysis. Thus, we identified seven genomic sequences at six loci (NOTCH1, HMGA2, 
HES1, MYCN, ID4, and ID2) that display regulatory activity in Schwann cells.  
To determine if the identified SOX10 consensus sequences are important for the regulatory 
activity of the seven active regions described above (Figure 4.8), we deleted the SOX10 
consensus sequence from each construct (termed ‘ΔSOX10’) and compared the activity to the 
wildtype construct using the more active orientation. Notch1-R1, Notch1-R2, Hmga2-R2, Hes1-
R1, and Id2-R1 contain dimeric SOX10 consensus sequences, which were deleted along with the 
intermonomeric sequence. Mycn-R1 contains a monomeric consensus sequence (ΔSOX10-1) and 
a dimeric consensus sequence (ΔSOX10-2), which were independently deleted. Id4-R1 contains 
a dimeric consensus sequence with a 20 base pairs intervening sequence. Since this intervening 
sequence is longer than those previously observed for validated dimeric SOX10 binding sites 
(Peirano and Wegner 2000; Jones et al. 2011a; Gokey et al. 2012; Hodonsky et al. 2012; Brewer 
et al. 2014) we studied each monomer independently. Specifically, we deleted the dimeric 
consensus sequence along with intermonomeric sequence (ΔSOX10-1), the first monomer only 
(ΔSOX10-2), and the second monomer only (ΔSOX10-3). Deleting the SOX10 consensus 
sequences in regions Notch1-R1, Hmga2-R2, Mycn-R1 (ΔSOX10-2), Id4-R1 (ΔSOX10-1 and 
ΔSOX10-3), and Id2-R1 reduced luciferase activity in S16 cells by at least 50% (Figure 4.8), 
indicating that the SOX10 consensus sequences in these five regions are required for the full 
regulatory activity of the genomic segment. In contrast deleting the SOX10 consensus sequences 
in Notch1-R2 and Hes1-R1 did not reduce the enhancer activity associated with these genomic 
segments (Figure 4.8). 
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Figure 4.8 SOX10 Consensus Sequence is Necessary for the Luciferase Activity of Five of the 
Seven Regions Active in Schwann Cells. (A) Eight genomics segments at the rat Notch1, Hmga2, 
Hes1, Mycn, Id4, and Id2 loci were cloned upstream of a luciferase reporter gene in both the 
forward (grey bars) and reverse (white bars) orientations and tested for luciferase activity in rat 
Schwann (S16) cells. Luciferase data are expressed relative to a control vector with no genomic 
insert (‘Empty’). Error bars represent standard deviations. (B) The conserved SOX10 consensus 
sequence(s) were deleted in each of the seven regions that were active in Figure 4.8A (see text 
for details). Luciferase reporter gene constructs containing the wildtype sequence (WT; blue 
bars) or the sequence lacking the SOX10 consensus sequence(s) (ΔSOX10; red bars) were 
transfected into S16 cells and luciferase assays performed. Luciferase activities are expressed 
relative to the wildtype expression constructs, and error bars represent standard deviations. 
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We next wanted to determine if SOX10 positively regulates the expression of Notch1, Hmga2, 
Hes1, Mycn, Id4, Id2, and Sox5 in cultured rat Schwann (S16) cells, and again utilized the Sox10 
siRNA that has been shown to efficiently down-regulate Sox10 expression (Gokey et al. 2012; 
Anido et al. 2015). After isolation of mRNA at 24 hours post-transfection, qRT-PCR shows that 
Sox10 depletion in S16 cells results in the reduced expression of all of the above genes except for 
Hmga2 (Figure 4.9). Similar findings—including the absence of reduced Hmga2 expression—
were observed upon repressing SOX10 function in vivo using primary Schwann cells; however, 
this system is prone to variability due to heterogeneous cell populations (Figure 4.10). 
To directly test if Notch1, Hmga2, Hes1, Mycn, Id4, Id2, Sox5, and Sox6 are developmentally 
regulated during myelination in vivo, we examined mRNA levels at three timepoints in rat sciatic 
nerve (n=3 at each timepoint). P1 corresponds to the onset of myelination, P15 is a peak 
timepoint of myelination in the PNS, and adult sciatic nerve is a timepoint where active 
myelination has subsided. Interestingly, the expression of all seven genes tested (Notch1, Hmga2, 
Hes1, Mycn, Id4, Id2, Sox5, and Sox6) are highest at P1 and then decreased at P15 and adult, 
consistent with a role in repressing precocious myelination (Figure 4.9). In summary, our 
preliminary data suggests a potentially novel role for SOX10 in positively regulating genes 
important for inhibiting glial cell differentiation. 
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Figure 4.9 SOX10 Regulates the Expression of Genes that Inhibitor Glial Cell Differentiation. 
(A) Rat Schwann (S16) cells were treated with a control siRNA (orange bars) or a siRNA 
targeted against Sox10 (green bars). Quantitative RT-PCR was used to measure expression levels 
of each indicated gene. Asterisks indicate a p-value less than 0.001, and error bars indicate 
standard deviations. (B) RNA was purified from three independent rat sciatic nerves at the P1 
(blue bars), P15 (orange bars), and adult (grey bars) timepoints. Quantitative RT-PCR was used 
to measure expression levels of each indicated gene with values expressed relative to expression 
levels at P1. Asterisks indicate a p-value less than 0.005, and error bars indicate standard 
deviations. Data for this figure was collected by our collaborator Dr. John Svaren at the 
University of Wisconsin. 
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Figure 4.10 SOX10 Regulates Genes that Inhibit Glial Cell Differentiation In Vivo. Primary 
Schwann cells were extracted and grown from three independent rat adult sciatic nerves. Cells 
were treated with a control siRNA or a siRNA targeted against Sox10 as in Figure 4.9B. 
Quantitative RT-PCR was used to measure expression levels of each indicated gene. The effect 
on expression of each gene (indicated across the bottom) is expressed relative to the control 
siRNA, and error bars indicate standard deviations. Please note that, consistent with the in vitro 
data, Hmga2 did not show a decrease in expression levels in vivo (data not shown). Data was 
collected by our collaborator Dr. John Svaren at the University of Wisconsin. 
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Discussion 
In the previous chapters, we developed a versatile computational pipeline to predict functional, 
non-coding regions of the genome important for peripheral nerve function in both a transcription 
factor blind (Chapter 2) and transcription factor centric (SOX10; Chapter 3) approach. In this 
chapter, we again modified the computational pipeline to identify conserved SOX10 binding 
sites that also resided within genes known to be involved in myelination in glia cells. Using this 
alternate filter, we were able to identify a novel SOX10-responsive promoter element at Sox6. 
This isoform appears to be Schwann cell specific, although the precise role of this isoform is 
unclear. Further studies, such as deletion of this novel first exon at Sox6, may elucidate a 
Schwann cell specific function. 
Of note, we only required the regions to exceed a 2.5-fold threshold, compared to the five-fold 
increase used in previous chapters. The reduction was chosen specifically for this chapter to 
reduce the chance for false-negatives. Despite reducing the threshold for activity, many of the 
identified regions exceeded a five-fold threshold, confirming that this threshold (in our system) is 
most likely appropriate for detecting functional SOX10 binding sites. 
Additionally from our dataset, we identified SOX10 responsive elements near eight loci with a 
known or predicted role in repressing glial cell development: Notch1, Hmga2, Hes1, Mycn, Id2, 
Id4, Sox5, and Sox6. These findings were unexpected due to the known role of SOX10 in 
regulating the expression of genes that encode pro-myelination proteins (e.g., MBP, MPZ, and 
PMP22) (Peirano et al. 2000; Wei et al. 2004; LeBlanc et al. 2006; Li et al. 2007; Jones et al. 
2011a; Jones et al. 2011b). We showed that all eight loci are developmentally regulated during 
myelination in vivo in a manner consistent with a role in inhibiting glial cell differentiation. We 
also validated a SOX10 binding site at seven of the eight loci. We identified a SOX10 ChIP-Seq 
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peak at HES1 and luciferase assays demonstrated that this genomic segment has strong enhancer 
activity (Figure 4.8). However, deletion of the predicted SOX10 binding sites in Hes1-R1 (Table 
3) did not reduce luciferase activity. Further mutagenesis of this genomic segment will be 
required to identify sequences necessary for the observed activity, which may reveal a 
degenerate SOX10 consensus sequence. Another possibility is that these are false positive results, 
which ChIP-Seq can be susceptible to, similar to some of the SOX10 regions overlapping ChIP-
Seq peaks identified in Chapter 3 (Fisher et al. 2012; Kvon et al. 2012; Leonid et al. 2013). 
When we depleted SOX10 activity in Schwann cells in vitro and in vivo seven of the eight loci 
were downregulated; while Hmga2 harbors a validated SOX10 response element (Figure 4.8), 
depletion of SOX10 activity did not reduce Hmga2 expression. Further analysis will be required 
to determine if this SOX10 response element regulates an adjacent locus or if depletion of 
SOX10 at specific developmental timepoints results in reduced HMGA2 expression. Consistent 
with our findings, previous global analyses of SOX10 function revealed that two of the above 
eight loci are downstream of SOX10: Id2 and Notch1 (Srinivasan et al. 2012). Our analysis now 
localizes at least some of the SOX10-dependent enhancers responsible for the regulation of Id2 
and Notch1. 
SOX5 and SOX6 are members of the SOXD family of transcription factors and act as negative 
regulators of myelination in the central nervous system (Stolt et al. 2006); these proteins inhibit 
the expression of SOX10 target genes (e.g., MBP) in oligodendrocytes by competing with 
SOX10 for DNA binding at sites within cis regulatory elements. SOXD family member lack a 
transcriptional activation (or repression) domain and are unable to stimulate gene expression 
upon binding to DNA (Hagiwara 2011). To allow oligodendrocyte differentiation and myelin 
production, SOX6 mRNA is targeted for degradation by two microRNAs (miR) in these cells: 
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miR-219 and miR-338 (Zhao et al. 2010). It was recently reported that SOX13 (the third and 
final member of the SOXD subgroup) also has an antagonistic effect on the ability of SOX10 to 
activate the expression of myelin genes in the central nervous system (Baroti et al. 2015). Indeed, 
SOX13 is among the group of 191 loci at which we identified a highly confident SOX10 binding 
site - a single genomic segment within SOX10 ChIP-Seq and DNase-Seq peaks approximately 
62 kilobase pairs upstream of Sox13 (rn5 coordinates chr13:55425486-55425636). Interestingly, 
a relationship between SOXD and SOXE (SOX8, SOX9, and SOX10) transcription factors has 
been previously proposed because ablation of SOX8 or SOX9, but not SOX10, reduces Sox6, but 
not Sox5, expression in the developing spinal cord (Stolt et al. 2006).  
In addition to genes that encode SOXD proteins, we identified NOTCH1, HES1, MYCN, ID2, 
and ID4 as SOX10 target genes. NOTCH1 is a transmembrane receptor that regulates Schwann 
cell proliferation, inhibits Schwann cell differentiation in perinatal nerves, and facilitates 
dedifferentiation of Schwann cells after nerve injury (Woodhoo et al. 2009). HES1 is an effector 
of NOTCH signaling, acts as a transcriptional repressor (Sasai et al. 1992; Jarriault et al. 1995), 
and is highly expressed during early stages of Schwann cell development (Woodhoo et al. 2009). 
In cultured mouse oligodendrocytes, HES1 maintains cells in an immature state, and 
overexpression of HES1 results in reduced expression of myelin related genes (Mbp and Plp) 
(Ogata et al. 2011). MYCN is a proto-oncogene and is known to inhibit astrocyte differentiation 
from neural precursor cells (Sanosaka et al. 2008); however, the role of MYCN during Schwann 
cell myelination has not been studied. 
Inhibitors of differentiation 2 and 4 (ID2 and ID4) proteins are known to inhibit oligodendrocyte 
differentiation and the lack of both proteins results in premature oligodendrocyte differentiation 
(Kondo and Raff 2000; Wang et al. 2001; Marin-Husstege et al. 2006). Furthermore, Id2 and Id4 
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expression declines in Schwann cell development, and ID2 limits induction of myelin protein 
zero (Mpz) expression in primary rat Schwann cells (Stewart et al. 1997; Mager et al. 2008). 
Consistent with our findings, RNA-Seq of oligodendrocytes isolated at various stages of mouse 
brain development (Zhang et al. 2014) show that Sox5, Sox6, Notch1, Hes1, Mycn, Id2, and Id4 
are developmentally regulated in the central nervous system—Hmga2 does not appear to be 
expressed in the cells assessed in this study. Therefore, these genes are predicted to play a role in 
preventing premature glial cell differentiation in the central nervous system and likely perform a 
similar role in the peripheral nervous systems. 
Combined with previous findings, our data suggest a model (Figure 4.11) where SOX10 
activates the expression of genes that inhibit Schwann cell differentiation during early stages of 
Schwann cell development, thus preventing the precocious expression of myelin proteins. 
Subsequently, EGR2, NAB, and microRNAs (see below) inhibit the expression of the negative 
regulators of myelination (e.g., SOXD proteins), which, in part, allows SOX10 to activate the 
expression of pro-myelination proteins. In addition to the data presented in this study, previous 
reports support specific aspects of this model. For example, EGR2 likely represses the 
expression of many of the eight loci reported here. Egr2 and Nab repress Id2 and Id4 before 
myelination via Nab binding to Chd4 (Mager et al. 2008) [conditional ablation of Chd4 in 
Schwann cells causes increased expression of immature Schwann cell genes including Id2 and 
delayed myelination, radial sorting defects, hypomyelination, and the persistence of 
promyelinating Schwann cells in conditional knockout mice (Hung et al. 2012)]. Furthermore, a 
comparison of Sox10 and Egr2 binding with expression profiles in Schwann cells treated with 
siRNA for Sox10 and Egr2-deficent peripheral nerves (Srinivasan et al. 2012) revealed that 
Notch1 and Id2 are Sox10-activated and Egr2-repressed, and Id2, Hmga2, Sox5, and Id4 remain 
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Figure 4.11 A Simplified Model for the Role of SOX10 in Maintaining a Pre-myelinating State in 
Developing Schwann Cells. Previous to myelination (anti-myelination; left side), SOX10 
activates the expression of negative regulators of myelination, which inhibit the expression of 
myelin genes such as MBP and MPZ. During the activation of the myelination program (pro-
myelination; right side), EGR2 and micro RNAs (miRs) inhibit the expression of negative 
regulators of myelination, which allows SOX10 (and EGR2) to positively regulate the expression 
of myelin genes. 
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high in peripheral nerves from Egr2- or Nab-deficient mice (Le et al. 2005; Mager et al. 2008). 
Finally, SOX10 directly regulates the expression of EGR2 (Ghislain and Charnay 2006) and 
miR-338 (Gokey et al. 2012). In sum, these findings indicate that SOX10 is directly responsible 
for maintaining a premyelinating state, the switch to a myelinating state, and the expression of 
myelin proteins (Kelsh 2006). While our data and the data of others supports the proposed model 
(Figure 4.11) there are additional, non-mutually-exclusive possibilities including: (1) decreased 
expression of SOX10 during or prior to myelination (D'Antonio et al. 2006) despite the fact that 
it is required by terminally differentiated Schwann cells (Bremer et al. 2011); and/or (2) the 
activity of histone deacetylases, which are known to inhibit another negative regulator of 
Schwann cell differentiation, NF-B (Chen et al. 2011). 
While previous efforts have been successful in globally identifying SOX10 binding sites and 
target genes (Srinivasan et al. 2012; Anido et al. 2015), our computational strategy afforded a 
glimpse of SOX10 function that is not dependent on gene activity in cultured cells or in tissues at 
specific developmental stages. In fact, this less-biased (albeit less biologically relevant) approach 
is likely the reason that we were able to identify specific repressors of myelination.  
In this chapter, we modified our computational and functional pipeline that resulted in expanding 
the panel of known SOX10 response elements and target loci. These efforts revealed a 
potentially novel function for SOX10 in repressing myelination in early stages of Schwann cell 
(and possibly neural crest) development; although additional in vivo functional studies will be 
necessary to support the proposed model. Furthermore, we provided useful datasets for the 
scientific community and expanded the mutational screening space for disease-causing 
mutations—or modifiers of disease—in patients with peripheral neuropathy and other SOX10-
related phenotypes. In the final chapter, I will provide a summary of the major findings from this 
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thesis and provide new questions and future experiments that arise from the knowledge 
generated from this body of work.
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Conclusions and Future Directions 
Summary 
The major aim of this thesis was to discover novel, functional non-coding cis-regulatory 
elements (CREs) important for the peripheral nervous system. We first developed a combined 
computational and functional pipeline to predict and rapidly evaluate candidate regulatory SNPs 
(rSNPs). This pipeline is highly versatile and capable of combining multiple different 
computational datasets to reprioritize candidate rSNPs. We next exploited a modified version of 
this pipeline to identify novel CREs, regardless of the presence of potential rSNPs. Throughout 
this work, we utilized this versatility to identify many novel CREs and rSNPs relevant for 
peripheral nerve and, more specifically, Schwann cell biology. 
In Chapter 2, we developed the computational pipeline based on sequence conservation between 
human, mouse, and chicken. This method, termed phylogenetic footprinting, relies on the 
hypothesis that non-coding regions conserved among diverse species may imply some function 
(Hardison 2000). While phylogenetic footprinting has been utilized successfully many times 
(Zerucha et al. 2000; Goode et al. 2003; Kimura-Yoshida et al. 2004; Antonellis et al. 2008), a 
limitation to these studies is that the presence of sequence conservation does not always result in 
function (at least in the assays used) (Bejerano et al. 2004; Pennacchio et al. 2006; Ahituv et al. 
2007). Similarly, a lack of sequence conservation does not necessarily mean lack of conserved 
function (Fisher et al. 2006; McGaughey et al. 2008). 
 174 
Despite these limitations, we identified over two million regions that were five base pairs or 
greater in length and identical among the three species: human, mouse, and chicken. We looked 
for overlap between these conserved regions with SNPs and excluded exons to ensure the regions 
were not conserved due to protein function. This analysis revealed 6,164 conserved non-coding 
regions harboring a SNP genome-wide. We prioritized regions located on chromosomes 21, 22, 
and X to test the efficacy of our approach, which yielded a pilot dataset of 159 regions. The 
regions were cloned upstream of a minimal promoter directing luciferase expression in both 
orientations relative to the promoter (Antonellis et al. 2006) and assessed in three cell lines that 
provide an in vitro model of a peripheral nerve (neurons and glia) and a target tissue (muscle): 
S16 (Schwann cells; (Goda et al. 1991)), MN-1 (motor neurons; (Salazar-Grueso et al. 1991)), 
and C2C12 (muscle cells; (Yaffe and Saxel 1977a)).  
Out of the 159 regions, we successfully assessed 144 regions in both orientations, which revealed 
28 unique regions that displayed a greater than five-fold increase in luciferase activity compared 
to the empty control vector whose activity had been set to ‘1’ (S16 = 13 regions, MN-1 = 11 
regions, C2C12 = 21 regions). Interestingly, we observed regions that displayed orientation-
dependent activity in the luciferase assays. While this may be a consequence of our artificial 
system, orientation-dependent enhancers have been described previously (Nishimura et al. 2000; 
Wei and Brennan 2000; Swamynathan and Piatigorsky 2002), and further studies are needed to 
distinguish if the regulatory activity of these regions is dependent on orientation. 
Of the 28 active regions, 13 displayed a significant allele-specific differences in at least one 
orientation and in at least one cell line. Using TRANSFAC (Matys et al. 2003), we predicted 
transcription factors that were predicted to have differential binding to the major and minor 
alleles. Combing these predictions with the different activity of the regions could give strong 
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candidate transcription factors. For example, regions that were active in all three cell lines and 
displayed similar significant allele-specific differences may be bound by a more ubiquitously 
expressed transcription factor. Conversely, regions that displayed cell-specific activity would be 
predicted to be regulated by a transcription factor that is expressed and restricted to that cell type. 
For example, SC21-27 displayed regulatory activity exclusively in muscle cells and the minor 
allele was significantly less active relative to the major allele. Our TRANSFAC analysis predicts 
the creation of a novel LEF-1 binding site, which has been shown to exert a repressive affect 
(Billin et al. 2000; Mao and Byers 2011). While additional work will be necessary to validate 
any of the TRANSFAC predictions, one of the limitations of our TRANSFAC analysis was only 
including binding sites that were either created or ablated, with no regard for predicted 
transcription factor binding affinity, which can be necessary for appropriate gene expression 
(Rowan et al. 2010; Ramos and Barolo 2013). 
Despite these limitations, the computational and functional pipeline developed in Chapter 2 was 
able to identify novel CREs and rSNPs. We wanted to further assess the functionality of this 
pipeline by incorporating transcription factor binding site information to determine if our 
computational pipeline can predict binding sites in a transcription factor centric manner. We 
choose the transcription factor SOX10 for three main reasons: (1) it is critical for Schwann cell 
function (Britsch et al. 2001; Finzsch et al. 2010; Bremer et al. 2011), (2) mutations within 
SOX10 binding sites can cause peripheral neuropathies (Houlden et al. 2004; Jones et al. 2011a), 
and (3) rSNPs within SOX10 binding sites can alter disease severity (Emison et al. 2005; Emison 
et al. 2010). Additionally, SOX10 has a well-characterized consensus sequence (Peirano and 
Wegner 2000; Srinivasan et al. 2012), and functional binding sites have been observed that are 
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conserved between human, mouse, and chicken (Antonellis et al. 2008; Gokey et al. 2012; 
Hodonsky et al. 2012). 
Using the SOX10 consensus site information, we were able to identify 224 conserved, non-
coding SOX10 monomers containing SNPs within the human genome. This dataset was further 
prioritized using SOX10 ChIP-Seq (nine regions) (Srinivasan et al. 2012) and dimeric SOX10 
sites where both monomers were conserved but only one monomer contained a SNP (13 regions). 
These 22 regions were assessed in our luciferase assay, and we identified four regions that 
displayed strong activity; however, only two regions displayed significant allele-specific 
differences in regulatory activity.  
We further characterized one region, rSOX-4, to determine the gene(s) regulated by this 
enhancer. rSOX-4 was selected because it overlaps many genomic features associated with 
enhancers (i.e., ChIP-Seq, DNase HSS, and H3K27Ac). Upon deleting this region from S16 cells, 
we performed RNA-Seq and ddPCR to ultimately identify one candidate target gene: Tubb2b. 
We further interrogated the function of rSOX-4 by generating transient transgenic mice 
harboring a rSOX-4:LacZ transgene. This revealed that rSOX-4 is active in vivo in both the 
dorsal root ganglia and melanoblasts. Since Tubb2b has been implicated in neuronal migration 
(Jaglin et al. 2009; Breuss et al. 2015), it is reasonable to predict it may perform a similar 
function in migratory cell populations derived from the neural crest. While these data strongly 
suggest that the target gene of rSOX-4 is Tubb2b, additional studies will be necessary to 
determine the role of Tubb2b in Schwann cells and other neural crest derivatives. 
In Chapter 4, we utilized the versatility of our pipeline to identify SOX10 regulated regions that 
resided near genes involved in myelination, which provided the surprising result that SOX10 
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potentially regulates genes that inhibit glial cell differentiation. Compared to Chapter 3, we 
identified conserved dimeric SOX10 binding sites (and also required the intermonomeric spacer 
to be conserved) that resided within genes (or 2.5 kilobase pairs upstream or downstream) with a 
known role in Schwann cells or myelination. We also included regions which resided within 
genes whose expression is significantly altered upon SOX10 depletion (Lee et al. 2008). By 
overlapping these datasets, we identify 57 regions that we assessed in our luciferase assays, of 
which seven demonstrated a greater than 2.5-fold increase compared to an empty vector control 
that has the activity set to ‘1’.  Interestingly, one of these regions (SOX10-CCS-13) resided 
within an intron of Sox6. Using SOX10 expression in MN-1 cells combined with RT-PCR, 5’-
RACE experiments, and our RNA-Seq dataset, we were able to demonstrate that SOX10-CCS-
13 acts as an alternative promoter.  
Since our computational strategy was successful in identifying novel SOX10 binding sites in this 
chapter (and in Chapter 3), we utilized the versatility of our pipeline and additional genome-wide 
datasets to repriortize our SOX10 binding sites to identify regions that overlapped both SOX10 
ChIP-Seq (Srinivasan et al. 2012) and S16 DNase HSS peaks (Chapter 3). We wanted to 
determine if combining all three datasets would enrich for strong candidate SOX10 binding sites. 
By overlapping all three datasets (i.e. sequence conservation, ChIP-Seq, and DNase HSS) we 
revealed 214 putative SOX10 binding sites that reside within 191 known genes. Using gene 
ontology (Ashburner et al. 2000), we identified 10 significantly enriched biological processes. 
Strikingly, of the 10 processes, three related to negative regulation of gliogenesis, which was due 
to the presence of six genes: NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2. 
We assessed each predicted SOX10 binding site in our luciferase assay and were able to 
demonstrate functional SOX10 binding to all regions, except Hes1. Interestingly, Hes1 is 
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developmentally downregulated at the onset of myelination in rats, suggesting additional SOX10 
binding sites reside within the locus or additional transcription factors regulate this region. 
Additionally, experiments utilizing siRNA knockdown of Sox10 in S16 cells demonstrated 
decreased expression for all genes, except for Hmga2. This data, combined with in vivo 
timecourse experiments assessing gene expression levels suggested that five of the six genes (not 
Hmga2) are regulated by SOX10. This data lead us to a model where SOX10 positively regulates 
both pro- and anti-myelinating genes. While the exact mechanisms governing the switch between 
these two states is unclear, one hypothesis involves repression of these genes by EGR2. This is 
supported by the observation that Notch1 and Id2 are SOX10-activated and EGR2-repressed, and 
Id2, Hmga2, Sox5, and Id4 remain highly expressed in peripheral nerves from Egr2-deficient 
mice (Le et al. 2005; Mager et al. 2008). 
Throughout this thesis, we generated many datasets which we feel will be useful to other 
investigators studying comparative genomics, SOX protein function, and Schwann cell biology. 
First, the conserved sequences we identified could be used to similarly prioritize consensus 
sequences for other transcription factors important for vertebrate development (e.g., THAP1; 
Chapter 3). Second, the SOX10 consensus sequences we identified could be used to prioritize 
putative binding sites in other SOX10-positive cells including oligodendrocytes, melanocytes, 
and developing enteric nervous system neurons (Kelsh 2006). Finally, our DNase-Seq dataset 
from rat Schwann (S16) cells will be useful for anyone studying transcriptional regulatory 
elements, highly expressed genes, or any other nuclear structure characterized by open chromatin 
in myelinating Schwann cells; S16 cells express many myelin-related genes (e.g., PMP22, MPZ, 
MBP, and MAG) and transcription factors (e.g., SOX10 and EGR2) and are biochemically 
similar to myelinating Schwann cells (Hai et al. 2002). 
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In addition to the datasets generated, the computational pipeline developed and employed during 
the thesis research is extremely malleable. This allows for easy incorporations of additional 
transcription factor binding site information, as well as future genome-wide datasets, which can 
be used to identify CREs. Finally, the results from this thesis have not only identified many 
novel enhancers and rSNPs important for the peripheral nerve but potentially implicated a new 
gene, Tubb2b, in Schwann cell, and more generally neural crest biology. 
 
Future Directions 
Massively Parallel Reporter Assays 
While the work in this thesis generated a computational and functional pipeline that was 
successful in both the identification and validation of CREs critical for the peripheral nerve and 
muscles, many questions and future experiments remain. In Chapter 2, we only assessed a small 
subset of the 6,164 conserved, non-coding regions harboring SNPs. When this work began, there 
was no effective way to assess thousands of regions simultaneously for regulatory activity; 
however, recent methods have been developed which address this problem: STARR-Seq (Arnold 
et al. 2013) and Cre-Seq (Kwasnieski et al. 2012). 
Both of these methods utilize next-generation sequencing technologies that allow assessment of 
thousands (potentially millions) of putative CREs simultaneously. Both methods involve cloning 
the regions into a reporter construct and transfecting millions of cells. Through sequencing of 
RNA to ascertain the reporter expression and normalizing these counts to the transfected DNA 
plasmid, it is possible to obtain the activity of CREs from multiple candidate regions. One 
limitation is the starting materials. STARR-Seq generally relies on fractionation of the entire 
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genome and is unable to assess a small handful of candidate regions. Comparatively, CRE-Seq 
generally utilizes synthetically synthesized oligonucleotides which are currently limited to 
approximately 150 base pairs. Recently, however, a modified approach for capturing candidate 
regions has been used to successfully identify CREs in conjunction with CRE-Seq (Shen et al. 
2016). 
This method leverages the advantages of both genome fractionation with targeted region capture. 
In the first step, biotinylated synthetic oligonucleotide probes are designed against the regions of 
interest. These probes are 80 base pairs in length, but are designed to overlap additional adjacent 
probes to cover the entire region targeted to be captured. For example, a 300 base pair target 
region may have five probes that overlap each other by approximately 20 base pairs. Next, the 
entire genome is fractionated to a predetermined size. This can be based on the average length of 
DNase-Seq peaks (approximately 300 base pairs) (Natarajan et al. 2012) or the average length of 
the regions assessed in Chapter 2 (approximately 900 base pairs). 
Once the genome has been fractionated, it is incubated with the targeted biotinylated probes, 
which hybridize to the targeted regions of the genome, and the complex can be isolated from the 
background (not targeted) genomic DNA by streptavidin-coated magnet beads. The RNA probes 
are then degraded away, linkers for PCR amplification and cloning are attached, double-stranded 
DNA molecules are generated through PCR, and finally the regions are cloned into the reporter 
construct. CRE-Seq requires an additional step to incorporate unique barcodes with each 
candidate region. This process occurs randomly but is ultimately resolved through DNA 
sequencing of the plasmid DNA. 
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An experiment similar to the one described above would allow us to assess all of our predicted 
regions containing SNPs. One potential problem would be the inability to control the sequence 
integrity (i.e., PCR induced mutations, allele-specific capture biases, additional SNPs in cis to 
the one under study, etc.). While these problems arose during the cloning procedures used in 
Chapter 2, they were not a major issue due to our ability to detect them during the cloning 
process. Depending on the number of confounding sequence changes, select regions could be 
assessed using tradition cloning methods, because the DNA sequencing of the plasmid DNA 
would inform us of any variants within the region.  
Based on our rates of identification of active regions (greater than five-fold; 19.4%) and rSNPs 
within active regions (46.4%), we anticipate the identification of 1,195 active regions (of the 
6,164 predicted regions). From these predicted regions displaying regulatory activity, we 
anticipate identifing 554 regions would contain a rSNP. While we should be cautious when 
extrapolating from data, the previously identified regions in Chapter 2 demonstrate there are a 
large number of CREs remaining to be identified that are functional in the peripheral nerve or 
muscle cells. 
A major advantage of using either CRE-Seq or STARR-Seq is the ability to clone the captured 
regions into multiple reporter constructs. This allows every region to be assessed with multiple 
promoter elements, which may uncover novel active CREs that are only active with a specific 
promoter. For example, utilizing a promoter derived from a gene that is specific for muscle cells 
may uncover novel, muscle cell-specific CREs that are unable, for example, to interact with the 
minimal E1B promoter. This effect has been observed before, but it is currently unclear what the 
mechanistic factors are that determine enhancer-promoter specificity (Zabidi et al. 2015). 
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CRE-Seq or STARR-Seq could also be leveraged to identify repressive elements. As discussed 
in Chapter 2, our method at present is unable to identify repressors. Utilizing the versatility of 
massively parallel reporter assays would allow the regions to be assessed with an extremely 
active promoter. Similarly, multiple active promoters could be assessed to examine potential 
repressor-promoter specificity. For example, a ubiquitously active promoter, such as the CMV 
promoter, element could be compared with the SOX10 promoter in Schwann cells. We would 
expect both promoters to direct high levels of reporter transcripts, and any element that caused a 
significant reduction in expression would be a candidate repressive element.  
 
SOX10 Binding Site Affinity 
In Chapter 3, we utilized our computational and functional pipeline to identify rSNPs disrupting 
conserved SOX10 consensus sites. While we are confident in the minimal SOX10 consensus 
sites used throughout the thesis, we can not be certain that SOX10 is incapable of binding to 
addition sequences, the effect of a SNP interconverting different SOX10 monomers, nor if any 
additional sequence information is required beyond the ‘core’ motif for SOX10 binding. For 
example, SOX proteins generally bind to the sequence 5’-(A/T)(A/T)CAA(A/T)G-3’ (Harley et 
al. 1992; Laudet et al. 1993; Harley et al. 1994). While SOX10 has a slightly different binding 
site (Chapters 2 and 3), we only considered the ‘core’ (five internal base pairs) binding site for 
predictions. In Chapter 3 we noticed a difference in the GC content of the intervening sequence 
of all SOX10 dimeric regions tested (GC content = 35%) and that of the active dimeric sites (GC 
content = 61%). While the number of sequences evaluated (57 regions total) was small, these 
data are consistent with the high GC content of the intervening sequence within other validated 
dimeric SOX10 binding sites (Peirano et al. 2000; Antonellis et al. 2008; Gokey et al. 2012; 
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Hodonsky et al. 2012; Brewer et al. 2014), and with a ‘G’ nucleotide being the most commonly 
observed nucleotide after the ‘core’ motif as seen via SOX10 ChIP-seq analysis (Srinivasan et al. 
2012). 
One approach to generate higher quality SOX10 consensus sites information and obtain greater 
predictive power of the effect of SNPs on SOX10 binding sites is through the use of programmed 
allelic series (PALS; (Kitzman et al. 2015)). PALS allows for the generation of every possible 
combination of mutations within a specific sequence. It has generally been applied to protein-
coding sequences; however, the method is applicable to determining the sequence requirements 
of bona fide SOX10 binding sites and could simultaneously assess the effect of individual SNP 
alleles within those regions. Using PALS to mutagenize previously characterized SOX10 binding 
sites, such as the dimeric SOX10 sites within the MPZ promoter (Peirano et al. 2000) and rSOX-
22 (Chapter 3), and the monomeric SOX10 site at the SH3TC2 promoter (Brewer et al. 2014) and 
rSOX-4 (Chapter 3), may uncover additional sequence requirements for SOX10 binding.  
The mutagenic primers could be designed to mutate each base pair of the ‘core’ motif, plus one 
additional base pair on both the 5’ and 3’ ends. For the dimeric SOX10 sites, it is currently not 
possible to mutagenize both monomers concurrently, due to both the length and number of 
primers required. To partially alleviate this problem, each monomer would be mutagenized 
independently, resulting in complete mutagenesis of six monomeric sites each seven base pairs in 
length. Once the SOX10 binding sites were, clonal libraries would be constructed and assessed 
using massively parallel reporter assays as described above. 
These data would be valuable in future predictions of the effect of both rSNPs and patient 
variants on SOX10 binding sites. For example, the patient variant assessed in Chapter 3 
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interconverts one predicted SOX10 monomeric site to another predicted SOX10 monomeric site. 
We were unsure what the functional consequence of the patient variant would be due to the lack 
of knowledge about the sequence constraints of SOX10. Additionally, while our computational 
pipeline predicted rSNPs which ablated the SOX10 ‘core’ motif, we identified two regions in 
Chapter 3 that overlapped SOX10 ChIP-Seq data, which were active in S16 cells, but the SNP 
had no effect. Understanding the effects of SNPs on the binding site would lead to more 
confident predictions. One caveat to our analyses is that it is unclear if these regions are truly 
SOX10 response elements, as we did not perform the requisite functional studies. Despite this, 
identification of the sequence constraints of SOX10 binding sites at multiple characterized CREs 
will lead to greater predictive power of the functional relevance of both rSNPs and patient 
variants that map to SOX10 binding sites. 
 
Tubb2b Function in Dorsal Root Ganglia, Melanoblasts, and Schwann Cells 
In Chapter 3, we identified Tubb2b as a candidate target gene of the rSOX-4 enhancer. We 
generated transient transgenic mice that harbored a LacZ reporter directed by rSOX-4 and 
observed expression within the dorsal root ganglia and melanoblasts at E11.5. There was also 
some variable expression observed in the dorsal portion of the head and brain, which may 
represent cranial neural crest cells. As it is known that Tubb2b plays a critical role in neuronal 
migration (Jaglin et al. 2009), we anticipate Tubb2b may be performing a similar function in 
migratory neural crest and derivative cells. 
To assess if Tubb2b is indeed the target gene of rSOX-4, a Tubb2b reporter mouse could be used. 
If rSOX-4 is regulating Tubb2b, we would anticipate the expression patterns of Tubb2b at E11.5 
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in mice to overlap the patterns observed in our rSOX-4:LacZ transgenic mice. Fortunately, a 
mouse reporter model harboring a BAC spanning Tubb2b and including approximately 150 
kilobase pairs upstream to 40 kilobase pairs downstream has already been generated with GFP 
knocked into the coding sequence of Tubb2b (Breuss et al. 2015). Interestingly, the authors 
observe GFP expression in the spinal cord and the developing head/brain at E14.5; however, the 
authors do not present any data at E11.5. 
Similarly, the generation of rSOX-4:GFP stably integrated mice into the endogenous rSOX-4 
locus would allow us to examine the spatial and temporal expression patterns globally. By 
constructing a homologous repair template harboring a floxed rSOX-4 allele directing GFP 
expression, we would be able to also assess the effects of removing rSOX-4 in any tissue through 
Cre recombination. We would anticipate the expression patterns of such a mouse to recapitulate 
our results observed in the transient transgenic mouse at E11.5. Furthermore, since this region 
was identified originally in our S16 Schwann cell model, we would predict the region to be 
active in Schwann cells, although the precise developmental window is unclear. This is due to 
the fact that rSOX-4 is a SOX10 response element, and SOX10 is necessary throughout all stages 
of Schwann cell development (Britsch et al. 2001; Finzsch et al. 2010; Bremer et al. 2011). 
Based on the known role of Tubb2b in migratory cells, we may predict rSOX-4 would be active 
in migratory Schwann cell precursor cells; however the S16 cells are a model of mature 
myelinating Schwann cells. Interestingly, Tubb2b is highly expressed in both oligodendrocyte 
precursor and ‘newly formed’ oligodendrocytes, but the expression levels are greatly reduced in 
mature myelinating oligodendrocytes (Zhang et al. 2014). It is possible for rSOX-4 to be active 
within both populations, as well as other cell types, and additional studies, such as the one 
described above, will be necessary to understand the in vivo role of rSOX-4. 
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If the mouse model was made as described above, it would be possible to use the same mouse to 
study the effects of rSOX-4 deletion in mice. Based on our current data, we would anticipate 
defects to arise in the dorsal root ganglia and melanoblasts; however, these predictions may 
change based on the previously described experiments. Interestingly, deletion of rSOX-4 from 
the S16 cells resulted in nearly complete loss of Tubb2b expression in the cell lines. This 
suggests that a mouse lacking rSOX-4 may display similar phenotypic defects observed in 
Tubb2b deleted mice. Unfortunately, a Tubb2b knockout mouse does not currently exist, and the 
only mouse model available to study Tubb2b harbors a point mutation that does not disrupt 
Tubb2b expression levels (Stottmann et al. 2013). 
To further study the role of Tubb2b in the tissues where rSOX-4 is active, a knockout mouse 
model would need to be generated. Through the Knockout Mouse Project (KOMP; 
www.komp.org), a conditional knockout allele of Tubb2b has been generated, and is available as 
both embryonic stem cells or incorporated into a vector. The generation of these conditional 
knockout mice would allow us to determine the functional role (if any) of Tubb2b in any rSOX-4 
affected tissue, through use of specific Cre expressing mouse lines. We may anticipate that a 
global knockout of Tubb2b will be lethal, since mice harboring a point mutation within a critical 
amino acid motif do not survive beyond the neonatal stage (Stottmann et al. 2013); however, 
since this mutation does not appear to affect the expression levels of Tubb2b, it may be acting as 
a gain of function mutation, and loss of Tubb2b may be tolerated due to redundant function of 
other tubulin genes (Tischfield et al. 2010). 
While generation of a Tubb2b conditional knockout mouse may uncover novel functions in 
migratory neural crest cells, we may conversely observe no phenotype in our candidate tissues 
(i.e. DRG, melanoblasts, or Schwann cells). Nevertheless, the generation of a conditional 
 187 
knockout mouse would be of use to the tubulin field, as this mouse could decipher any 
compensatory actions of other tubulins and help elucidate the unique function of Tubb2b in 
cortical neurons.  
In addition to studying the potential function of Tubb2b in neural crest cells and tissue 
derivatives, assessing the rSNP within human populations may help elucidate any potential 
functional effects. While we have not applied minor allele frequency thresholds in our 
experiments, the minor allele frequency of the rSNP (rs16886790) within rSOX-4 is 0.2001, 
making it feasible to study in human populations. Studies are currently being conducted by Dr. 
Stephan Züchner (University of Miami) that are collecting DNA from patients with CMT caused 
by molecularly indistinguishable duplications of PMP22. The patients are being classified based 
on their disease severity, and SNP genotyping is being performed. We have been in contact with 
the researchers, and our SNP did not have any association within their preliminary results; 
however currently the sample size is small, and additional patients are being included in the 
study that may lead to an association between our SNP of interest and CMT disease severity. 
While we originally identified regulatory function of rSOX-4 within Schwann cells, based on our 
rSOX-4 transient transgenic mouse data and the predicted role of Tubb2b in migration defects, 
utilizing patients with CMT may not be the most appropriate patient sample. To address this, 
generating mice harboring the human minor allele would allow for direct functional assessment 
of the rSNP. By definition, the SOX10 binding site is conserved within mice, but no mouse 
strain assessed harbors the human SNP. Utilizing CRISPR and a short homologous repair 
template harboring the human minor allele, we could knock-in the human minor allele into the 
endogenous mouse locus (Singh et al. 2015). From these mice, Tubb2b expression could be 
determined in multiple tissues and developmental time points. We would predict the minor allele 
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would result in decreased Tubb2b expression in tissues where rSOX-4 demonstrated in vivo 
regulatory activity (i.e. dorsal root ganglia, melanoblasts, and potentially Schwann cell 
precursors [based on the regulatory activity in S16 cells]). 
 
Global Characterization of SOX10 Binding Sites and Regulated Transcripts Important for 
Schwann Cells 
One of the main goals of this thesis was to uncover novel CREs critical for both Schwann cells 
and the peripheral nerve in general. While initially we were limited to sequence conservation, 
and later SOX10 ChIP-Seq (Srinivasan et al. 2012), to identify a small number of putative 
SOX10 binding sites and rSNPs, the era of genomics has allowed us to greatly refine our 
computational predictions. We have started to utilize genome-wide approaches such as DNase-
Seq and RNA-Seq to more globally characterize Schwann cells. Reassuringly, these new datasets 
generally overlap with the previous regions that were selected based exclusively on conservation, 
while also identifying novel candidates that are not conserved. 
One of the more striking observations that arose from these detailed studies are novel SOX10 
regulated (potentially Schwann cell specific) alternative promoters. Indeed, we identified a 
previously uncharacterized promoter at Sox6 (Chapter 4), and work from our lab has previously 
identified novel alternative promoters at Sh3kbp1 (Hodonsky et al. 2012) and Mtmr2 (Brewer et 
al, manuscript under review at Human Molecular Genetics). 
From these observations, we hypothesized that there may be additional uncharacterized 
promoters regulated by SOX10. To identify these using a genome-wide approach, our lab is 
employing CAGE-Seq on the S16 cell line (Shiraki et al. 2003; Takahashi et al. 2012). The 
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preliminary results have confirmed the presence of alternative promoters at Sox6 (Chapter 4), 
Sh3kbp1, and Mtmr2. Additional work is being performed to optimize the CAGE-Seq protocol, 
and methods are being developed to utilize existing datasets to identify novel alternative 
promoters in Schwann cells. 
Another major finding from Chapter 4 was preliminary data suggesting that SOX10 influences 
expression of genes involved in negative regulation of myelination. While we were able to 
demonstrate functional SOX10 response elements near these genes, further studies will be 
necessary to link these binding sites to the genes and to determine the importance of these 
findings during peripheral nerve development. One experiment to assess this could be deletion of 
these elements in S16 cells using the CRISPR and RNA-Seq approaches developed in Chapter 3. 
One caveat of this approach is that the S16 cells are a model of mature myelinating Schwann 
cells, and would not be predicted to express negative regulators of myelination. To alleviate this 
potential problem (and utilize an in vivo system), our lab has begun to isolate pre and post-
myelinating Schwann cells from mice. Once pure populations of Schwann cells have been 
isolated, we will perform RNA-Seq experiments on both myelination states to compare what 
genes are up or downregulated. To identify genes regulated by SOX10, these cell populations 
could be reisolated from mice harboring a floxed Sox10 allele (Finzsch et al. 2010). The cell 
populations could then be transduced with lentiviral Cre:GFP (Ahmed et al. 2004) to excise 
Sox10, flow sorted for GFP positive cells to select for the removal of Sox10, and RNA-Seq 
performed to compare the Sox10 knockout cells to the wildtype cells. This analysis would reveal 
genes that are regulated by SOX10 in both pre and post-myelinating cells and may support our 
preliminary work suggesting that the genes identified in Chapter 3 are indeed SOX10 regulated. 
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The results from this work could greatly expand our knowledge of the transcriptional hierarches 
in Schwann cell development. 
 
Concluding Remarks 
Throughout this thesis, we developed and employed a pipeline utilizing both computational 
predictions and functional evaluations. When these studies began, we were limited to assessing 
only conserved regions harboring SNPs. As we continued our efforts, genome-wide datasets 
became available either though collaborations (Sox10 ChIP-Seq; (Srinivasan et al. 2012)) or 
through our own efforts (DNase-Seq and RNA-Seq; Chapters 3 and 4). These datasets were used 
to reprioritize our predictions and lead us to novel Schwann cell biology. In the future, we plan 
to continue to refine our predictions through additional genome-wide datasets. While the 
computational and functional pipeline has lead to novel and exciting results, it is the hope of the 
author that the work performed in this thesis will be applicable not only in a basic biological 
context towards understanding both Schwann cell development and genetic modifiers of 
peripheral neuropathies, but also as a translational step towards potential therapeutic options for 
patients.
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Appendices 
Appendix 1 Genomic Information and Primers for Regions Assessed in Chapter 2. 
Name Conserved Region (hg18)1 rs Number Left Primer (Forward)2 Right Primer (Reverse)2 Size3 
SC21-1 chr21:14647869-14647874 rs13048016 TCAATTTCCCAGAGGAGAGG ATCCACCAGGACAGAAAAGC 511 
SC21-2 chr21:15299507-15299521 rs7280064 PCR Failure PCR Failure   
SC21-3 chr21:15652270-15652285 rs16982386 TTGCACCATTATTGCTCAGG CATTGGAGTTTCCACCATCC 913 
SC21-4 chr21:15729880-15729886 rs2823280 TAGGGCTCCTTGAGAACTCTG TCACAGCCTTAGGTGACTTCC 670 
SC21-5 chr21:16880688-16880703 rs3803997 AGGGATGCTTTTGTATTGATGA AGTTCTCTGGCATCTGTGTCC 619 
SC21-6 chr21:16880718-16880725 rs3803998 Same primers as region SC21-5 Same primers as region SC21-5   
SC21-7 chr21:16887088-16887093 rs2823898 PCR Failure PCR Failure   
SC21-8 chr21:19230871-19230876 rs460825 PCR Failure PCR Failure   
SC21-9 chr21:19661559-19661570 rs2825543 TGTGAATGAAATGGCAGTCC GTGCACACGGATGTAGATTG 700 
SC21-10 chr21:21313182-21313188 rs7277262 AAAGCATTTCCATATTTTCAGG TGAGCATGGAACAGAACTGG 503 
SC21-11 chr21:21778651-21778662 rs233760 GCCATTCTTGTTTTGTATGAAAG GGTTGATAATTGGGGGAAGG 483 
SC21-12 chr21:22535874-22535880 rs2827297 TTACCGTTGTTTCCAAAGTGC TGGTCTCTGTTTTTCCCTAGC 1085 
SC21-13 chr21:27318695-27318702 rs233616 CGCTGTTCTAAACACGTCCA ATGATGGCTCCTATGTAAAACC 520 
SC21-14 chr21:28550903-28550909 rs2206849 TTCAGAGGCTTTGGAACTGC AAAATGGACTGGCTTTCCTC 958 
SC21-15 chr21:28681566-28681571 rs2831741 GAAATGTGGGCACAGTGAAG TCATGCCCATGTTCTACAGG 538 
SC21-16 chr21:29424534-29424540 rs2832203 AACCTCAAAAATCACAATCCA AAAACCCTCCTCCTGTCAGA 477 
SC21-17 chr21:29449389-29449394 rs9305393 GAAAGCACCAGACGTAGCTG CGGTTCATAGCAAGCTCCTC 789 
SC21-18 chr21:33139128-33139135 rs2833975 CTCCTTCCCATCTCACATCC TTGTCCCTTGAGGCTTTGG 554 
SC21-19 chr21:33213365-33213372 rs7281293 GGAGCAGACAGACCACACTC CAGCTCCTTAAGCCCAACTG 1383 
SC21-20 chr21:33273214-33273219 rs2834040 CTCTCTTCTCCACCCCAAGC CTCCAGCAACCAGTCTCTCC 1254 
SC21-21 chr21:33431020-33431029 rs8132254 ATGCTGTGAGTCTGGCTGTG CCTTCCACCCCAAACCTATC 642 
SC21-22 chr21:33431167-33431196 rs8132292 Same primers as region SC21-21 Same primers as region SC21-21   
SC21-23 chr21:35234522-35234528 rs8130590 ATGAGGCTGGAGCATTTCAG TGAGCATTGCGCTATCAGAG 494 
SC21-24 chr21:35366984-35366996 rs2834747 ACTCCAGGTGAGGATTGTGC GGTGATGGTTGGAGATCAGG 1236 
SC21-25 chr21:35367060-35367117 rs17227266 Same primers as region SC21-24 Same primers as region SC21-24   
SC21-26 chr21:36033307-36033313 rs2835112 TGGAAGCTCCAGAGAACTCC TGCAATTTTCCCTGATTTGG 1022 
SC21-27 chr21:36269198-36269214 rs2835196 GGCATTTGTGTGATTCTTTCC CGGTTAGATCAAAAGGATCTGC 361 
SC21-28 chr21:36281865-36281876 rs2249599 CCAGCACCTTCTGACAAACC TTGCAAACCACATTGAGAGG 368 
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SC21-29 chr21:36317420-36317426 rs4817761 ATGTCCTGCTCTGGAAAAGC TCTCTTTCCTGTGGCTTTGG 986 
SC21-30 chr21:36846163-36846171 rs376590 AGACAAGCCATCCTTCTTGG TCTTTGCAGTTGCCAGAACC 415 
SC21-31 chr21:37916579-37916585 rs878307 TGCACTTGGTTTGCTAATGG GTCTGGTTGGAAGAGCAAGC 513 
SC21-32 chr21:38112515-38112521 rs2835986 PCR Failure PCR Failure   
SC21-33 chr21:38940551-38940556 rs16996658 TAGGACTGCAGGTGATGAGG GGACAAAAGCAGAAGGTTGC 620 
SC21-34 chr21:38958107-38958118 rs8130434 TTGAGAGGCCGAAAGAAAAC TAGGAATGGGACAGGACAGG 967 
SC21-35 chr21:40499095-40499101 rs16999481 PCR Failure PCR Failure   
SC21-36 chr21:41127253-41127260 rs2837850 TCCTCTTCAAGCGTTTCTCC TCTCAGTTGCAATTCCTTTGG 526 
SC21-37 chr21:41133606-41133612 rs8131683 CTTCTCATCCCCAGCTTCC TCAGCTTTTGATTTTTGGACA 563 
SC22-1 chr22:16689437-16689442 rs5992119 AAACCTGCCTGTGTCTGTCC CATACAAAAGGGGCATTTCC 709 
SC22-2 chr22:25493989-25493999 rs2051623 AGGGAATCTGGGGTACTTGG GGTGGCTTTTGTCTTCTTGC 631 
SC22-3 chr22:25540690-25540696 rs713974 TTTAGCCCCTTCTCTTGTGC AATGGAGCACCAGGTTTCTG 720 
SC22-4 chr22:25556945-25556960 rs6005195 CAAAGTGACCCGAGATGTCC CCCCTCCATCTGAATAAAGG 726 
SC22-5 chr22:25581021-25581028 rs16982950 TACACAGACCCCTCCCTCTC GTGCAGCACCTGTCTCTCC 868 
SC22-6 chr22:25588565-25588572 rs136557 GCCTCCATCTCTGTGAATCC CAAACACCTTGGGAATTTGG 920 
SC22-7 chr22:25653869-25653874 rs739251 TGCCTCATTCCTCAGAAACC TGTGTTTCTTTATGCCCTTCG 888 
SC22-8 chr22:25678449-25678472 rs5761863 ATGTCAACGAGGGAGCTAGG AAGGGAGGAGGAGAATGAGG 492 
SC22-9 chr22:25749225-25749250 rs17343778 GCATGTCACCATCAATCAGC AGCTTTCCTGCTTCAACAGC 896 
SC22-10 chr22:25769441-25769477 rs17429199 TCAGTGGGAACTCACCATAGC ATTTGAGACCCTGATTTCTTAGC 901 
SC22-11 chr22:25884083-25884096 rs4822861 CGGTTTGGCTACACAGAAGG GAACCCTTAGGAACCCTTGTC 945 
SC22-12 chr22:26012528-26012599 rs17173861 CCTGGGGAAACAGACATCC TGCGCACACACGTATTTACC 773 
SC22-13 chr22:26012622-26012627 rs7293113 Same primers as region SC22-12 Same primers as region SC22-12   
SC22-14 chr22:26146779-26146784 rs733164 CCCCTAAATAGCCCTGATCC GAGCTCCTGGCTTTGAACC 881 
SC22-15 chr22:26247799-26247804 rs17466256 GGCCACAGTTGATAGTCTGG GAGGATGAAGGGGCTTGG 266 
SC22-16 chr22:26274397-26274404 rs16985013 GGAACTTATAGGCCCCAAGG TTACACCTCGTTCCCTCTGC 422 
SC22-17 chr22:26913737-26913746 rs7284814 TCCAGGTGGGTTACATTTCC TCAACTGAATAAACTTTGCTTTGC 422 
SC22-18 chr22:26995094-26995113 rs16986240 CACCCTTCACTTCATCATGG TGGGAAGAGTGTTGAGACACC 611 
SC22-19 chr22:27167830-27167847 rs16986429 PCR Failure PCR Failure   
SC22-20 chr22:27544643-27544648 rs2301429 GTGTTTCAGCTCTCCCTTGG TTCTCAGGAAGGCCACTGC 515 
SC22-21 chr22:28015405-28015410 rs16987366 AATGCAGCTGTTTTCCACAG GCCTGTTGTCAAATGACTTTC 684 
SC22-22 chr22:33205230-33205249 rs130593 TGGTTGGAGGAGAAGTTTGG TTTCCCACTTGGATTGATGG 482 
SC22-23 chr22:33363804-33363815 rs11089687 CAGCAGGATGTCATTGTTGG GATCTGGTCCTTTGCTCTGC 479 
SC22-24 chr22:35426848-35426890 rs2284017 CCAACCCACCCATTTCTG AAAACTCCTGTGGGTCATCC 932 
SC22-25 chr22:35430194-35430211 rs2267361 GGACGGGTAATTACAAACACG AAACATGAACCCATCTCATGC 628 
SC22-26 chr22:41020252-41020259 rs6002672 BP Failure BP Failure   
SC22-27 chr22:42090126-42090141 rs695648 TGGATTTGGATTTTGGATCG GTTGGAGGAATGCTCAGAGG 848 
SC22-28 chr22:42438983-42438993 rs6006534 TGAAATTAGAGTGTGGCGTTC TAGCGTGGGCTCACAGTAGG 340 
SC22-29 chr22:42438997-42439002 rs17568513 Same primers as region SC22-28 Same primers as region SC22-28   
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SCX-1 chrX:10519616-10519621 rs10284156 ATCCCCAAGGGAGTTGACTT ACCCTAAAGACGCTCGATCA 1159 
SCX-2 chrX:13701570-13701575 rs13187 GGGTGAGCATGATGGCTAGT TGTTAGAGCCCACAAAATTGG 866 
SCX-3 chrX:15529186-15529192 rs4646115 TTCATCCTGGAGAGGACAGA GGGAAAATGTTGCCCAAGTA 344 
SCX-4 chrX:17730099-17730104 rs2187846 CTGCAACACAGAACATACAA GCAACTTGGACTGAAACTTCG 343 
SCX-5 chrX:18560920-18560932 rs34122505 GCTCAGAGCTATGCTGTCAGTCT TCACAAAAGTATGAGTCTGTGGA 545 
SCX-6 chrX:22421316-22421332 rs5970650 TGCAGTCAAAATGCACTCAT CATAATCTGGGAAAAACTAAAGCA 747 
SCX-7 chrX:23089136-23089146 rs17343199 CCCCTTAGCTGCTTCTTTCA CTAGTGCCTCCCCAAAGGTA 777 
SCX-8 chrX:24566571-24566586 rs1921918 CAGGAATGGGCTTTCAACAT ATGGCAGTATGGGCTTGAAC 793 
SCX-9 chrX:24688106-24688116 rs5944676 CACCCCTCACCAGAATGAGT AAAGGGAAAGCCTGTGAGGT 477 
SCX-10 chrX:25170446-25170451 rs5986762 AAGGAAATGTGGAGGCCTTT TTCCTGTGTGAGACAATGCAG 1057 
SCX-11 chrX:25376363-25376368 rs5944057 GGGCACTTTCATGAGGCTTA TCATGGCAGAGGAACAGACA 936 
SCX-12 chrX:25411586-25411596 rs17286168 GCAAGACTCCTTTTGATTTTGA CTTCAAAACATTAAATATGGGTTC 1044 
SCX-13 chrX:29185519-29185525 rs16988485 CATTTGAGTGCATGGGAAGA ATTCCAGCGGTGAAAACTTG 438 
SCX-14 chrX:29403341-29403347 rs7065816 TTTCAGCACTTAGAATGACATGG AAGACACGGATGCCCTTATG 1271 
SCX-15 chrX:29847765-29847774 rs7063049 CAGGGACTCAAGCAAACACA CAAAAATCCACACAAACAGACA 1375 
SCX-16 chrX:30959319-30959330 rs444301 TGAGAGACAGCATTGGTTGG GACCTTGATGGCTGCTGTTT 772 
SCX-17 chrX:31226760-31226769 rs11797901 TTCACCAGAGGATCTAACAGCA CGAACAATTAGTTGACTTTTCTTCAGT 898 
SCX-18 chrX:31252044-31252049 rs7884417 AGAAAGGCAAGGAGGTCAAA GCATCAGCTGTGCTTCAAAT 1037 
SCX-19 chrX:31420373-31420379 rs16989672 TCCCCATAAAAAGCATCAGC ACTTGTAGTTTGGCGCAATG 576 
SCX-20 chrX:31435143-31435149 rs3788892 TCCAAAGAAAGCTGGCACAT AGCAAAAAGGCCACAAATGA 613 
SCX-21 chrX:31764702-31764707 rs1379871 TGGACATTAAGCTCAGGTGC GCCACTCAGCCAGTGAAGG 1116 
SCX-22 chrX:31803223-31803228 rs1800275 TGATACCAAATGAGAAAATTCAGTG CCAAGAAGGACCATTTGACG 105 
SCX-23 chrX:39008367-39008377 rs5917286 CCTGTCTTTGGCCCATTCTA CATACATTGTACCCATAAAACATACA 833 
SCX-24 chrX:39175198-39175203 rs2029475 GCTTCAGCCAGATTTCATCC CAACCACTGCATTTCTGGTG 688 
SCX-25 chrX:39190395-39190404 rs6610273 CTGGTATGCAGAGCCCACTT CACTTGAGGTTCTCAGGACAG 872 
SCX-26 chrX:43712864-43712876 rs12833438 GCAAATGACTGCCAGAGACA ACCAATTCCCCTCCACTACC 501 
SCX-27 chrX:82478122-82478130 rs1299087 ATGCCACACTGCCTTCAGTA CAAGAAAACAGGGGAGTCTGA 2497 
SCX-28 chrX:82637870-82637946 rs12860283 TTTCACATTTAGGCCCGAAG TCCTGTAGCTTCTCCCATTGA 1384 
SCX-29 chrX:85043549-85043617 rs16980331 GATAAGCATACCATAAAAGTTCA AGGCAAGAGCTCTAGTTCAATG 1430 
SCX-30 chrX:85287194-85287201 rs242849 TTCAGTTGGCTGAGGGTTTC GGCCATTGATCATTGAAAGG 940 
SCX-31 chrX:85367482-85367493 rs16980456 CACATTTGGAAGCCAGGAGT TTGGAATACTTGGCTTTTCTTTG 1433 
SCX-32 chrX:85404361-85404385 rs6653101 TCCCATATAGATCCACAAAACTGA GGGATGGGGGTTGTTTTAAT 587 
SCX-33 chrX:85443058-85443064 rs6623642 TTTGGCATGGGAGAGAAAAG ACCCCATGGAAATGTTTGAA 1256 
SCX-34 chrX:85764274-85764279 rs16980611 GAAGGCTCTTTGCCATTTACA TGCCAACTGCAACTTAACCA 1464 
SCX-35 chrX:85809671-85809677 rs5922268 CAGCAATGTCTTCCCTGGAT GCAAACGAATGCAACATGAC 1427 
SCX-36 chrX:85913194-85913210 rs1419032 CAGTGTCATATGCCCCAATG TGGAATGATGAGGCTTTGGT 1068 
SCX-37 chrX:85961901-85961908 rs2185879 PCR Failure PCR Failure   
SCX-38 chrX:85971813-85971836 rs11092827 CAGGCAGTGCTGTGCTAAAG CCAGGGACCAGAAGAAAACA 1254 
 194 
SCX-39 chrX:86429198-86429205 rs16980794 GCTGAATCTGAGGCACCTTC TGGAATGGCTCTCCTTTCAC 1380 
SCX-40 chrX:86890323-86890341 rs5922480 AATCATGCCTTTCTCGGATG TCTTCCCATACCCAATTCCA 1383 
SCX-41 chrX:86890482-86890495 rs5924110 CAGTAAAAAGATTTGTTGGCAAT TGTAGTAATTTACCGGTTTAGTAACCT 977 
SCX-42 chrX:87641465-87641470 rs6522112 TTAGGCCCTTTAATGCTTGC CAGATTAGTAGCTTCCCACAGTAGC 2126 
SCX-43 chrX:91308657-91308662 rs4021810 CATGTCTGTTATAAGGAATTCATCTG TTTCCAAATTTTGCCGATTC 1175 
SCX-44 chrX:91336826-91336843 rs6618904 GGGACAAGAATGATGCCAAT CAACAAATCACCAGGTGGAA 1977 
SCX-45 chrX:92656893-92656900 rs12687113 GGCGACAGCATCAAAGAAAT GAAGTGCAGAGGGCAAAGAC 1034 
SCX-46 chrX:93640694-93640700 rs6619561 TGTAATTAGTACAAGGGTCTGATTT TTGCCATTAACTTCCTGATGC 953 
SCX-47 chrX:94777246-94777251 rs5990383 CAGAGGCTCCCTTTCTACCA TTTCCTGTTGCTGGGGTTAG 930 
SCX-48 chrX:96687553-96687558 rs5967326 TGTGGCCATCTGCTAAAATG TTTCCCCACCACTGAGAAAG 524 
SCX-49 chrX:96740407-96740415 rs5921859 AAGGGATTTTCACCCCACAT TGTAAGACAAACAGAAAAAGGA 783 
SCX-50 chrX:98164479-98164486 rs16982964 TGAATGCTTTGGCATTGGTA GAAGCTAAATAGATTATTTTTCCTCCA 2370 
SCX-51 chrX:99217165-99217172 rs985251 AGGCAAGCAGACATCACCTC GGCAAGTGCATCTATCAGCA 781 
SCX-52 chrX:99454087-99454093 rs7064056 GGGTGGGGAAGCTAAGAAAC AAGAGCACTGGGACAAGCAT 1082 
SCX-53 chrX:103711687-103711695 rs1004122 CATCCATTGATGTGCAGGAC TGGCAGGCAAGGATTAGAAC 780 
SCX-54 chrX:104030456-104030461 rs1343409 TTTTCCCAACAAGTCCTCCA GCCCAAGGGAAAACAACTTT 640 
SCX-55 chrX:104181005-104181031 rs16984615 GAGACCTGTGGCATCTTGTG GGAAGCAAAGCATCCAAGAA 921 
SCX-56 chrX:120221829-120221834 rs1861522 GGATATTCCGTTGGTTTTGC CCATGTTTTATTGTTTCATTCACA 718 
SCX-57 chrX:120428002-120428008 rs6608251 TATCTGGCCACTTTCCCTGT GCCAAGTATCCTTTCCCACA 1425 
SCX-58 chrX:121682472-121682478 rs17273301 CCCTCCATAGAGGCCTTGTT TGTCAGTGGCAGAATTGCTC 572 
SCX-59 chrX:122196457-122196480 rs7890100 AAATTGACTGGGTGGCAATC GGTGATCTCTGGCTTTCAGG 607 
SCX-60 chrX:123382405-123382410 rs2076164 GTGGGAGAAAGACTTGATTTTAAC TTAGGCCAGAGGAGTCAGGA 626 
SCX-61 chrX:123612555-123612568 rs16999342 CCCCACTGAGCCTGTCAATA TAAGCTGCTTTGCCTAATATG 1179 
SCX-62 chrX:124339837-124339845 rs3126112 TGATACGTCTGCTATTAGTGAAAGA GCTGAAAAATGCTGATGGAA 1500 
SCX-63 chrX:125247437-125247470 rs16998722 AGGAAGGGTGGCTGGTTATT TGATTTCACTATGAAACCCACTC 2296 
SCX-64 chrX:125729275-125729280 rs17303490 ATCCAGCTCTTCCTGAACCA CCAACCTCAGGACAAGTTGC 1394 
SCX-65 chrX:125925884-125925893 rs5930055 TTGCTTGCTTTCGAGTTGTTT ACGGAACAAATGTCCTCACC 814 
SCX-66 chrX:125954394-125954405 rs17332319 AGAGGGCTTCTTTGGCATTT GGGGTCTGCATTAATGATGTG 1336 
SCX-67 chrX:127229700-127229720 rs17266605 GGGTATCCTCCAGGTCTAGCA TTGATCTGGCACTGGTTTCA 681 
SCX-68 chrX:127874030-127874040 rs9887026 GGGCCAGTCAGATCCCTAGT TGTCTGCCCCATTTATGTGA 681 
SCX-69 chrX:128107907-128107918 rs722439 AAGTGGTTGGTGGCTGAATC GGCAGTGGAGACAAGTGGTT 1076 
SCX-70 chrX:131733694-131733707 rs7878720 GAAATGGGGAAGCACATCAC CTTGAGACGGCATGGAAAAT 690 
SCX-71 chrX:131733885-131733892 rs5933189 Same primers as region SCX-70 Same primers as region SCX-70   
SCX-72 chrX:135102713-135102725 rs2300913 TCTGATGGGTATGCCATGAA GGGCAAGAGGCTGATAACAA 436 
SCX-73 chrX:136737672-136737678 rs708697 GTTTTGCTTTGGGGTCGATA TATCCTGCCTTTGAGGGATG 1222 
SCX-74 chrX:136795666-136795675 rs6635500 CACCTTGGGAAAGAAGGACA TTCCCTTTTCCACATCACCT 864 
SCX-75 chrX:136916407-136916412 rs6633954 GCAGGAAACATGGCTCAAAT GTTCCCAAGTGTCCCATACG 620 
SCX-76 chrX:137579834-137579839 rs17510193 CTTCTGCCTCTCCCCTTCTC AAATTTCAAAGTAGCGAAATTGG 588 
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SCX-77 chrX:139502708-139502777 rs5954039 TAAACCAAGCCAACCCAGAG GGCTACAATCCTGCAAATCA 1425 
SCX-78 chrX:146960885-146960891 rs6525876 TCCCATCCAGTCTTCCAAAC CTCCCAAAGGGCTCTCTCTT 465 
SCX-79 chrX:147139773-147139778 rs16994500 TGAAAAGAAGTTCATAGAAGGGAAA GAAAAGTTTGCATTTTGTTTGAA 723 
SCX-80 chrX:147303281-147303289 rs6641405 AAATAGCCCCCGTGTGATTA TTCAGTTTGGCCCTTGGTAG 671 
SCX-81 chrX:147430625-147430635 rs17252118 TGGACATCCTTCAGGAAAGC CCAAACATAAAAGAGCATGGTG 952 
SCX-82 chrX:147466469-147466477 rs5936216 TCTAGGGCTGCTCAGTCACA CCGAGGAAGATCCCCACTAT 774 
SCX-83 chrX:147612978-147612994 rs5980583 AACGTCCTCTGGCAAAAATG GGCACAGCAATCTTCCTAGC 967 
SCX-84 chrX:147637143-147637154 rs12686890 CTTGAGCACTCACGCAAAAA TATGGGCTGACACTCATGGA 1137 
SCX-85 chrX:147661284-147661318 rs17252278 AGCCTGATCTTGGCCTGTTA TTGCCATTCTTTCCTCTTGG 623 
SCX-86 chrX:147714683-147714691 rs1372593 GTGAGGGAGCTTTGTTCCTG ACCCTCTGAGAATCCACTGC 1075 
SCX-87 chrX:147759881-147759889 rs16994786 AGCCCATTTCCTGAATTTCC CACAGGCAAAATGGGACTCT 1431 
SCX-88 chrX:147991975-147991988 rs9308376 TCCATGGGAAAAATGCTTCT ATAGGGATTGCTTGCTGCTC 1216 
SCX-89 chrX:148185049-148185065 rs764908 CCTGGCACAAATACCGATCT TGACTCCTTTGACCGTGTGA 1809 
SCX-90 chrX:149322258-149322264 rs5924948 TGAGGCAAGAAAAGATTTGTG AGCCTGAAACCAGATGTTGG 961 
SCX-91 chrX:149632616-149632621 rs6627325 AAAACTGGCTGCACTGAAAAA ATTTGGACAGGAGGGCACTA 1324 
SCX-92 chrX:153231488-153231493 rs2070819 CGTGTTCACGACGAACTCAG GTCTGCTTACGGAGCAGGTC 230 
SCX-93 chrX:153239964-153239969 rs5987247 PCR Failure PCR Failure   
 
1Regions are given in bed format for the human genome (hg18) and only encompass the base pairs identical among human (hg18), 
mouse (mm9), and chicken (Gal3). 
2Primers sequences are displayed in the 5’ to 3’ orientation and do not include the gateway adapter sequences. The adapter sequences 
for the forward and reverse primers are 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCT-3’ and 5’-
GGGGACCACTTTGTACAAGAAAGCTGGGT-3’ respectively. 
3Sizes are given in base pairs and do not reflect the additional size of the gateway adapter sequences. An additional 58 base pairs 
should be added to the size to account for the gateway adapters. 
Regions without primers represent the regions that were dropped due to technical errors or amplified with another conserved region. In 
place of primer sequences, the technical failure is listed: ‘Same primers as’ represents two conserved regions amplified in a single 
PCR product, ‘PCR Failure’ represents multiple primers tested without proper amplification, and ‘BP Failure’ represents proper PCR 
amplification (and product sequence verified) but unable to clone into pDONR221. 
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Appendix 2 Genomic Information and Primers for SOX10 Regions Assessed in Chapter 3. 
Name Conserved Region (hg18)1 rs Number Left Primer (Forward)2 Right Primer (Reverse)2 Size3 
rSOX-1 chr2:44834620-44834625 rs3738980 ACAGGAAGTTGCCAGAGTGC TTGAGAAGAGAGCAGAATCC 321 
rSOX-2 chr3:62426974-62426979 rs6445273 TGGCAGAATTCCTTATTACCG CAGGTGAAATGTTTCATTGTGA 319 
rSOX-3 chr4:146183931-146183936 rs34577920 AGATTTTAAAGGGCAAACATCA GCAGCAGATATCAGCCTTCA 1340 
rSOX-4 chr6:22818474-22818479 rs16886790 CCACTTCTATCTGGGCAAGG TGTGAGTCCACTTGCAGAGC 922 
rSOX-5 chr6:98577359-98577364 rs12524696 TCTTGCCAATTTAAGGTGCTC CCATTTATCCAGACATGCACA 1084 
rSOX-6 chr6:98692222-98692227 rs17814604 TCTTCCCAGTGTGGTCCAGT GGCAGGGAATATGACAAACC 677 
rSOX-7 chr7:131601713-131601718 rs1364510 ATCAATGTGTGGCTCAGCAG TGGAGAAACCACCCAAGTTC 678 
rSOX-8 chr13:66589464-66589469 rs17082112 AGGTGTCAAACCCATTCTGG TGTGATTCAGAGCTCCAGTG 821 
rSOX-9 chr15:55214627-55214632 rs2703617 TGTGCAAGTTTAAAGCAAAATC GCTTGGCGAAATAACAAACC 1834 
rSOX-10 chr1:48904340-48904354 rs1966247 ACACTGACCCCATCTTCCAG AGTGTGCCCTTGTACCCTTG 624 
rSOX-11 chr1:168449895-168449935 rs16863114 GTTGCTTGGGTGAAATGGAC AAGACCAGGAAGGAGGTGCT 411 
rSOX-12 chr6:118599910-118599921 rs17335828 GTGTGTCCCAGTGGACTCCT TACCATGGAACCCAAAATCC 442 
rSOX-13 chr7:9853948-9853966 rs12702949 ATGCTAAATGAGAATGCTGG GTGCAATTCCAGTGCATGTG 615 
rSOX-14 chr7:95350538-95350566 rs10249566 TATGTCAGCTGCCCAAAATG TGCCAACATATTGCTGGTGT 596 
rSOX-15 chr8:37281347-37281384 rs17333409 CACACCACCTCCCTCTTTGT TAACCCAACTGCATGCTCAG 623 
rSOX-16 chr8:138460036-138460047 rs16907090 CACAGACCCCTTTGCCTCTA GAGTGGGGAGTGGTAATGGA 665 
rSOX-17 chr9:80243161-80243189 rs17788061 AAAACAAGGCACGCTCTGAT TCCTCAAATGAGCCACACTG 747 
rSOX-18 chr10:78070796-78070831 rs17469556 TTGCACTTCTGTCTGCATCC TCTCTCACCTCTCCCCTCAA 635 
rSOX-19 chr10:130596685-130596718 rs11819115 CCAAGCCAGCTCTGGTAAAG AATGCCTGCATGGTAAGGTC 605 
rSOX-20 chr11:31400150-31400183 rs1376362 GGGGATGTGATGATCATGTG AAACAAAATACGGCCATTCG 980 
rSOX-21 chr11:125354123-125354139 rs11607720 TTCCCTTTCTTGGCAGTCAG CTGTTGCTGGTTGGATCAGA 600 
rSOX-22 chr16:53169712-53169728 rs1186802 GGCCTGAGCTGTATTTGAGC CTTCAACTATCCGGCATTGG 489 
 
1Regions are given in bed format for the human genome (hg18) and only encompass the SOX10 consensus site. For dimeric sites the 
coordinates include both monomers and the intermonomeric region. 
2Primers sequences are displayed in the 5’ to 3’ orientation and do not include the gateway adapter sequences. The adapter sequences 
for the forward and reverse primers are 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCT-3’ and 5’-
GGGGACCACTTTGTACAAGAAAGCTGGGT-3’ respectively. 
3Sizes are given in base pairs and do not reflect the additional size of the gateway adapter sequences. An additional 58 base pairs 
should be added to the size to account for the gateway adapters. 
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Appendix 3 Primers Used in Gibson Assembly to Construct Drug Resistance Repair Templates in Chapter 3. 
Names Primer used in Gibson Assembly1 Size2 
CSOX4 5 Hom Arm For AGCTTGCATGCCTGCAGGTCGACTCTAGAGTTCAGGGAAGGACAAATTTCA 1085 
CSOX4 5 Hom Arm Rev 
AACCAATAGGCCGAAATCCCCAAAATCCCTATAACTTCGTATAATGTATGCTATACGAAGTTAT 
AGCAGTGACGAGTCATAACCAG 
 
CSOX4 5 Blast Rev 
TACCGTAAGTTATGTAACGGACCTCGAGCTATAACTTCGTATAATGTATGCTATACGAAGTTAT 
AGCAGTGACGAGTCATAACCAG 
 
CSOX4 3 Hom Arm Rev CGGCCAGTGAATTCGAGCTCGGTACCCGGGTCAAATGGTAACTGTGCCTACC 1059 
CSOX4 3 Hom Arm For 
CTCTAGCTAGAGCTTGGCGTAATCATGGTCATAACTTCGTATAGCATACATTATACGAAGTTAT 
TCAGATGCTCTTTCACATAGCC 
 
CSOX4 3 Blast For 
CAAACTCATCAATGTATCTTATCATGTCTGATAACTTCGTATAGCATACATTATACGAAGTTAT 
TCAGATGCTCTTTCACATAGCC 
 
NeoR hCAS9 For AGGGATTTTGGGGATTTCG 1620 
NeoR hCAS9 Rev GACCATGATTACGCCAAGC  
Bsd For AGCTCGAGGTCCGTTACATA 1273 
Bsd Rev CAGACATGATAAGATACATTGATGAG  
 
1Primers used in in Gibson assembly to generate the drug resistant repair templates. Both blasticidin and neomycin resistance 
templates used identical 5’ forward and 3’ reverse primers for the 5’ and 3’ arms respectively. The Gibson assembly primers have 
been color coded to reflect different portions of the primers: black represents unique primer sequences to amplify the product, red 
represents homologous overlap with pUC19 backbone, blue represents homologous overlap with the drug resistance cassette, and 
green represents loxP sites. 
2Size is given in base pairs and does include additional size of adapter sequences. 
The 5’ and 3’ arms of homology were amplified from unmodified rat S16 genomic DNA, neomycin resistance template was amplified 
from the hCas9 expression plasmid (Addgene plasmid #41815), and the blasticidin resistance template was amplified from pCMV/Bsd 
plasmid (ThermoFisher - Cat no. V510-20). 
Please note that CSOX-4 and rSOX-4 are the same region. The names were changed for the thesis, but the primers were called by the 
original CSOX-4 nomenclature. 
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Appendix 4 Screening Primers Used to Verify Proper Recombination of rSOX-4 Mutant Cells in Chapter 3. 
Name Primer1 Size1    
C-SOX4 5 SCRN For TGATCATCTCATCTCCATTTTAGAG 1180    
Blast Seq Rev GCGTTACTATGGGAACATACG     
C-SOX4 3 SCRN 3R ATGTAGGCTCAAGGTGACAC 1414    
Bsd Scrn For CTGCCCTCTGGTTATGTGTG     
C-SOX4 5 SCRN For TGATCATCTCATCTCCATTTTAGAG 1253    
NeoR Seq Rev GACTTTCCACACCTGGTTGC     
C-SOX4 3 SCRN 3R ATGTAGGCTCAAGGTGACAC 1479    
Neo SCRN 3F CTATGAAAGGTTGGGCTTCG     
C-SOX4 WT For CCGTCTTCCTCTGACTCTCC 634    
C-SOX4 WT Rev CAGATCTCCTCTCTCCTTAGCC     
SOX6 MCS 3 For CAGGGGAGTCTAAGCCACAG 1759    
SOX6 MCS 3 Rev CCAGGTGTCTGTCCTGTCC     
Name Primer1 LoxP3 WT3 Blast3 Neo3 
C-SOX4 5 SCRN For TGATCATCTCATCTCCATTTTAGAG 1181 1798 2488 2835 
C-SOX4 Cre 2R CCTCAACACTTAACATAGCC     
C-SOX4 Cre 2F GGATGCCGCAGAAATCATTG 1256 1873 2563 2910 
C-SOX4 3 SCRN 3R ATGTAGGCTCAAGGTGACAC     
 
1Primer sequences are given in the 5’ to 3’ direction and were designed against the rat genome (rn5) or drug resistance repair 
templates. 
2Size of the PCR product is given in base pairs. 
3Varying sizes of PCR product depending on the allele amplified: LoxP is the post Cre transfection allele (i.e. loxP scar), WT is the 
unmodified original S16 allele, Blast is the blasticidin resistance cassette inserted into rSOX-4 genomic location allele, and Neo is the 
neomycin resistance cassette inserted into rSOX-4 genomic location allele. 
Shading indicates matching PCR primer pairs for a given reaction. 
Please note that CSOX-4 and rSOX-4 are the same region. The names were changed for the thesis, but the primers were called by the 
original CSOX-4 nomenclature.  
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Appendix 5 Probe and Primer Sets Used for ddPCR in Chapter 3. 
Name1 Sequence2 
Gmnn For TCATCTTCAGCGTTCTCCTTG 
Gmnn Rev GAATCTCAGTATGAAGCAGAAACAG 
Gmnn Probe /56-FAM/ACTCTTCAC/Zen/GTTCTCTTGGGCTCC/3IABkFQ/ 
Gmnn Probe Seq Only ACTCTTCACGTTCTCTTGGGCTCC 
Tubb2B For TCGATACCATGCTCATCACTG 
Tubb2B Rev GCAAGAAGCTAACGAGGCA 
Tubb2B Probe /56-FAM/AGTGCGGCA/Zen/ACCAGATCGGT/3IABkFQ/ 
Tubb2B Probe Seq Only AGTGCGGCAACCAGATCGGT 
Aldh5a1 For GATACACCCTATTCTGCCCTG 
Aldh5a1 Rev GGAGATTTTGGACACGAGGG 
Aldh5a1 Probe /56-FAM/AAGGAAGTG/Zen/GGAGAGGTGCTGTG/3IABkFQ/ 
Aldh5a1 Probe Seq Only AAGGAAGTGGGAGAGGTGCTGTG 
Gapdh For GTAACCAGGCGTCCGATAC 
Gapdh Rev TCTCTGCTCCTCCCTGTTC 
Gapdh Probe /5HEX/CACACCGAC/Zen/CTTCACCATCTTGTCT/3IABkFQ/ 
Gapdh Probe Seq Only CACACCGACCTTCACCATCTTGTCT 
 
1Primers are indicated by the suffix ‘For’ and ‘Rev’ while probes are indicated by the suffix ‘Probe’. The probe is listed twice to 
indicate the modifications (‘Probe’) and with the modifications removed (‘Probe Seq Only’). 
2Sequence are listed for both the primers and the probes in the 5’ to 3’ direction and were designed against the rat genome. For probes 
the modifications are: 5’ contains a 6-FAM fluorophore, an internal quencher Zen, and a 3’ quencher Iowa Black FQ. 
Shading indicates probe and primer sets. 
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Appendix 6 Genomic Information and Primers for Regions Assessed in Chapter 4. 
Name1 Locus Coordinates (hg18)2 Forward Primer3 Reverse Primer3 Size4 
CCS-01 PAX7 chr1:18854774-18854793 ATTCCAGTTTCCACGGTCAG GCTCAAGTCTGATGCTGCAA 756 
CCS-02 ZEB2 chr2:144876412-144876428 AGCCCAGTTTTTCCTGAGGT GAGAACAGCTCATGTAAATTATTCCA 942 
CCS-03 ZEB2 chr2:144901336-144901354 GCTCAATGTGTGAAAATGAAACA TGGCTATTTGGACCAAGAAACT 940 
CCS-04 ZEB2 chr2:144944487-144944503 GAGTTGCAAGCAACCTGTGA TGAAGAACAACAGGCTTTGG 938 
CCS-05 ZEB2 chr2:144974425-144974443 TATGGCAGCATTTGTTCAGC GAGCAATCCTTCCATTTCCA 948 
CCS-06 ZEB2 chr2:144989286-144989301 AAGCAATGGACAGGCTTGAT TCCCCAAGATTCAGTTCAGG 807 
CCS-07 PAX3 chr2:222845536-222845551 CGCCACTGTTTATCCCAG GAGAAACCTGGCAAGGG 805 
CCS-08 SLIT2 chr4:20089434-20089450 TGCCCCTTCATATGAGTAACC CCTTGATGTCATGCAAATGG 953 
CCS-09 PPARGC1A chr4:23484867-23484883 CAACAAGAAAGCTTGCCAGAG AGTGTGTGCCTGTGTATGTG 891 
CCS-10 SOX6 chr11:16100023-16100041 CCAGTTTTCAGCTTACTTTGG CTGGAAATAAGACAGGGTGG 787 
CCS-11 SOX6 chr11:16268685-16268703 CGGTTACTACCCTCAGAATGGA TTATTGGTGGCCAAAGCACT 999 
CCS-12 SOX6 chr11:16273199-16273219 TGAAGTTGCCAGTTTTAATGC GGGAGTTCTGTTTTGGGACA 987 
CCS-13 SOX6 chr11:16334769-16334784 TGACACCTTCCCAAATCACA TTCGTGCCAATGATGACCT 978 
CCS-14 SOX6 chr11:16383201-16383216 CAACCAGGTTTCACCATCAA CTGGCTGAGAGTGTTCTGGA 946 
CCS-15 SOX6 chr11:16420069-16420089 GGTCAGCACCTCTCCAACAT TTCCAGAGGCAGGTTTCATT 935 
CCS-16 HTATIP2 chr11:20351219-20351236 TGTCTGTCCACATGGTTAGG AGCAAGATTGATTGGAAGG 946 
CCS-17 NTM chr11:130816648-130816666 ACAGCTCTTTTTGGTCATGCAG TTTTCTCCAGGCCTCCAGTG 752 
CCS-18 SOX5 chr12:24059368-24059383 GACTCCTTAAATTCACAATCTGG GGCCCTGCTACTTTATCAGC 885 
CCS-19 SOX5 chr12:24059689-24059706 AAGCGAGTGTCGCCTAGGTA TCCTCCCTCTGTGCTGTCTT 768 
CCS-20 SOX5 chr12:24064859-24064874 CATTAACCAACCCCTGATGC TCCATGCACTTCCTTTGTGT 953 
CCS-21 IGF1R chr15:97238999-97239016 TTCCTGGTAAACAGTTCTGCTG CCCCAGTACTGTGAGCAACA 796 
CCS-22 TCF4 chr18:51243898-51243915 TCTTAGCATGGGCCCTATC GGGTTGTATCCATCTCAGAGC 750 
CCS-23 AKT3 chr1:241943595-241943614 ACATGAATAAGGGAGAGAAGAGGA TGTGCCTTAACTTAGAAACACTCC 1101 
CCS-24 FOXP1 chr3:71182835-71182854 GCCACTCCCTTCCCAAACTC CCTGGAGTCCTGTTGAGCAG 1239 
CCS-25 FOXP1 chr3:71373671-71373689 GTCTGACTTAGGGGCGAGTG TGCTTGTTCGAGACAGGTCA 791 
CCS-26 FOXP1 chr3:71441367-71441382 ACACACTGTTGACTTCACAAGT ACTGCATTGTGTAAATTTGCTGTG 319 
CCS-27 FOXP2 chr7:113841891-113841906 AGTCAGTTCTTGCAATAGGAGG CTTTGGTGTGCAACGTGAGG 993 
CCS-28 FOXP2 chr7:113853298-113853316 CACAGCCAGGTTGTTTCTGC CAAGATGTCCCTCTCTGCCA 1123 
CCS-29 FOXP2 chr7:113860154-113860173 AGAAATGGGAAAATGTGGCATCT ATGGACTAGGACACAAATGCTCA 592 
CCS-30 FOXP2 chr7:113930143-113930163 AGAAACTGACAGTGTTTTGGAAGT TGCTTGAGGAGAAAGGGGATC 875 
CCS-31 FOXP2 chr7:114082514-114082532 AGACATGTATCTTTTTGAATCTGACA TGGCACATTCAGAACCCAGA 1204 
CCS-32 LRPPRC chr2:44053319-44053338 TGTGGTTCCAAAACACTGGGT TGGTCATTTTCTTTGTGGGCC 685 
CCS-33 NFIA chr1:61419393-61419408 CGGGGCTGGCATATAAGAGC TCCATCTTACAGACTTTCACAATGA 530 
CCS-34 NFIA chr1:61482461-61482477 TGGGGTGTATGTGTATGCTGG ACAGCTAAACCCCTAGCCCT 463 
CCS-35 NFIA chr1:61686010-61686028 CACCCAGAAAATCCGGCAGT TTCTGGAGCCGCTTATGACG 306 
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CCS-36 ROBO2 chr3:77704023-77704038 CACTGAAGTGTGCAAGTGTGC TGAAATAAGGCAACCAAGAGGC 391 
CCS-37 ST18 chr8:53370592-53370610 TACCTCTAAGGAGCCTGCCA AGGGGGAAGTCAGAGATATGTCA 553 
CCS-38 TCF7L2 chr10:114809423-114809439 GCTTTCAAGGCTGGACCACT AGGAGAAAACAATCTGCTCTTTTCC 557 
CCS-39 TCF7L2 chr10:114895622-114895642 TGAACATGAGCTTGTGACCCA GGGGTGTCTGAATCCTCCTG 829 
CCS-40 ZFP536 chr19:35553939-35553959 ATCCAGGCAAAACAGAGGGG ATACAGCAGGGAGGCAGATG 1106 
CCS-41 ZFP536 chr19:35584775-35584790 TTTGTGGGTGGTAGGTGTGT GCTGGGAGAGGTAGAACAGG 833 
CCS-42 BCAS3 chr17:56264318-56264334 GTCATTTGTCAAACGAAGCAGC GCACACTTTAAGATCCAAATTCTCC 685 
CCS-43 BCAS3 chr17:56684299-56684319 AGACTGCTAGGTTCCCAGCT CTCTGGAGCCCTGGGTTATG 753 
CCS-44 CELF4 chr18:33340240-33340259 TGCCTTCGTGTCTTGAAGCC CCATGGGCTTGACCTACAGG 246 
CCS-45 CNTLN chr9:17440492-17440507 CAGATTGGCATTTTCAGACCCA TCTGAAAAATCCACTGAGTTACTGC 636 
CCS-46 EHBP1 chr2:63084089-63084109 TCCTACAAGTTGCATTCTGAACT CAGCATCAAGATGGTATTGTCTCAC 951 
CCS-47 EHBP1 chr2:63115438-63115454 ATGGCTTTCAATATTGTATGTCTTGAA AGGACACATTACTCATTGCTTCAC 1016 
CCS-48 HAT1 chr2:172529073-172529092 TGTGAATGAGTTGCAAGGACTG GTGACACAATTCTTACAGACCTGG 889 
CCS-49 LRBA chr4:151496934-151496949 CCATGTAATACGGCCTTCTTCC TGCTAAAGTAACTCAGATTCACTGC 549 
CCS-50 NFIB chr9:14293789-14293808 CCCAAGAATCATTGGACGTCT ATGTCTCCCTGCACTTCACC 477 
CCS-51 NFIB chr9:14299587-14299605 GGAAGGAGTACATGTCCCATCC GGAAGTGAGTTTCCAAAGCACA 465 
CCS-52 NFIB chr9:14302131-14302147 CCAGCCGATGGGTAATATTAATGG AAGTGTCAGCCAGTCTTGGG 454 
CCS-53 POLA1 chrX:24774936-24774951 CCCTGGTCCTTGTTGGTTCC TGTGGCTGCTTCTTGGATGG 680 
CCS-54 SORBS2 chr4:186930629-186930648 TGCTTGCAATGTTCCCTTGG GTTTGTAGCCGTGGGATCGA 331 
CCS-55 TLE4 chr9:81473523-81473540 TGACAGGCATGACGTTGAGG ACAATCCTAAGCCAGGGAGAC 428 
CCS-56 ZFHX3 chr16:71426880-71426895 GGAGGGTGGGATGTTTGAGG TTTCCCACCTGCTTCAGTGG 477 
CCS-57 MPP7 chr10:28530972-28530987 ATACAGAGCCAGCTCACCAC TTGGCATGTTCCAGCTGTCA 416 
 
1The SOX10- has been omitted for clarity. Full names of regions are SOX10-CCS-(number). 
2Regions are given in bed format for the human genome (hg18) and encompass the SOX10 consensus sequence and intermonomeric 
sequences identical among human (hg18), mouse (mm9), and chicken (Gal3). 
3Primers sequences are displayed in the 5’ to 3’ orientation and do not include the gateway adapter sequences. The adapter sequences 
for the forward and reverse primers are 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCT-3’ and 5’-
GGGGACCACTTTGTACAAGAAAGCTGGGT-3’ respectively. 
4Sizes are given in base pairs and do not reflect the additional size of the gateway adapter sequences. An additional 58 base pairs 
should be added to the size to account for the gateway adapters. 
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Appendix 7 Primers Used in RT-PCR in Chapter 4. 
Name Sequence1 Size3 
rnmmB-Actin RTPCR_F2 CGCGGGCGACGATGCTCC 532 - Rat 
rnmmB-Actin RTPCR_R2 GTAGCCACGCTCGGTCAGG 532 - Mouse 
rnSOX6_RTPCR_Fwd2 GTGCTGTATCTCCCCACAGG 402 - Rat 
rnSOX6_RTPCR_Rev2 TGGGTCATTGTTTCCTCTCC 349 - Mouse 
rnSox6_RTPCR_F34 GCCAGGAGTCTTCACTGCTCC 3062 
rnSox6_3'UTR_R24 GGGAGCGAAATGTCAGAGTG  
 
1Primers written in the 5’-3’ directions and designed against the rat (rn5) genome. 
2Both primer sets were designed to amplify both the rat (rn5) and mouse (mm9) sequences. 
3Size is written in base pairs and are displayed for either the rat or mouse genome. 
4Primer set was designed to amplify full length transcript starting within exon 1G from S16 cells. 
Please note that while the same primers were used for the SOX6 RT-PCR reaction, the rat (S16) PCR product was 402 bp and the 
mouse (MN-1) PCR product was 349 bp; the rat genome harbors a 53 base pair rat-specific insertion, which was confirmed via DNA 
sequence analysis. 
Shading indicates primer sets used. 
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Appendix 8 Primers Used in 5’RACE in Chapter 4. 
Name Primer1 
rnSOX6_GSP1 GATTTCTCCAAGAAGTTCACTCG 
rnSOX6_GSP2 TCTCCTCCAGCTTCTTCTGC 
rnSOX6_GSP3 TGGGTCATTGTTTCCTCTCC 
 
1Primers written in the 5’-3’ direction and designed against the rat (rn5) genome. 
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